<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005219.pub3" GROUP_ID="SYMPT" ID="524504070513574363" MERGED_FROM="" MODIFIED="2016-01-04 10:18:51 +0000" MODIFIED_BY="Anna Hobson" REVIEW_NO="108" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2016-01-04 10:17:40 +0000" MODIFIED_BY="Anna Hobson">
<TITLE MODIFIED="2015-10-20 15:34:57 +0100" MODIFIED_BY="Anna Hobson">Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache</TITLE>
<CONTACT>
<PERSON ID="4464" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>Bennett</LAST_NAME>
<SUFFIX>FANZCA, MM(Clin Epi), MD</SUFFIX>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>m.bennett@unsw.edu.au</EMAIL_1>
<EMAIL_2>s9400356@unsw.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Anaesthesia</DEPARTMENT>
<ORGANISATION>Prince of Wales Clinical School, University of NSW</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP/>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 9382 3880</PHONE_1>
<PHONE_2>+61 2 9382 2222</PHONE_2>
<FAX_1>+61 2 9382 3882</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-01-04 10:16:48 +0000" MODIFIED_BY="Anna Erskine">
<PERSON ID="4464" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>Bennett</LAST_NAME>
<SUFFIX>FANZCA, MM(Clin Epi), MD</SUFFIX>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>m.bennett@unsw.edu.au</EMAIL_1>
<EMAIL_2>s9400356@unsw.edu.au</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Anaesthesia</DEPARTMENT>
<ORGANISATION>Prince of Wales Clinical School, University of NSW</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Sydney</CITY>
<ZIP/>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 2 9382 3880</PHONE_1>
<PHONE_2>+61 2 9382 2222</PHONE_2>
<FAX_1>+61 2 9382 3882</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="18576" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Christopher</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>French</LAST_NAME>
<SUFFIX>FRACP</SUFFIX>
<POSITION/>
<EMAIL_1>frenchc@unimelb.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine (RMH)</DEPARTMENT>
<ORGANISATION>University of Melbourne</ORGANISATION>
<ADDRESS_1>MBC Neurosciences Building</ADDRESS_1>
<ADDRESS_2>Parkville</ADDRESS_2>
<CITY>Melbourne</CITY>
<ZIP/>
<REGION>Victoria</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B0F2D5A782E26AA20130726FEFEAE5AA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Alexander</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schnabel</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>alexander_schnabel@gmx.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Anaesthesia and Critical Care</DEPARTMENT>
<ORGANISATION>University of Würzburg</ORGANISATION>
<ADDRESS_1>Oberduerrbacher Str. 6</ADDRESS_1>
<ADDRESS_2/>
<CITY>Würzburg</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 251 4909541</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11165" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Jason</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wasiak</LAST_NAME>
<SUFFIX/>
<POSITION>Research Manager</POSITION>
<EMAIL_1>Jason.Wasiak@epworth.org.au</EMAIL_1>
<EMAIL_2>jwasiak1971@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Radiation Oncology</DEPARTMENT>
<ORGANISATION>The Epworth Hospital</ORGANISATION>
<ADDRESS_1>89 Bridge Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Richmond</CITY>
<ZIP>3121</ZIP>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 9426 6666</PHONE_1>
<PHONE_2/>
<FAX_1>+61 3 9427 0353</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11171" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Kranke</LAST_NAME>
<SUFFIX>MD, PhD, MBA</SUFFIX>
<POSITION>Professor of Anaesthesia</POSITION>
<EMAIL_1>kranke_p@ukw.de</EMAIL_1>
<EMAIL_2/>
<URL>http://anaesthesie.uk-wuerzburg.de/klinische-studien.html</URL>
<MOBILE_PHONE>+49 160 90 55 11 74</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Anaesthesia and Critical Care</DEPARTMENT>
<ORGANISATION>University of Würzburg</ORGANISATION>
<ADDRESS_1>Oberdürrbacher Str. 6</ADDRESS_1>
<ADDRESS_2/>
<CITY>Würzburg</CITY>
<ZIP>97080</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 931 201 30050</PHONE_1>
<PHONE_2>+49 931 201 30021 (secretary)</PHONE_2>
<FAX_1>+49 931 201 30053</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1402250836578477627303389096760" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Stephanie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Weibel</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Weibel_S@ukw.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Anaesthesia and Critical Care</DEPARTMENT>
<ORGANISATION>University of Würzburg</ORGANISATION>
<ADDRESS_1>Oberduerrbacher Str. 6</ADDRESS_1>
<ADDRESS_2/>
<CITY>Würzburg</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49-931-201-30310</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-01-04 10:17:18 +0000" MODIFIED_BY="Anna Hobson">
<UP_TO_DATE>
<DATE DAY="15" MONTH="6" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="6" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="6" YEAR="2020"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2016-01-04 10:17:40 +0000" MODIFIED_BY="Anna Hobson">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2016-01-04 10:17:40 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="4" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>This review will be assessed for further updating in 2020.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-01-04 10:17:25 +0000" MODIFIED_BY="Anna Hobson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-01-04 10:17:23 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="15" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>We updated the literature searches to 15 June 2015.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-01-04 10:17:25 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="15" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>We updated the review and included two new RCTs to the review (two to the qualitative analysis and one to the quantitative analysis). We added 'Risk of bias' tables for each included trial and a 'Summary of findings' table to the review. A review author has been added. We have modified the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> and <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> sections using the available subheading structure in <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-09-29 08:39:08 +0100" MODIFIED_BY="Michael H Bennett">
<DATE DAY="10" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="24" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>We incorporated feedback (26 March 2009) and response.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-10 21:13:01 +0100" MODIFIED_BY="Rebecca Gray">
<DATE DAY="24" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="10" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>We updated contact details for the Contact Person.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-08-07 15:03:51 +0100" MODIFIED_BY="Rebecca Gray">
<DATE DAY="30" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-12-18 11:11:58 +0000" MODIFIED_BY="Anna Hobson">
<INTERNAL_SOURCES MODIFIED="2015-11-06 16:25:27 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-11-06 16:25:27 +0000" MODIFIED_BY="[Empty name]">
<NAME>No internal source of support</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-12-18 11:11:58 +0000" MODIFIED_BY="Anna Hobson">
<SOURCE MODIFIED="2015-11-06 16:25:46 +0000" MODIFIED_BY="[Empty name]">
<NAME>No external source of support</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-01-04 10:18:51 +0000" MODIFIED_BY="Anna Hobson">
<SUMMARY MODIFIED="2015-12-18 13:50:31 +0000" MODIFIED_BY="Anna Hobson">
<TITLE MODIFIED="2015-11-06 11:12:56 +0000" MODIFIED_BY="[Empty name]">Normal pressure oxygen therapy and hyperbaric oxygen therapy for migraine and cluster headaches</TITLE>
<SUMMARY_BODY MODIFIED="2015-12-18 13:50:31 +0000" MODIFIED_BY="Anna Hobson">
<P>
<B>Background</B>
</P>
<P>Migraine and cluster headaches are severe and disabling. Hyperbaric oxygen therapy (HBOT, that is the breathing of pure oxygen at pressures greater than one atmosphere in a pressurised chamber) and normal pressure oxygen therapy (NBOT) can be delivered via a mask at home or in a clinic. These treatments may help to end acute attacks and prevent future attacks.</P>
<P>
<B>Results</B>
</P>
<P>We originally searched the literature widely in May 2008, and most recently in June 2015. We looked for high quality trials that would help define whether or not there was good evidence for or against the use of oxygen for migraine or cluster headache. We included 11 trials in this review. </P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We found some low quality evidence to suggest that HBOT relieves pain with acute migraine headaches and possibly cluster headaches, and that NBOT may relieve pain with cluster headache. We found no evidence that either treatment can prevent future attacks. Many migraines can be treated simply with appropriate drug therapy, so further research is needed to help choose the most appropriate patients (if any) to receive HBOT.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-12-18 13:49:23 +0000" MODIFIED_BY="Anna Hobson">
<ABS_BACKGROUND MODIFIED="2015-11-10 09:35:22 +0000" MODIFIED_BY="Anna Hobson">
<P>Migraine and cluster headaches are severe and disabling. Migraine affects up to 18% of women, while cluster headaches are much less common (0.2% of the population). A number of acute and prophylactic therapies are available. Hyperbaric oxygen therapy (HBOT) is the therapeutic administration of 100% oxygen at environmental pressures greater than one atmosphere, while normobaric oxygen therapy (NBOT) is oxygen administered at one atmosphere. This is an updated version of the original Cochrane review published in Issue 3, 2008 under the title 'Normobaric and hyperbaric oxygen for migraine and cluster headache'.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-12-04 03:51:18 +0000" MODIFIED_BY="[Empty name]">
<P>To examine the efficacy and safety of normobaric oxygen therapy (NBOT) and hyperbaric oxygen therapy (HBOT) in the treatment and prevention of migraine and cluster headache.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-12-18 10:48:45 +0000" MODIFIED_BY="Anna Hobson">
<P>We updated searches of the following databases up to 15 June 2015: CENTRAL (the Cochrane Library), MEDLINE, EMBASE, and CINAHL. For the original review we searched the following databases up to May 2008: CENTRAL, MEDLINE, EMBASE, CINAHL, DORCTIHM, and reference lists from relevant articles. We handsearched relevant journals and contacted researchers to identify trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Randomised controlled trials comparing HBOT or NBOT with one another, other active therapies, placebo (sham) interventions, or no treatment in participants with migraine or cluster headache.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Three review authors independently extracted data and assessed the quality of the evidence using the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-12-18 13:49:23 +0000" MODIFIED_BY="Anna Hobson">
<P>In this update, we included 11 trials with 209 participants. Five trials (103 participants) compared HBOT versus sham therapy for acute migraine, three trials compared NBOT to sham therapy or ergotamine tartrate for cluster headache (145 participants), two trials evaluated HBOT for cluster headache (29 participants), and one trial (56 participants) compared NBOT to sham for a mixed group of headache. The risk of bias varied considerably across these trials but in general trial quality was poor to moderate. One trial may not have been truly randomised and two included studies were reported as abstracts only. Seven trials did not indicate allocation concealment or randomisation method. Notably, 10 of the 11 trials used a sham comparator therapy and masked the outcome assessor to allocation.</P>
<P>We pooled data from three trials, which suggested that HBOT was effective in relieving migraine headaches compared to sham therapy (risk ratio (RR) 6.21, 95% CI 2.41 to 16.00; 58 participants, three trials). The quality of evidence was low, having been downgraded for small crossover studies with incomplete reporting. There was no evidence that HBOT could prevent migraine episodes, reduce the incidence of nausea and vomiting, or reduce the requirement for rescue medication. There was no evidence that HBOT was effective for the termination of cluster headache (RR 11.38, 95% CI 0.77 to 167.85; P = 0.08) (one trial), but this trial had low power.</P>
<P>NBOT was effective in terminating cluster headache compared to sham in a single small study (RR 7.88, 95% CI 1.13 to 54.66), but not superior to ergotamine administration in another small trial (RR 1.17, 95% CI 0.94 to 1.46; P = 0.16). A third trial reported a statistically significant difference in the proportion of attacks successfully treated with oxygen (117 of 150 attacks were successfully treated with NBOT (78%) versus 30 of 148 attacks treated with NBOT (20%)). The proportion of responders was consistent across these three trials, and suggested more than 75% of headaches were likely to respond to NBOT.</P>
<P>No serious adverse events during HBOT or NBOT were reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Since the last version of this review, two new included studies have provided additional information to change the conclusions. There was some evidence that HBOT was effective for the termination of acute migraine in an unselected population, and some evidence that NBOT was similarly effective in cluster headache. Given the cost and poor availability of HBOT, more research should be done on patients unresponsive to standard therapy. NBOT is cheap, safe, and easy to apply, so will probably continue to be used despite the limited evidence in this review.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-12-18 13:43:43 +0000" MODIFIED_BY="Anna Hobson">
<BACKGROUND MODIFIED="2015-12-18 13:14:33 +0000" MODIFIED_BY="Anna Hobson">
<P>This is an updated version of the original Cochrane review published in Issue 3, 2008 under the title 'Normobaric and hyperbaric oxygen for migraine and cluster headache' (<LINK REF="REF-Bennett-2008" TYPE="REFERENCE">Bennett 2008</LINK>).</P>
<CONDITION MODIFIED="2015-12-18 13:14:33 +0000" MODIFIED_BY="Anna Hobson">
<P>Migraine and cluster headache are disabling health problems among adults and migraine has been identified as a leading contributor to years lived with disability in an analysis for the Global Burden of Disease Study 2010 (<LINK REF="REF-Vos-2013" TYPE="REFERENCE">Vos 2013</LINK>). Both types of headache are frequently severe and associated with features other than pain (<LINK REF="REF-IHS-2014" TYPE="REFERENCE">IHS 2014</LINK>). While the diagnosis and classification of headaches can be difficult and complex, migraine and cluster headaches are generally distinguished by the nature of associated symptoms (nausea, vomiting, and photophobia occur commonly with migraine, while cluster headaches are typically accompanied by tearing and nasal congestion), the pattern in which they occur (cluster headaches typically occur daily for up to several weeks before resolving, often for lengthy periods) and their location and character (cluster headaches are periorbital and unilateral, while migraines can be bilateral and are often described as throbbing). Migraine may be preceded by an aura&#8212;most often a visual disturbance&#8212;in some people.</P>
<P>Severe headache is common; in a review of studies on the prevalence of severe headache, <LINK REF="REF-Smitherman-2013" TYPE="REFERENCE">Smitherman 2013</LINK> suggests about 16% of the adult population in the USA will complain of at least one severe headache over a three-month period, most of which are labelled as 'migraine' or 'probable migraine'. Surveys from the USA and elsewhere suggest that 6% to 7% of men and 15% to 18% of women experience migraine headaches, while about 0.1 to 0.2% of the population suffer with cluster headache (<LINK REF="REF-Mathew-2001" TYPE="REFERENCE">Mathew 2001</LINK>; <LINK REF="REF-Nesbitt-2012" TYPE="REFERENCE">Nesbitt 2012</LINK>; <LINK REF="REF-Russell-2004" TYPE="REFERENCE">Russell 2004</LINK>). First-degree relatives of those with cluster headaches are five to 18 times more likely to have such headaches than individuals in the general population. The mechanisms involved in both types of headache remain incompletely understood and are active areas of research (<LINK REF="REF-Nesbitt-2012" TYPE="REFERENCE">Nesbitt 2012</LINK>). Migraine is generally seen as a vascular headache that seems to result from a mixture of environmental and genetic factors (<LINK REF="REF-Piane-2007" TYPE="REFERENCE">Piane 2007</LINK>), while cluster headache is classified among the trigeminal autonomic cephalalgias and probably involves the hypothalamus (<LINK REF="REF-Nesbitt-2012" TYPE="REFERENCE">Nesbitt 2012</LINK>). Migraine results in significant disability, work loss, and costs to the individual (<LINK REF="REF-Burton-2002" TYPE="REFERENCE">Burton 2002</LINK>; <LINK REF="REF-Hu-1999" TYPE="REFERENCE">Hu 1999</LINK>; <LINK REF="REF-Munakata-2009" TYPE="REFERENCE">Munakata 2009</LINK>; <LINK REF="REF-Stokes-2011" TYPE="REFERENCE">Stokes 2011</LINK>); estimated aggregate indirect costs to employers in the USA for reduced productivity due to migraine range from USD 5.6 billion to USD 17.2 billion annually (<LINK REF="REF-Munakata-2009" TYPE="REFERENCE">Munakata 2009</LINK>; <LINK REF="REF-Osterhaus-1992" TYPE="REFERENCE">Osterhaus 1992</LINK>). The social and economic impact of cluster headache is less clear, but data from Germany suggest time lost to work and healthcare costs are substantial (<LINK REF="REF-Gaul-2011" TYPE="REFERENCE">Gaul 2011</LINK>).</P>
<P>The traditional view has been that migraine is primarily a vascular event. This view focuses on explaining the pain involved, but more recently migraine is seen as a sensory processing disturbance, primarily of the sub-cortical aminergic sensory modulatory systems. Such a brain-centered explanation helps to explain the symptomatology of migraine beyond the headache and has implications for treatment (<LINK REF="REF-Goadsby-2012" TYPE="REFERENCE">Goadsby 2012</LINK>).</P>
<P>Therapy for headache falls into two categories: acute and preventive. Acute therapy aims at the symptomatic treatment of the head pain and other symptoms associated with an acute attack or cluster. The goal of preventive therapy is to reduce the frequency or intensity of attacks, or both, and thereby improve patient functioning and quality of life. Preventive therapy is especially well-suited to patients with very frequent or severe attacks, significant headache-related disability, or resistance to acute therapy.</P>
<P>There are many accepted drug therapies for acute migraine, including non-specific analgesics such as non-steroidal anti-inflammatory drugs, and specific agents such as sumatriptan, ergotamine, and dihydroergotamine (DHE) (<LINK REF="REF-Law-2013a" TYPE="REFERENCE">Law 2013a</LINK>; <LINK REF="REF-Law-2013b" TYPE="REFERENCE">Law 2013b</LINK>; <LINK REF="REF-G_x00e9_raud-2004" TYPE="REFERENCE">Géraud 2004</LINK>). Epidemiological studies suggest that 80% of all analgesic prescriptions for migraine are triptans, mainly sumatriptan (<LINK REF="REF-Smitherman-2013" TYPE="REFERENCE">Smitherman 2013</LINK>). These drugs are effective in most cases, although headache may recur within 48 hours (<LINK REF="REF-Bateman-1993" TYPE="REFERENCE">Bateman 1993</LINK>). Most people with migraine are able to manage even these recurrent headaches successfully at home with self-administered medication. Thus, while migraine is a common problem, the number of cases unresponsive to accepted therapeutic approaches may be quite small. It is these patients who may benefit from a therapy delivered at a health facility, such as intravenous DHE, parenteral analgesics or antinauseants or, potentially, hyperbaric oxygen therapy (HBOT).</P>
<P>Pharmacological and non-pharmacological therapies used for the prevention of migraine include various beta-blockers, amitriptyline, topiramate; sodium valproate, gabapentin, relaxation, biofeedback, feverfew, and cognitive-behavioural therapy (<LINK REF="REF-G_x00e9_raud-2004" TYPE="REFERENCE">Géraud 2004</LINK>; <LINK REF="REF-Linde-2013a" TYPE="REFERENCE">Linde 2013a</LINK>; <LINK REF="REF-Linde-2013b" TYPE="REFERENCE">Linde 2013b</LINK>; <LINK REF="REF-Wider-2015" TYPE="REFERENCE">Wider 2015</LINK>). Again, while most patients respond to such therapies, they are not always effective. Refractory patients may be offered preventive drug treatments with potentially serious toxicities, such as methysergide; these patients may also be candidates for other resource-intensive treatments, such as HBOT.</P>
<P>The standard acute treatment for cluster headache is sumatriptan and inhalation of 100% oxygen, while steroids are commonly used both as treatment and prophylaxis (<LINK REF="REF-Law-2013c" TYPE="REFERENCE">Law 2013c</LINK>). Secondary agents include methysergide, lithium, and topiramate. A number of agents have been used for prophylaxis, including verapamil, ergotamine, lithium, and steroids (<LINK REF="REF-May-2006" TYPE="REFERENCE">May 2006</LINK>). Again, most patients respond well to the administration of specific acute therapy. For example, in one randomised study, 74% of attacks responded to subcutaneous sumatriptan within 15 minutes (<LINK REF="REF-Ekbom-1993" TYPE="REFERENCE">Ekbom 1993</LINK>). Only a subset of cluster headache patients would therefore be candidates for the administration of therapies such as hyperbaric oxygen where hospital attendance is required. Most recently, there have been promising advances in the search for a more permanent cure, particularly with deep hypothalamic stimulation techniques and subsequent surgical procedures (<LINK REF="REF-May-2006" TYPE="REFERENCE">May 2006</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>This review considers the evidence for the effectiveness and safety of oxygen administration for migraine or cluster headache. It includes both the use of oxygen at high percentage of normal atmospheric pressure (normobaric oxygen therapy (NBOT)) and the use of 100% oxygen at pressures above one atmosphere (HBOT). NBOT is delivered by a mask connected to an oxygen cylinder and may be administered in a hospital, general practice, or home setting. HBOT requires the patient to be subjected to a higher than atmospheric pressure in a specialised vessel designed for the purpose. For the treatment of headache, each session of therapy typically involves exposure to pressure for 30 minutes to one hour at between 2.0 and 2.4 atmospheres absolute (ATA, equivalent to 101.3 kPa of 760 mmHg), although some workers cease treatment on the resolution of headache. Treatment therefore takes place at 2.0 to 2.4 times the normal air pressure at sea level (1 ATA). While at pressure, the patient breathes 100% oxygen via a hood tent or a tight-fitting mask designed for the purpose. We will consider oxygen both as an acute therapy for terminating individual attacks and as a preventive therapy for reducing the frequency of headache episodes.</P>
<P>Precautions against fire are required and standard practice in areas where oxygen is in use. Prolonged administration to premature neonates may be implicated in the development of retinopathy of prematurity, and oxygen has produced respiratory arrest in chronically hypercarbic patients relying on an hypoxic drive for respiration. Neither of these groups of individuals is likely to be relevant in this review. Regardless of the particular pathology being treated, HBOT is associated with some risk of adverse events, including damage to the ears, sinuses, and lungs from the effects of pressure; temporary worsening of shortsightedness; claustrophobia; and oxygen poisoning. Although serious adverse events are rare, HBOT cannot be regarded as an entirely benign intervention.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-11-05 13:58:26 +0000" MODIFIED_BY="[Empty name]">
<P>NBOT has been used with some success to treat both migraine and cluster headaches for many years (<LINK REF="REF-Alvarez-1939" TYPE="REFERENCE">Alvarez 1939</LINK>; <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>), presumably through the ability of oxygen to constrict distal cerebral resistance vessels (<LINK REF="STD-Drummond-1985" TYPE="STUDY">Drummond 1985</LINK>; <LINK REF="REF-Iversen-1990" TYPE="REFERENCE">Iversen 1990</LINK>). The observation that oxygen administered at higher pressures produced even further vasoconstriction (with preservation of tissue oxygenation) led directly to the suggestion that HBOT might favourably influence vascular headache resistant to conventional drug therapy (<LINK REF="REF-Fife-1994" TYPE="REFERENCE">Fife 1994</LINK>). It has been suggested that HBOT may also exert therapeutic effects through the action of oxygen as a serotonergic agonist and an immunomodulator of response to substance P (a short chain neuropeptide involved in pain signal transmission) (<LINK REF="STD-Di-Sabato-1996" TYPE="STUDY">Di Sabato 1996</LINK>; <LINK REF="STD-Di-Sabato-1997" TYPE="STUDY">Di Sabato 1997</LINK>). Indeed, while acknowledging that vascular mechanisms are involved, it has been suggested that inflammation plays a critical role in the genesis of a migraine episode (<LINK REF="REF-Goadsby-1997" TYPE="REFERENCE">Goadsby 1997</LINK>). If this is correct, then the well-described moderation of inflammatory pathways by HBOT may both influence acute attacks and provide useful prophylaxis (<LINK REF="REF-Slotman-1998" TYPE="REFERENCE">Slotman 1998</LINK>; <LINK REF="REF-S_x00fc_men-2001" TYPE="REFERENCE">Sümen 2001</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-12-18 13:14:33 +0000" MODIFIED_BY="Anna Hobson">
<P>While the use of NBOT is relatively common for cluster headache, the evidence for this practice is less well known. For this reason we felt an assessment of the strength of the evidence was appropriate. NBOT is rarely used for the treatment of migraine. Clinically, HBOT has been reported as a successful treatment for headache since at least 1989 (<LINK REF="STD-Fife-1989" TYPE="STUDY">Fife 1989</LINK>; <LINK REF="REF-Weiss-1989" TYPE="REFERENCE">Weiss 1989</LINK>), and sporadic reports have followed since that time, including some comparative trials. On the other hand, oxygen in high doses may increase oxidative stress through oxygen free radical species and is potentially toxic (<LINK REF="REF-Yusa-1987" TYPE="REFERENCE">Yusa 1987</LINK>). Indeed, the brain is particularly at risk (<LINK REF="REF-Clark-2003" TYPE="REFERENCE">Clark 2003</LINK>). For this reason, it is appropriate to postulate that in some migraine or cluster headache patients, HBOT may do more harm than good.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>To examine the efficacy and safety of normobaric oxygen therapy (NBOT) and hyperbaric oxygen therapy (HBOT) in the treatment and prevention of migraine and cluster headache.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-12-18 13:41:59 +0000" MODIFIED_BY="Anna Hobson">
<SELECTION_CRITERIA MODIFIED="2015-12-18 13:14:33 +0000" MODIFIED_BY="Anna Hobson">
<CRIT_STUDIES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>All randomised controlled trials (RCTs) that evaluate the effectiveness of NBOT or HBOT for the prevention or treatment of migraine or cluster headache were included. We accepted any comparator including drug or sham interventions.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-12-23 03:29:03 +0000" MODIFIED_BY="Michael H Bennett">
<P>We sought to identify trials that included patients of any age and either sex with migraine (with or without aura) or cluster headache. Headache classification followed the guidelines of the International Headache Society where possible (<LINK REF="REF-IHS-2014" TYPE="REFERENCE">IHS 2014</LINK>). </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We considered interventions that included NBOT at any concentration above ambient air (whether administered in a health facility or at home) or HBOT administered in a compression chamber. We included trials where NBOT was compared to HBOT, or where either was compared to a standard therapy or no treatment. The comparator groups included any standard treatment regimen designed to prevent or terminate headache or prevent recurrence, including combined therapies, as well as placebo (sham) interventions and no treatment. We included regimens where adjunctive NBOT or HBOT was compared against similar regimens excluding NBOT or HBOT. Where regimens differed significantly between studies, we have stated this clearly and discussed the implications.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-12-18 13:14:33 +0000" MODIFIED_BY="Anna Hobson">
<P>We anticipated that short-term response would be of greatest clinical importance. Primary outcome assessments were generally made during or immediately following therapy.</P>
<P>For outcomes relating to headache intensity, we preferred those that measured headache relief or change in headache intensity, since these are more comparable among participants with different baseline scores. The outcomes we considered eligible for inclusion in this review were:</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-12-18 13:14:33 +0000" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="5">Treatment of acute attack</HEADING>
<OL>
<LI>Proportion of participant with pain-free response (complete resolution of headache pain). Assessment times preferred were one and two hours for migraine, and 15 and 30 minutes for cluster headache.</LI>
<LI>Proportion of participants with headache pain reduction from moderate/severe to mild or none (timing as for 1, above).</LI>
<LI>Proportion of participants with sustained relief for 24 hours.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Prevention</HEADING>
<OL>
<LI>Frequency of attacks.</LI>
<LI>Number of days with headache in the week after therapy.</LI>
<LI>Days lost to work.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-12-18 11:04:10 +0000" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="5">Treatment of acute attack</HEADING>
<OL>
<LI>Degree of headache relief or headache intensity.</LI>
<LI>Functional status or disability.</LI>
<LI>Pain-free response at four hours for migraine and two hours for cluster headache.</LI>
<LI>Proportion of participants requiring rescue medication.</LI>
<LI>Proportion of participants with sustained relief for 48 hours.</LI>
<LI>Proportion of participants with photophobia or phonophobia (migraine only).</LI>
<LI>Proportion of participants with nausea and/or vomiting, after therapy (migraine only).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Prevention</HEADING>
<OL>
<LI>Self-reported assessment of treatment success.</LI>
<LI>Frequency of attacks rated by participant as 'severe'.</LI>
<LI>Quality of life.</LI>
<LI>Functional status or disability.</LI>
<LI>Headache index (nature and calculation discussed).</LI>
<LI>Proportion of participants requiring rescue medication.</LI>
<LI>Proportion of participants with nausea and/or vomiting, or both (migraine only).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events/safety</HEADING>
<OL>
<LI>Adverse events during HBOT, such as the proportion of participants with visual disturbance (short- and long-term), barotrauma (aural, sinus, pulmonary in the short- and long- term) and oxygen toxicity (short-term).</LI>
<LI>Any other recorded adverse events were reported and discussed.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>We intended to capture both published and unpublished trials. We did not impose language restrictions.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>We searched the following databases up to 15 June 2015:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL; the Cochrane Library), Issue 6 2015;</LI>
<LI>MEDLINE &amp; MEDLINE in Process (OVID) (1966 to 15 June 2015);</LI>
<LI>EMBASE (OVID) (1980 to 15 June 2015);</LI>
<LI>CINAHL (EBSCO) (1982 to June 2015);</LI>
<LI>An additional database developed in our hyperbaric facility (the Database of Randomised Trials in Hyperbaric Medicine (<LINK REF="REF-Bennett-2004" TYPE="REFERENCE">Bennett 2004</LINK>) was searched for the original review in 2005 and for subsequent updates).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>In addition we made a systematic search for relevant RCTs by other means available. For the initial review in 2005 we contacted experts in the field of headache and leading hyperbaric therapy centres and asked authors of relevant studies for details of any unpublished or ongoing investigations.</P>
<P>Both <LINK REF="REF-Bennett-2005" TYPE="REFERENCE">Bennett 2005</LINK> and all subsequent updates, we handsearched relevant hyperbaric textbooks (latest editions for this update: <LINK REF="REF-Jain-2009" TYPE="REFERENCE">Jain 2009</LINK>; <LINK REF="REF-Kindwall-2008" TYPE="REFERENCE">Kindwall 2008</LINK>; <LINK REF="REF-Mathieu-2006" TYPE="REFERENCE">Mathieu 2006</LINK>), relevant journals up to 15 June 2015 (<I>Undersea and Hyperbaric Medicine</I>; <I>Hyperbaric Medicine Review</I>; <I>Diving and Hyperbaric Medicine</I>; and <I>Aviation, Space and Environmental Medicine Journal</I>) and conference proceedings (<I>Undersea and Hyperbaric Medical Society</I>, <I>South Pacific Underwater Medicine Society</I>, <I>European Undersea and Baromedical Society</I>, <I>International Congress of Hyperbaric Medicine</I>) from first editions to 15 June 2015. We also searched the USA NIH database of registered trials at <A HREF="https://clinicaltrials.gov/">https://clinicaltrials.gov/</A>. Finally, we checked the reference lists of the trials and reviews identified by the above strategies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-12-18 13:41:59 +0000" MODIFIED_BY="Anna Hobson">
<P>We analysed data from trials enrolling patients with migraine separately from those enrolling patients with cluster headache.</P>
<STUDY_SELECTION MODIFIED="2015-12-18 13:30:04 +0000" MODIFIED_BY="Anna Hobson">
<P>Two review authors (MB and JW) scanned the records retrieved by the initial search and the updated searches and excluded obviously irrelevant studies by title. Subsequently, MB and AS read the abstracts of the citations remaining in order to identify trials that may have met the inclusion criteria. We retrieved the full-text articles and these were assessed by three review authors (MB, AS, and CF) independently and a decision made on inclusion/exclusion. We resolved any differences of opinion by discussion among the review authors.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-12-18 10:50:04 +0000" MODIFIED_BY="Anna Hobson">
<P>Two review authors (MB and AS) independently extracted data from the included trials using standardised forms we developed for this review. We collected data on trial methodology, numbers of participants enrolled, number reaching analysis and all outcomes reported. We contacted primary study investigators to provide further information when we encountered missing data. We resolved any differences in opinion by discussion among the review authors. All included trials were available in English.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-12-18 10:50:09 +0000" MODIFIED_BY="Anna Hobson">
<P>Two review authors (MB and SW) independently undertook assessment of the risk of bias of the included trials with the following taken into consideration, as guided by the<I> Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>):</P>
<UL>
<LI>Sequence generation;</LI>
<LI>Allocation concealment;</LI>
<LI>Blinding;</LI>
<LI>Incomplete outcome data;</LI>
<LI>Selective outcome reporting; and</LI>
<LI>Other sources of bias.</LI>
</UL>
<P>We used the Cochrane &#8216;Risk of bias&#8217; assessment tool in RevMan 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>,) in which each of these domains is described as reported in the trial and then a judgement assigned about the adequacy of each entry: either 'low', 'high', or 'unclear' (or unknown) risk of bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-12-04 04:23:43 +0000" MODIFIED_BY="[Empty name]">
<P>For proportions (dichotomous outcomes), we used relative risk (RR). </P>
<P>We converted continuous data to the mean difference (MD) using the inverse variance method, and calculated an overall MD. </P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-12-18 10:50:54 +0000" MODIFIED_BY="Anna Hobson">
<P>We intended to include cluster randomised trials but did not find any.</P>
<P>When data from cross-over trials contributed to an analysis, we intended to use the Peto method for taking joint conditional probabilities into account, as described in <LINK REF="REF-Curtin-2002" TYPE="REFERENCE">Curtin 2002</LINK>. However this was not possible with the data available and we have analysed these trials as if they were parallel-group in design. This is a generally conservative approach that ignores the reduction in inter-participant variability in cross-over studies.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-12-04 04:20:27 +0000" MODIFIED_BY="[Empty name]">
<P>All analyses were made on an intention-to-treat (ITT) basis where possible. In the case of missing data, we employed different approaches to imputing missing data. The best-case scenario assumed that none of the originally enrolled patients missing from the primary analysis in the treatment group had the negative outcome of interest while all those missing from the control group did. The worst-case scenario was the reverse.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-12-18 10:50:21 +0000" MODIFIED_BY="Anna Hobson">
<P>We assessed statistical heterogeneity using the I² statistic, and gave consideration to the appropriateness of pooling and meta-analysis by interpretation of both statistical and clinical heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-12-04 04:25:52 +0000" MODIFIED_BY="[Empty name]">
<P>If 10 or more trials contributed data to a meta-analysis, we intended to investigate the possibility of publication bias through the use of funnel plots, however this was inappropriate. </P>
</BIAS_ASSESSMENT>
<SUBGROUP_ANALYSIS MODIFIED="2015-12-18 13:41:59 +0000" MODIFIED_BY="Anna Hobson">
<P>Tests of interaction were calculated to determine if the results for subgroups were significantly different. We used a fixed-effect model where there was no evidence of significant heterogeneity between studies, and a random-effects model when such heterogeneity was likely (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>).</P>
<P>We performed subgroup analyses where appropriate by calculation of RR or MD in each subgroup and examination of the 95% confidence intervals (CIs). Non-overlap in intervals was taken to indicate a statistically significant difference between subgroups.</P>
<P>We considered subgroup analyses based on the following factors, but such analyses were inappropriate:</P>
<UL>
<LI>Dose of oxygen received: NBOT versus HBOT;</LI>
<LI>Dose of oxygen received during HBOT: variables to be considered: pressure (&lt; 2.0 atmospheres absolute [ATA] versus &#8805; 2.0 ATA), time (&lt; 60 min versus &#8805; 60 min), and length of treatment course (&lt; five sessions versus &#8805; five sessions);</LI>
<LI>Migraine with aura versus without aura;</LI>
<LI>Comparator treatment (where oxygen has been compared to different alternative treatments).</LI>
</UL>
<P>We assumed statistical heterogeneity to be significant if the I² statistic analysis suggested more than 30% of the variability in an analysis was due to differences between trials. Consideration was then given to the appropriateness of pooling and meta-analysis; when analysis was undertaken in the face of statistical or clinical heterogeneity, we used a random-effects model.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-12-18 10:51:02 +0000" MODIFIED_BY="Anna Hobson">
<P>We performed sensitivity analyses for missing data where appropriate, but sensitivity analysis for study quality was inappropriate.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-12-18 13:43:43 +0000" MODIFIED_BY="Anna Hobson">
<STUDY_DESCRIPTION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<SEARCH_RESULTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>In the previous version of this review, nine trials met the inclusion criteria (<LINK REF="REF-Bennett-2008" TYPE="REFERENCE">Bennett 2008</LINK>). For this review update we identified seven potential articles for inclusion after searching the literature up to 15 June 2015 (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Two of these articles were reviews of the treatment of cluster or migraine headache with no new data and a third was a third party report on an included trial. We excluded these three articles (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'). Of the remaining three reports, two dealt with a single trial (<LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK> (an abstract) and <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK> (full report)). Therefore two new trials met the inclusion criteria (<LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>; <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>) and we pooled data where possible with the nine trials included in <LINK REF="REF-Bennett-2008" TYPE="REFERENCE">Bennett 2008</LINK> (<LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK>; <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK>; <LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>; <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK>; <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>; <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>; <LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK>; <LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK>; <LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>). <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK> was a crossover trial and four cluster headache attacks were treated in each individual. The trial authors reported the proportion of attacks that responded to normobaric oxygen rather than the proportion of participants. We requested further information but at this time this report is included in qualitative analysis of this review only.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>We included 11 trials in the quantitative analysis. Included trials were published between 1981 (<LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>) and 2012 (<LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>), and we are unaware of any ongoing RCTs in the area. One trial, <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>, enrolled all types of headache and evaluated one atmosphere oxygen breathing (NBOT). We included the results of those with migraine (56 participants) and cluster headache (two participants) in the relevant analyses in this review. Six trials enrolled a total of 159 patients experiencing acute migraine; all of which, except <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>, employed HBOT in one arm (<LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK>; <LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>; <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>; <LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK>; <LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>). Six trials enrolled a total of 209 patients with cluster headache. Four of these evaluated NBOT (<LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>; <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK>; <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>; <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>), and the other two administered HBOT (<LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK>; <LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK>). Several studies utilized a cross-over design (<LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>; <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK>; <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>; <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>; <LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK>; <LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>). In total, these 11 trials included 363 participants. We have listed details of the methodology and interventions in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<P>The dose of oxygen per treatment session and for the total course of treatment varied somewhat between studies. Of the trials investigating the treatment of migraine with HBOT, all administered HBOT at 2.0 ATA except <LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>, who utilized 2.4 ATA. The period of exposure to HBOT varied from 30 minutes on three consecutive days (<LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK>) to a maximum of 60 minutes (<LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>). All migraine trials except <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> gave a single exposure only. The single trial using NBOT for migraine employed 15 litres of 100% oxygen versus air for 15 minutes (<LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>). The three cluster headache trials investigating NBOT administered oxygen for 15 minutes. The two trials investigating HBOT both administered oxygen at 2.5 ATA; <LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK> for 30 minutes on a single occasion and <LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK> for 70 minutes on two consecutive days.</P>
<P>All trials, except <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>, provided a sham therapy and blinded participants and assessors to the treatment received. For the HBOT trials sham procedures varied, with the use of air at atmospheric pressure (<LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK>), air at 2.0 ATA (<LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>; <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK>), 10% oxygen at 2.0 to 2.5 ATA in order to maintain inspired oxygen tension near that of air at atmospheric pressure (<LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>; <LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK>) and 100% oxygen administration at or near atmospheric pressure (<LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK>; <LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>). <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK> had masked cylinders of air or oxygen to maintain blinding to participant and assessor.</P>
<P>Inclusion and exclusion criteria varied widely across the trials. Of the migraine trials, three accepted patients with confirmed diagnoses by a neurologist or physician (<LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>; <LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK>; <LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>), while <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> and <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK> used the criteria of the International Headache Society (<LINK REF="REF-IHS-1988" TYPE="REFERENCE">IHS 1988</LINK>) and <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK> used the criteria of the Ad Hoc Committee of the National Institute of Neurological Diseases and Blindness (<LINK REF="REF-AHC-1962" TYPE="REFERENCE">AHC 1962</LINK>). Of the cluster headache trials, two RCTs used the <LINK REF="REF-AHC-1962" TYPE="REFERENCE">AHC 1962</LINK> criteria (<LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK>; <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK>), three RCTs used the criteria of the <LINK REF="REF-IHS-1988" TYPE="REFERENCE">IHS 1988</LINK> (<LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>; <LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK>; <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>), and <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> did not define the diagnosis. Most trials investigated the efficacy of oxygen for the termination of an acute headache attack, while <LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK> and <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> were primarily designed to investigate prophylaxis. We have given details of both inclusion and exclusion criteria, where recorded, in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<P>For most studies, control arms used no specific anti-headache treatment (other than sham oxygen), except for <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> which used sublingual ergotamine tartrate in the control group, and <LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK> which used NBOT in the control group. Most trials did not follow participants after the end of the therapy period with the exception of <LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK> (one week), and both <LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK> and <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> (two months).</P>
<P>Other outcomes (including non-clinical) reported included: number of doses of attack-terminating medicine and plasma endothelin levels (<LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK>); jugular venous plasma levels of calcitonin gene-related peptide, vasoactive intestinal peptide, and neuropeptide Y (<LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK>), length of stay in the emergency department (<LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>); and pericranial tenderness with algometry (<LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>We excluded 18 reports following examination of the full report. We have listed the details of these reports in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. Ten were reviews with no new data, four were non-random comparative studies, three were case series, and one was a third party report of an included study.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>See the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table for further details. These trials varied in methodological quality and only eight were full reports of completed trials and available in a peer-reviewed publication. Two of the included reports were presented as abstracts only (<LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>; <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>). We have presented the 'Risk of bias' assessments for each included RCT in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Patient baseline characteristics</HEADING>
<P>Most included trials poorly described patient baseline diagnosis.</P>
<SUBSECTION>
<HEADING LEVEL="4">Migraine</HEADING>
<P>All trials used published diagnostic criteria (either <LINK REF="REF-AHC-1962" TYPE="REFERENCE">AHC 1962</LINK> or <LINK REF="REF-IHS-1988" TYPE="REFERENCE">IHS 1988</LINK>) or diagnosis by a specific neurologist or physician. <LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK> accepted only patients at least 18 months from first diagnosis of migraine with aura and <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> required from two to eight attacks per month for the preceding three months. All trials entered patients during acute attacks except <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> where the main outcome was prophylaxis rather than acute headache termination.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cluster</HEADING>
<P>All trials used published diagnostic criteria (either <LINK REF="REF-AHC-1962" TYPE="REFERENCE">AHC 1962</LINK> or <LINK REF="REF-IHS-1988" TYPE="REFERENCE">IHS 1988</LINK>), except <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> who did not define diagnosis. <LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK> enrolled both episodic and chronic cluster patients who had experienced at least six attacks in the previous week and in whom the cluster was expected to persist for at least four further weeks, <LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK> enrolled only episodic cluster patients in the 'florid phase' from day 10 to 15 of their cluster and <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK> enrolled both episodic and chronic cluster patients, while <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> and <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK> did not report further baseline details.</P>
</SUBSECTION>
</SUBSECTION>
<ALLOCATION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Allocation concealment was inadequate in one RCT (<LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK>), clearly indicated in three RCTs (<LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK>; <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>; <LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>), and unclear in the remaining studies. <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK> and <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK> described the randomisation procedure, but the remaining studies gave no details. <LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK> did not specifically use the term 'randomisation' and this trial may not have been truly randomised. Sensitivity analyses with and without this trial were considered during analysis. There is not a clear indication for any of the included trials that the trial authors were unable to predict the prospective group to which a participant would be allocated.</P>
<P>
<LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK> was a cross-over design where the cross-over occurred after a five-minute period breathing air at 2.0 ATA. As any individual with relief from the first treatment period could not receive further relief during the second, we accepted only the response to the initial treatment period into this review. In general, the cross-over trials were poorly reported and we could only extract data for <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK> on the response of each individual to both study arms.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>All trials blinded the outcome assessor to therapy except <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> (no blinding). <LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK> and <LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK> blinded the assessor only, while all other trials blinded participants, investigators, and assessors. All trials provided a sham therapy except <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>, who provided a sublingual preparation as the comparator therapy.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>One participant was lost to final follow-up in the control group of <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK>. Six participants were enrolled but did not complete therapy and were not analysed (one hyperbaric and five control): one suffered a technical problem with the chamber and could not be treated, two withdrew because of claustrophobia, one withdrew with a respiratory tract infection, one had a pathological chest X-ray, and the final participant withdrew for unknown reasons. Some participants failed to cross for the second arm of therapy in five included trials (<LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>; <LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>; <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK>; <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>; <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>) and this accounts for the uneven numbers of participants in the different therapy arms of those trials. Cohen enrolled 109 participants but 33 dropped out (17 came out of the headache, nine were lost to follow-up, six withdrew from the study, and one died). None of the remaining studies suffered any losses to follow-up, or reported any violation of allocated treatment.</P>
<P>Most trials delivered the intended therapy and analysed by ITT. No data were generated or analysed where participants withdrew from the study before therapy was delivered or where an individual failed to cross and receive the alternative therapy. <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> supplied the raw data to allow ITT analysis for the missing participant in the control group.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>There was little evidence of any selective reporting of pre-determined outcomes, mainly because there was no evidence of trial registration for all included trials except <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>. We included this trial in the qualitative review only. The trial authors indicated an intention to report the proportion of participants pain free after 15 minutes of treatment comparing oxygen and air, but actually reported the proportion of attacks treated that had responded.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-12-04 05:55:35 +0000" MODIFIED_BY="[Empty name]">
<P>There was no indication of other potential sources of bias in the included trials.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-12-18 13:43:43 +0000" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="3">Migraine</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">HBOT for an acute attack</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Proportion of participant with pain-free response (complete resolution of headache pain)</HEADING>
<P>No trials specifically reported on complete resolution of headache. Three trials reported the proportion of participants with resolution or significant relief of migraine with 40 to 45 minutes of HBOT (<LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>; <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>; <LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK>). These studies involved a total of 58 participants receiving 56 occasions of therapy (29 HBOT versus 27 sham). Two were of cross-over design, and in these, following initial group assignment, cross-over was undertaken at five minutes (<LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>) and 30 minutes (<LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>). Individual participant responses to each arm were not reported in <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>, nor were any cross-over effects reported in either trial. Our detailed approach to data extraction is indicated in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. There was a statistically significant increase in the proportion of participants with substantial relief of headache with HBOT (RR 6.21, 95% CI 2.41 to 16.00; I² statistic = 40%; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). We investigated the evidence of moderate heterogeneity by subgroup analysis by comparator therapy. There was no evidence of a substantially different effect when HBOT was compared to air or 100% normobaric oxygen (administered as an HBOT sham). The absolute risk difference of 0.72 between sham and HBOT suggests the number needed to treat for an additional beneficial outcome (NNTB) to achieve one extra case of relieved headache is two (95% CI 1 to 2). <LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK> compared HBOT with NBOT (administered as an HBOT sham). With subgroup analysis by comparator therapy on the grounds of clinical heterogeneity, <LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK> reported a similar magnitude of effect to the other two trials, and did not account for the heterogeneity between trials. There were no data reported for longer term outcomes.</P>
<P>The evidence for this outcome was of low quality (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Proportion of participants with headache pain reduction from moderate/severe to mild or none</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Proportion of participants with sustained relief for 24 hours</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Degree of headache relief or headache intensity</HEADING>
<P>Only <LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK> reported on this outcome (immediately following therapy), enrolling eight participants in a cross-over study of NBOT versus HBOT. The cross-over was made when the individual participant presented for treatment of a second headache. Pain intensity on a visual analogue scale of 0 (no pain) to 10 (worst pain) was significantly lower following HBOT (7.9 Standard Deviation (SD) 0.64 pre-treatment versus 3.5 SD 1.34 after treatment, P = 0.03), but not when receiving NBOT (6.5 SD 0.87 pre-treatment versus 6.3 SD 1.75, P = 0.99 after treatment).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Functional status or disability</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Pain-free response at four hours for migraine and two hours for cluster headache</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4. Proportion of participants requiring rescue medication</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5. Proportion of participants with sustained relief for 48 hours</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6. Proportion of participants with photophobia or phonophobia</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7. Proportion of participants with nausea and/or vomiting, after therapy</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">HBOT for prevention of attacks</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Frequency of attacks</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Number of days with headache in the week after therapy</HEADING>
<P>Only <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> reported on this outcome, enrolling 40 participants (20 HBOT, 20 sham). There was no statistically significant difference in the mean number of days with headaches for the first week after therapy (HBOT 3.0 SD 1.63 versus sham 2.87 SD 2.07), nor during the fourth week (HBOT 2.52 SD 1.78 versus sham 2.27 SD 1.94). P values were not given in the report.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Days lost to work</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Self-reported assessment of success</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Frequency of attacks rated by participant as 'severe'</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Quality of life</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4. Functional status or disability</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5. Headache index</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6. Proportion of participants requiring rescue medication</HEADING>
<P>Only <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> reported on this outcome, enrolling 40 participants (20 HBOT, 20 sham). There was no statistically significant reduction in the proportion of participants requiring rescue medication after being given HBO as a prophylaxis. Most participants who were followed-up required therapy at week 1, 4, and 8 after the intervention (e.g. at week 1: 18 of 19 for the HBOT group versus 12 of 15 for the sham therapy required some rescue medication; no P -values were given; RR 0.84, 95% CI 0.64 to 1.11; P = 0.23). The best case scenario for the allocation of withdrawals did not alter this finding (RR 0.94, 95% CI 0.75 to 1.19; P = 0.63); however, on a worst case scenario the risk of requiring rescue medication was significantly lower with sham (RR 0.63, 95% CI 0.44 to 0.92; P = 0.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7. Proportion of participants with nausea and vomiting after therapy</HEADING>
<P>Only <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> reported on this outcome, enrolling 40 participants (20 HBOT, 20 sham). There was no statistically significant reduction in the proportion of participants suffering nausea with or without vomiting after being given HBO as a prophylaxis. Roughly half of the participants reported nausea with or without vomiting at week 1, 4, and 8 after the intervention (e.g. at week 1: 9 of 19 for the HBOT group versus 9 of 15 for the sham therapy. No P values were given).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">NBOT for an acute attack</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Proportion of participants with pain-free response (complete resolution of headache pain)</HEADING>
<P>No trials reported this outcome</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Proportion of participants with headache pain reduction from moderate/severe to mild or none</HEADING>
<P>No trials reported this outcome</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Proportion of participants with sustained relief for 24 hours</HEADING>
<P>No trials reported this outcome</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Degree of headache relief or headache intensity</HEADING>
<P>Only <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK> reported on this outcome, enrolling 56 participants (27 HBOT, 29 sham). There was a significant reduction in the intensity of pain recorded on a VAS (0 - 100) at one hour after administration of 15 minutes of 100% oxygen at 15 litres per minute versus air on the same schedule. Mean pain intensity score in the sham group was 30 (SD 14) versus 17 (SD 14) in the NBOT group, 13 points lower in the NBOT group, 95% CI -5.5 to -20.5).</P>
<P>(<LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK> used NBOT (administered as an HBOT sham) as the comparator intervention for a trial of HBOT; see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>, above.)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Functional status or disability</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Pain-free response at four hours for migraine and two hours for cluster headache</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4. Proportion of participants requiring rescue medication</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5. Proportion of participants with sustained relief for 48 hours</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6. Proportion of participants with photophobia or phonophobia</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7. Proportion of participants with nausea and/or vomiting, after therapy</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">NBOT for prevention of attacks</HEADING>
<P>No trials studied the use of NBOT for prevention of attacks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>
<LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK> noted that "no untoward effects were reported". <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK> reported that following enrolment, two participants refused to complete therapy due to claustrophobia, one developed an upper respiratory chest infection and was withdrawn by the trial investigators and a further participant was withdrawn following a pathological chest X-ray. No other trials made any reference to adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cluster headache</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">HBOT for an acute attack</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Proportion of participant with pain-free response (complete resolution of headache pain)</HEADING>
<P>Only one small trial reported on the use of HBOT to relieve cluster headache (<LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK>). This trial enrolled 13 participants and reported the proportion achieving complete resolution within 20 minutes (six of seven (86%) with HBOT versus none of six with sham). No measure of statistical significance was given in the report.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Proportion of participants with headache pain reduction from moderate/severe to mild or none</HEADING>
<P>No trials reported this outcome</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Proportion of participants with sustained relief for 24 hours</HEADING>
<P>No trials reported this outcome</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Degree of headache relief or headache intensity</HEADING>
<P>No trial reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Functional status or disability.</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Pain-free response at four hours for migraine and two hours for cluster headache</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4. Proportion of participants requiring rescue medication</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5. Proportion of participants with sustained relief for 48 hours</HEADING>
<P>Only one small trial reported on this outcome following HBOT (<LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK>). This trial enrolled 13 participants and reported the proportion achieving sustained resolution for at least 48 hours (six of seven (86%) with HBOT versus none of six with sham). No measure of statistical significance was given in the report.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">HBOT for prevention of attacks</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Frequency of attacks</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Number of days with headache in the week after therapy</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Days lost to work.</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Self-reported assessment of treatment success</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Frequency of attacks rated by participant as 'severe'</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Quality of life</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4. Functional status or disability</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5. Headache index</HEADING>
<P>One trial reported on this outcome and enrolled 16 participants in a cross-over design comparing HBOT with a sham therapy (<LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK>). Twelve participants were defined as having episodic cluster headaches, while four were classified as having chronic cluster headache. Each headache was scored on a scale of 0 to 4 and the headache index (HI) was defined over a week as the sum of the number of headaches multiplied by severity on each occasion (for example, a week with two headaches scoring 3 and one headache scoring 4 would have a headache index of (2 x 3) + (1 x 4) = 10). Treatment was regarded as effective if the HI was reduced by 50% or more in the week following therapy compared to the week before therapy. Individual participant responses to each therapy were not reported. Overall, treatment was effective in five of 14 participants (36%) receiving HBOT versus six of 16 (38%) receiving sham. There was no advantage for sham or HBOT.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6. Proportion of participants requiring rescue medication</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">NBOT for an acute attack</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Proportion of participant with pain-free response (complete resolution of headache pain)</HEADING>
<P>Three cross-over trials reported the proportion of participants responding to the administration of NBOT versus control (<LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>; <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK>; <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>). <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> used a control of subcutaneous ergotamine tartrate and defined successful response to treatment as "complete or almost complete reduction of pain in seven of ten attacks, within 15 minutes", while <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK> and <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK> compared NBOT to air. <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK> reported the mean relief score (0 = no relief to 3 = complete relief) obtained from between one and 10 episodes of treatment with each of NBOT and air. <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK> reported the number of attacks that were successfully treated and enrolled 109 participants of whom 76 were analysed for a total of 298 cluster episodes. These trials together enrolled a total of 178 participants, with <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> enrolling 50 and <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK> enrolling 19. <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK> reported individual participant responses and an overall mean response, while <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> reported the proportion of participants and <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK> the proportion of attacks responding to treatment. Given the clear clinical and reporting heterogeneity we did not pool the results.</P>
<P>The two trials using air as the comparator reported a better outcome following NBOT versus control. <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK> reported a statistically significant difference in the proportion of attacks successfully treated with oxygen. Of 150 attacks, 117 were successfully treated with NBOT (78%, 95% CI 71% to 85%) versus 30 of 148 attacks treated with NBOT (20%, 95% CI 17% to 24%). <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK> reported a significantly increased chance of benefit from NBOT. Three participants did not have any headaches treated with NBOT, while five different individuals did not have any headaches treated with air. Nine of 16 participants (56%) versus one of 14 (7%) reported complete relief or significant reduction in headache intensity (defined as a mean relief score of &#8805; 2, that is, where the mean score was at least rated as 'significant relief') and this result suggests an NNT of 2 (95% CI 1 to 5) to obtain this outcome with NBOT. <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> reported a successful response in 41 of 50 participants with NBOT (82%) versus 35 of 50 participants with ergotamine (70%), but this difference was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Proportion of participants with headache pain reduction from moderate/severe to mild or none</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Proportion of participants with sustained relief for 24 hours</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1. Degree of headache relief or headache intensity</HEADING>
<P>One trial reported the pain intensity score following treatment with NBOT versus sham (air) and enrolled 19 participants in a cross-over design where 16 received NBOT and 14 sham (<LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK>). Relief was measured on a scale of 0 (no relief) to 3 (complete relief). After NBOT administration, participants rated their degree of relief at 1.93 Standard Error (SE) 0.22 and after air at 0.77, SE 0.23, and this was reported as statistically significant (P &lt; 0.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Functional status or disability</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Pain-free response at four hours for migraine and two hours for cluster headache</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4. Proportion of participants requiring rescue medication</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5. Proportion of participants with sustained relief for 48 hours</HEADING>
<P>No trials reported this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">NBOT for prevention of attacks</HEADING>
<P>No trials studied the use of NBOT for prevention of attacks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>
<LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK> reported that no adverse reactions were noted in any participant while <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK> reported there were no serious adverse events related to the treatments. Two participants reported an empty cylinder before completing the trial gas administration. No other trial made any reference to adverse events.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-12-18 13:20:58 +0000" MODIFIED_BY="Anna Hobson">
<SUMMARY_OF_RESULTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Since the last version of this review, <LINK REF="REF-Bennett-2008" TYPE="REFERENCE">Bennett 2008</LINK>, two new included studies have provided additional information to change the conclusions of this review. In this review update we included data from 11 trials in total and believe these represent all RCTs in this area, both published and unpublished. We found some evidence using pooled data from three trials that the administration of HBOT can substantially relieve an acute migraine attack (<LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>; <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>; <LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK>). This analysis suggests more than 70% of participants obtained relief within about 40 minutes, with a NNT = 2 (95% CI 1 to 2) compared to a sham therapy. We have presented our pooled estimate in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>. One trial showed no evidence to suggest that HBOT could prevent migraine episodes, reduce the incidence of nausea and vomiting, or reduce the requirement for rescue medication (<LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK>). Only one very small cross-over trial reported pain intensity following HBOT (<LINK REF="STD-Wilson-1998" TYPE="STUDY">Wilson 1998</LINK>). While this trial reported a significant reduction in pain intensity in the HBOT group but not in the NBOT group, there was no statistically significant reduction in intensity when directly comparing HBOT and NBOT.</P>
<P>Only a single trial investigated HBOT use for the termination of cluster headache, and this very small trial (13 participants) was underpowered to reliably demonstrate even a large difference between groups (<LINK REF="STD-Di-Sabato-1993" TYPE="STUDY">Di Sabato 1993</LINK>). Eleven of 13 participants in the HBOT group obtained relief versus none of the same 13 when they received sham therapy; all of these participants were reported as remaining free of headache for at least 48 hours. There was some evidence that NBOT may also terminate acute cluster headache. <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK> reported 78% of cluster headaches were terminated with HBOT versus 20% with air, and this supported the findings of <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK> (more than 50% of participants achieved relief from headache within 15 minutes). <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK> demonstrated no benefit from NBOT when compared to the administration of ergotamine tartrate. However, combining the NBOT arms of each of these studies suggests that a high proportion of cluster headaches will respond to NBOT (50 of 66 participants). We could not pool these trials because of clinical heterogeneity, specifically because comparators and outcomes measured differed between trials. There was no evidence from a single trial that HBOT can prevent cluster headaches (<LINK REF="STD-Nilsson-Remahl-2002" TYPE="STUDY">Nilsson Remahl 2002</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>While we can have some confidence that HBOT will terminate a migraine headache in many people, and similarly that NBOT can terminate a cluster headache, there is little evidence in answer to our other clinical questions. In particular, there is no indication based on the sparse evidence available that either HBOT or NBOT can prevent headaches of either type, and very little evidence that HBOT has any added value over NBOT for cluster headache.</P>
<P>Data from the included trials suggest both potential treatments are relatively safe. Only two trials specifically mentioned adverse events (<LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>; <LINK REF="STD-Eftedal-2004" TYPE="STUDY">Eftedal 2004</LINK>). There were two reported cases of claustrophobia in the former, while two participants ran out of trial gas in the other. Otherwise no complications directly related to HBOT or NBOT were noted.</P>
<P>HBOT is regarded as a relatively benign intervention. There are few major adverse events (pulmonary barotrauma, drug reactions, injuries, or death related to chamber fire). There are a number of more minor complications that may commonly occur. Visual disturbance, usually a reversible reduction in visual acuity secondary to conformational changes in the lens, is very commonly reported; perhaps as many as 50% of those having a course of 30 treatments (<LINK REF="REF-Khan-2003" TYPE="REFERENCE">Khan 2003</LINK>). This is unlikely to be a problem after the single exposures used in most of these included trials. The second most common adverse effect associated with HBOT is barotrauma. Barotrauma can affect any air-filled cavity in the body (including the middle ear, lungs, and respiratory sinuses) and occurs as a direct result of compression. Aural barotrauma is by far the most common as the middle ear air space is small, largely surrounded by bone and the sensitive tympanic membrane, and usually requires active effort by the patient in order to inflate the middle ear through the eustachian tube on each side. Barotrauma is thus not a consequence of HBOT directly, but rather of the physical conditions required to administer it. Most episodes of barotrauma are mild, easily treated, or recover spontaneously and do not require the therapy to be abandoned. While HBOT administration may be an effective means for terminating migraine, there are problems of both cost and availability in applying this therapy in routine clinical practice. For safe administration, HBOT requires relatively sophisticated equipment, and for this reason is generally available only in specialist units whether free-standing or hospital based. Many migraineurs would not have easy access to such facilities. While the cost of hyperbaric therapy varies greatly around the world, one facility in Australia has recently estimated the cost of a single session of treatment for an uncomplicated patient at AUD 304.00 (<LINK REF="REF-Gomez_x002d_Castillo-2005" TYPE="REFERENCE">Gomez-Castillo 2005</LINK>). This is unlikely to be cost-effective compared to established therapeutic options. HBOT may be a useful option for patients who are refractory to other medications; however, this subgroup of patients has not been selected for study and the efficacy of HBOT in these patients is unknown.</P>
<P>NBOT has been widely recommended for the treatment of cluster headache since <LINK REF="REF-Horton-1956" TYPE="REFERENCE">Horton 1956</LINK>. It is generally accepted that about 70% of patients will receive significant relief, based on the small studies of <LINK REF="STD-Fogan-1985" TYPE="STUDY">Fogan 1985</LINK>, <LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>, and the larger study from <LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>.</P>
<P>We planned to perform subgroup analyses with respect to the dose of oxygen received (HBOT versus NBOT), session time, and length of treatment course. This was only appropriate with respect to oxygen dose in the relief of migraine. In that analysis, HBOT appeared equally effective when compared to either air or NBOT.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-12-18 13:20:58 +0000" MODIFIED_BY="Anna Hobson">
<P>We rated the quality of the evidence as low for HBOT for the relief of acute migraine (<LINK REF="REF-GRADEPro-GDT-2015" TYPE="REFERENCE">GRADEPro GDT 2015</LINK>). Generally we assessed the methodological quality of the 11 included trials as moderate to low. Randomisation was poorly described in all but three included trials and none appear to have been based on sound sample size calculations for expected differences. One trial did not attempt to blind participants to therapy (<LINK REF="STD-Kudrow-1981" TYPE="STUDY">Kudrow 1981</LINK>). Other problems were the failure to clearly report on primary outcomes in many of the trials, poor reporting of means and standard deviations, and the variable methods used to report similar outcomes. The results of this review must therefore be interpreted with great caution.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Six trials evaluated HBOT for the termination of an acute migraine attack (161 migraine participants), two trials evaluated HBOT for cluster headache, and three evaluated NBOT for cluster headache (202 cluster headache patients). While we have made every effort to locate further unpublished data, it remains possible this review is subject to a positive publication bias, with generally favourable trials more likely to achieve publication.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>There are few recent reviews of oxygen therapy for migraine headache. In a review concentrating on potential mechanisms of action, <LINK REF="REF-Taylor-2011" TYPE="REFERENCE">Taylor 2011</LINK> discussed the use of HBOT for both migraine and cluster headaches, but did not make therapeutic recommendations. In agreement with our review, <LINK REF="REF-Holland-2012" TYPE="REFERENCE">Holland 2012</LINK> considered the prevention of migraine and concluded there was insufficient evidence to justify the use of HBOT for this purpose. For cluster headache, a recent review recommends both sumatriptan and oxygen to abort ongoing headaches and suggest the evidence available to support their use is good (Class I) (<LINK REF="STD-Leone-2010" TYPE="STUDY">Leone 2010</LINK>). </P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<IMPLICATIONS_PRACTICE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>While there is some evidence that HBOT may effectively terminate migraine headache in a general population of migraineurs, the practical problems involved in delivery of therapy suggest that HBOT should be reserved for those migraineurs resistant to standard pharmacological therapies. There is, however, insufficient evidence of the efficacy of HBOT in this subgroup of patients to support the use of HBOT for this purpose. The use of HBOT as a prophylactic therapy for migraine is not supported by the evidence. While one small trial supports the practice of administering NBOT to patients with acute migrainous headache, further evidence is required to support the use of NBOT for this purpose.</P>
<P>There is insufficient evidence from good quality RCTs to establish the effects of HBOT on cluster headache as a treatment for an acute episode or as a prophylaxis against future clusters. Three RCTs suggest that the administration of NBOT to treat acute cluster headache is likely to be effective in more than 70% of cases, and given the safety and ease of administration of NBOT, NBOT use is likely to continue. There is no evidence to support NBOT use as a prophylactic measure.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Given the findings of this review update, there is a case for further investigation of HBOT as a possible therapy for acute migraine and cluster headache resistant to standard therapies. There is also a case for confirming the apparent effectiveness of NBOT for cluster headache in a study with sufficient power to produce valid conclusions. Any further investigations would need to be carefully justified. The effect of differing oxygen dosage and of other therapies administered simultaneously is not known. Any future trials would need to consider in particular:</P>
<UL>
<LI>Appropriate sample sizes with power to detect expected differences;</LI>
<LI>Careful definition and selection of target patients;</LI>
<LI>Appropriate range of oxygen doses per treatment session (pressure and time);</LI>
<LI>Appropriate and carefully defined comparator therapy;</LI>
<LI>Use of an effective sham therapy;</LI>
<LI>Effective and explicit blinding of outcome assessors;</LI>
<LI>Appropriate outcome measures including all those listed in this review;</LI>
<LI>Careful elucidation of any adverse events;</LI>
<LI>The cost-utility of the therapy;</LI>
<LI>Appropriate and full reporting.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>We acknowledge the support and suggestions of the Cochrane Pain, Palliative and Supportive Care review group (PaPaS), particularly Frances Fairman, Becky Gray, and Doug McCrory (PaPaS staff), and Drs Claude Piantadosi and Peer Tfelt-Hansen (peer reviewers) for their assistance in the preparation of the original review (<LINK REF="REF-Bennett-2005" TYPE="REFERENCE">Bennett 2005</LINK>). We gratefully received the suggestions of Sheena Derry (Pain Research, University of Oxford) in preparing this review update.</P>
<P>Funding: The authors have received no funding for this review.</P>
<P>Cochrane Review Group funding acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane PaPaS Group. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, National Health Service (NHS) or the Department of Health.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Michael Bennett has no relevant conflict of interest to declare.<BR/>Christopher French has no relevant conflict of interest to declare.<BR/>Alexander Schnabel has no relevant conflict of interest to declare.<BR/>Jason Wasiak has no relevant conflict of interest to declare.<BR/>Peter Kranke has no relevant conflict of interest to declare.<BR/>Stephanie Weibel has no relevant conflict of interest to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-12-18 13:33:59 +0000" MODIFIED_BY="Anna Hobson">
<P>MB conceived and coordinated this review, wrote to authors of papers for additional information, provided additional data about articles, and entered data into <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>.<BR/>MB and AS performed manual literature searches.<BR/>MB and JW screened the search results.<BR/>MB and AS organized retrieval of papers.<BR/>MB, AS, and CF screened retrieved papers against inclusion criteria.<BR/>MB and SW extracted data from articles, appraised the quality of included trials, performed data management, and performed double-entry of data in this review update; MB and AS did so for <LINK REF="REF-Bennett-2008" TYPE="REFERENCE">Bennett 2008</LINK>.<BR/>MB and AS obtained and screened data on unpublished studies. MB and AS performed statistical analyses using <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>.<BR/>MB performed statistical inferences and other statistical analysis not using <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>.<BR/>MB, AS, PK, and SW interpreted data.<BR/>AS and MB wrote the review.<BR/>NR secured funding for the review.<BR/>MB and PK performed previous work that was the foundation of this review update.<BR/>MB is guarantor for this review.<BR/>CF, JW, and PK were responsible for reading and checking this review before submission.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-12-18 13:37:08 +0000" MODIFIED_BY="Anna Hobson">
<P>For this 2015 update, we added an author (SW) and two new trials (<LINK REF="STD-Cohen-2009" TYPE="STUDY">Cohen 2009</LINK>; <LINK REF="STD-Ozkurt-2012" TYPE="STUDY">Ozkurt 2012</LINK>). We have also amended the title from 'Normobaric and hyperbaric oxygen therapy for migraine and cluster headache' to 'Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache' for clarity.</P>
<P>We have formulated a <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and estimated the quality of the evidence using the GRADE Pro Guideline Development Tool software and methodology (<LINK REF="REF-GRADEPro-GDT-2015" TYPE="REFERENCE">GRADEPro GDT 2015</LINK>) .</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2016-01-04 10:18:51 +0000" MODIFIED_BY="Anna Hobson">
<P>The authors and editors have agreed that this review will be assessed for further updating in 2020. It is unlikely that new evidence will be published that has the potential to change the conclusions.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<STUDIES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<INCLUDED_STUDIES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2009" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Cohen 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen AS, Burns B, Goadsby PJ</AU>
<TI>High-flow oxygen for treatment of cluster headache: a randomized trial</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>302</VL>
<NO>22</NO>
<PG>2451-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Sabato-1993" MODIFIED="2015-11-05 12:34:47 +0000" MODIFIED_BY="[Empty name]" NAME="Di Sabato 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-11-05 12:34:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Sabato F, Fusco BM, Pelaia P, Giacovazzo M</AU>
<TI>Hyperbaric oxygen therapy in cluster headache</TI>
<SO>Pain</SO>
<YR>1993</YR>
<VL>52</VL>
<NO>2</NO>
<PG>243-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eftedal-2004" MODIFIED="2015-11-05 12:35:14 +0000" MODIFIED_BY="[Empty name]" NAME="Eftedal 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-11-05 12:35:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eftedal OS, Lydersen S, Helde G, White L, Brubakk AO, Stovner LJ</AU>
<TI>A randomised, double blind study of the prophylactic effect of hyperbaric oxygen therapy on migraine</TI>
<SO>Cephalalgia</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>8</NO>
<PG>639-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fife-1992" MODIFIED="2015-11-05 12:35:40 +0000" MODIFIED_BY="[Empty name]" NAME="Fife 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-11-05 12:35:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fife CE, Meyer JS, Berry JM, Sutton TE</AU>
<TI>Hyperbaric oxygen and acute migraine pain: preliminary results of a randomised blinded trial</TI>
<SO>Undersea Biomedical Research</SO>
<YR>1992</YR>
<VL>19</VL>
<PG>106-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fogan-1985" MODIFIED="2015-11-05 12:37:08 +0000" MODIFIED_BY="[Empty name]" NAME="Fogan 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-11-05 12:37:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fogan L</AU>
<TI>Treatment of cluster headache. A double-blind comparison of oxygen v air inhalation</TI>
<SO>Archives of Neurology</SO>
<YR>1985</YR>
<VL>42</VL>
<NO>4</NO>
<PG>362-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1992" MODIFIED="2015-11-05 12:37:32 +0000" MODIFIED_BY="[Empty name]" NAME="Hill 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-11-05 12:37:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill RK</AU>
<TI>A blinded, crossover controlled study of the use of hyperbaric oxygen in the treatment of migraine headache</TI>
<SO>Undersea Biomedical Research</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>S</NO>
<PG>106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kudrow-1981" MODIFIED="2015-11-05 12:38:03 +0000" MODIFIED_BY="[Empty name]" NAME="Kudrow 1981" YEAR="1981">
<REFERENCE MODIFIED="2015-11-05 12:38:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kudrow L</AU>
<TI>Response of cluster headache attacks to oxygen inhalation</TI>
<SO>Headache</SO>
<YR>1981</YR>
<VL>21</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myers-1995" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Myers 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myers DE, Myers RA</AU>
<TI>A preliminary report on hyperbaric oxygen in the relief of migraine headache</TI>
<SO>Headache</SO>
<YR>1995</YR>
<VL>35</VL>
<NO>4</NO>
<PG>197-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-Remahl-2002" MODIFIED="2015-11-05 12:38:51 +0000" MODIFIED_BY="[Empty name]" NAME="Nilsson Remahl 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-11-05 12:38:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson Remahl AI, Ansjon R, Lind F, Waldenlind E</AU>
<TI>Hyperbaric oxygen treatment of active cluster headache: a double-blind placebo-controlled cross-over study</TI>
<SO>Cephalalgia</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>9</NO>
<PG>730-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozkurt-2012" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Ozkurt 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ozkurt B, Cinar O, Cevik E, Acar AY, Arslan D, Eyi EY, et al</AU>
<TI>Efficacy of high-flow oxygen therapy in all types of headache: A prospective, randomized, placebo-controlled trial</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2011</YR>
<VL>1</VL>
<PG>S184</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ozkurt B, Cinar O, Cevik E, Acar AY, Arslan D, Eyi EY, et al</AU>
<TI>Efficacy of high-flow oxygen therapy in all types of headache: a prospective, randomized, placebo-controlled trial</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>2012</YR>
<VL>30</VL>
<NO>9</NO>
<PG>1760-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1998" MODIFIED="2015-11-05 12:40:45 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-11-05 12:40:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson JR, Foresman GH, Gamber RG, Wright T</AU>
<TI>Hyperbaric oxygen in the treatment of migraine with aura</TI>
<SO>Headache</SO>
<YR>1998</YR>
<VL>38</VL>
<NO>2</NO>
<PG>112-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<STUDY DATA_SOURCE="PUB" ID="STD-Capobianco-2006" MODIFIED="2015-11-05 13:15:41 +0000" MODIFIED_BY="[Empty name]" NAME="Capobianco 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-11-05 13:15:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capobianco DJ, Dodick DW</AU>
<TI>Diagnosis and treatment of cluster headache</TI>
<SO>Seminars in Neurology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>2</NO>
<PG>242-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-2010" MODIFIED="2015-11-05 13:23:32 +0000" MODIFIED_BY="[Empty name]" NAME="Chu 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-11-05 13:23:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu J, Singh J</AU>
<TI>Relief from cluster headaches</TI>
<SO>American Journal of Nursing</SO>
<YR>2010</YR>
<VL>110</VL>
<NO>6</NO>
<PG>63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Sabato-1996" MODIFIED="2015-11-05 13:18:31 +0000" MODIFIED_BY="[Empty name]" NAME="Di Sabato 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-11-05 13:18:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Sabato F, Giacovazzo M, Cristalli G, Rocco M, Fusco BM</AU>
<TI>Effect of hyperbaric oxygen on the immunoreactivity to substance P in the nasal mucosa of cluster headache patients</TI>
<SO>Headache</SO>
<YR>1996</YR>
<VL>36</VL>
<NO>4</NO>
<PG>221-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Sabato-1997" MODIFIED="2015-11-05 13:18:54 +0000" MODIFIED_BY="[Empty name]" NAME="Di Sabato 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-11-05 13:18:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Sabato F, Rocco M, Martelletti P, Giacovazzo M</AU>
<TI>Hyperbaric oxygen in chronic cluster headaches: influence on serotonergic pathways</TI>
<SO>Undersea &amp; Hyperbaric Medicine</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>2</NO>
<PG>117-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drummond-1985" MODIFIED="2015-11-05 13:20:55 +0000" MODIFIED_BY="[Empty name]" NAME="Drummond 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-11-05 13:20:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drummond PD, Anthony M</AU>
<TI>Extracranial vascular responses to sublingual nitroglycerine and oxygen inhalation in cluster headache patients</TI>
<SO>Headache</SO>
<YR>1985</YR>
<VL>25</VL>
<NO>2</NO>
<PG>70-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ekbom-2004" MODIFIED="2015-11-05 13:21:17 +0000" MODIFIED_BY="[Empty name]" NAME="Ekbom 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-11-05 13:21:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ekbom K, Waldenlind E</AU>
<TI>Cluster headache: the history of the Cluster Club and a review of recent clinical research</TI>
<SO>Functional Neurology</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>2</NO>
<PG>73-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evers-1996" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Evers 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evers S, Husstedt IW</AU>
<TI>Alternatives in drug treatment of chronic paroxysmal hemicrania</TI>
<SO>Headache</SO>
<YR>1996</YR>
<VL>36</VL>
<NO>7</NO>
<PG>429-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fife-1989" MODIFIED="2015-11-05 13:22:06 +0000" MODIFIED_BY="[Empty name]" NAME="Fife 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-11-05 13:22:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fife WP, Fife CE</AU>
<TI>Treatment of migraine with hyperbaric oxygen</TI>
<SO>Journal of Hyperbaric Medicine</SO>
<YR>1989</YR>
<VL>4</VL>
<PG>7-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fife-1991" MODIFIED="2015-11-05 13:23:06 +0000" MODIFIED_BY="[Empty name]" NAME="Fife 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-11-05 13:23:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fife CE, Meyer JS</AU>
<TI>Hyperbaric oxygen treatment of acute migraine headache</TI>
<SO>Headache Quarterly</SO>
<YR>1991</YR>
<VL>2</VL>
<NO>4</NO>
<PG>301-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francis-2010" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Francis 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francis GJ, Becker WJ, Pringsheim TM</AU>
<TI>Acute and preventive pharmacologic treatment of cluster headache</TI>
<SO>Neurology</SO>
<YR>2010</YR>
<VL>75</VL>
<NO>5</NO>
<PG>463-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-2003" MODIFIED="2015-11-05 13:24:58 +0000" MODIFIED_BY="[Empty name]" NAME="Green 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-11-05 13:24:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green MW</AU>
<TI>The emergency management of headaches</TI>
<SO>Neurologist</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>2</NO>
<PG>93-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leone-2010" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Leone 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leone M,  Franzini A, Proietti Cecchini A, Mea E, Broggi G, Bussone G</AU>
<TI>Management of chronic cluster headache</TI>
<SO>Current Treatment Options in Neurology</SO>
<YR>2011</YR>
<VL>13</VL>
<NO>1</NO>
<PG>56-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendizabal-1998" MODIFIED="2015-11-05 13:26:14 +0000" MODIFIED_BY="[Empty name]" NAME="Mendizabal 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-11-05 13:26:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendizabal JE, Umana E, Zweifler RM</AU>
<TI>Cluster headache: Horton's cephalalgia revisited</TI>
<SO>Southern Medical Journal</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>7</NO>
<PG>606-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-Remahl-2003" MODIFIED="2015-11-05 13:26:40 +0000" MODIFIED_BY="[Empty name]" NAME="Nilsson Remahl 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-11-05 13:26:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson Rehmal AI, Laudon Meyer E, Cordonnier C, Goadsby PJ</AU>
<TI>Placebo response in cluster headache trials: a review</TI>
<SO>Cephalalgia</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>7</NO>
<PG>504-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 0800-1952"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nwosu-2005" MODIFIED="2015-11-05 13:27:15 +0000" MODIFIED_BY="[Empty name]" NAME="Nwosu 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-11-05 13:27:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nwosu IA, Khan AA</AU>
<TI>Hyperbaric oxygen therapy in primary headache: a research review</TI>
<SO>Biomedical Research</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>3</NO>
<PG>143-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pascual-1995" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Pascual 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pascual J, Peralta G, Sánchez U</AU>
<TI>Preventive effects of hyperbaric oxygen in cluster headache</TI>
<SO>Headache</SO>
<YR>1995</YR>
<VL>35</VL>
<NO>5</NO>
<PG>260-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rozen-2004" MODIFIED="2015-11-05 13:27:57 +0000" MODIFIED_BY="[Empty name]" NAME="Rozen 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-11-05 13:27:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rozen TD</AU>
<TI>High oxygen flow rates for cluster headache</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>3</NO>
<PG>593</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rozen-2005" MODIFIED="2015-11-05 13:28:22 +0000" MODIFIED_BY="[Empty name]" NAME="Rozen 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-11-05 13:28:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rozen TD</AU>
<TI>Cluster headache: diagnosis and treatment</TI>
<SO>Current Pain &amp; Headache Reports</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>2</NO>
<PG>135-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN 1531-3433"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-10-30 02:06:00 +0000" MODIFIED_BY="Michael H Bennett"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<ADDITIONAL_REFERENCES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<REFERENCE ID="REF-AHC-1962" MODIFIED="2015-11-05 13:30:40 +0000" MODIFIED_BY="[Empty name]" NAME="AHC 1962" TYPE="JOURNAL_ARTICLE">
<AU>Ad Hoc Committee on the Classification of Headache of the National Institute of Neurological Diseases and Blindness</AU>
<TI>Classification of headache</TI>
<SO>JAMA</SO>
<YR>1962</YR>
<VL>179</VL>
<NO>9</NO>
<PG>717-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alvarez-1939" MODIFIED="2015-11-05 13:31:51 +0000" MODIFIED_BY="[Empty name]" NAME="Alvarez 1939" TYPE="JOURNAL_ARTICLE">
<AU>Alvarez WC</AU>
<TI>The new oxygen treatment for migraine</TI>
<SO>American Journal of Digestive Diseases</SO>
<YR>1939</YR>
<VL>6</VL>
<PG>728</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bateman-1993" MODIFIED="2015-11-05 13:32:25 +0000" MODIFIED_BY="[Empty name]" NAME="Bateman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bateman DN</AU>
<TI>Sumatriptan</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8839</NO>
<PG>221-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8093509"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bennett-2004" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Bennett 2004" TYPE="OTHER">
<AU>Bennett M, Connor D</AU>
<TI>The Database of Randomised Controlled Trials in Hyperbaric Medicine (updated monthly)</TI>
<SO>http://hboevidence.unsw.wikispaces.net/</SO>
<YR>(accessed 4th December 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burton-2002" MODIFIED="2015-11-05 13:33:40 +0000" MODIFIED_BY="[Empty name]" NAME="Burton 2002" TYPE="JOURNAL_ARTICLE">
<AU>Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW</AU>
<TI>The economic burden of lost productivity due to migraine headache: a specific worksite analysis</TI>
<SO>Journal of Occupational and Environmental Medicine</SO>
<YR>2002</YR>
<VL>44</VL>
<NO>6</NO>
<PG>523-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1076-2752"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clark-2003" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Clark 2003" TYPE="BOOK_SECTION">
<AU>Clark JM, Thom SR</AU>
<TI>Oxygen under pressure</TI>
<SO>Bennett and Elliott's Physiology and Medicine of Diving</SO>
<YR>2003</YR>
<PG>358-418</PG>
<EN>5th</EN>
<ED>Brubakk AO, Neuman TS</ED>
<PB>Saunders</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002" MODIFIED="2015-11-05 13:34:29 +0000" MODIFIED_BY="[Empty name]" NAME="Curtin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Elbourne D, Altman DG</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>15</NO>
<PG>2145-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2015-11-05 13:35:03 +0000" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ekbom-1993" MODIFIED="2015-11-05 13:35:48 +0000" MODIFIED_BY="[Empty name]" NAME="Ekbom 1993" TYPE="JOURNAL_ARTICLE">
<AU>Ekbom K, Monstad I, Prusinski A, Cole JA, Pilgrim AJ, Noronha D</AU>
<TI>Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1993</YR>
<VL>88</VL>
<NO>1</NO>
<PG>63-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8396833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fife-1994" MODIFIED="2015-11-05 13:36:16 +0000" MODIFIED_BY="[Empty name]" NAME="Fife 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fife CE, Powell MG, Sutton TE, Meyer JS</AU>
<TI>Transcranial doppler evaluation of the middle cerebral artery from 1ATA to 3ATA PO2</TI>
<SO>Undersea and Hyperbaric Medicine</SO>
<YR>1994</YR>
<VL>21 Suppl</VL>
<PG>77</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="10662936"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gaul-2011" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Gaul 2011" TYPE="JOURNAL_ARTICLE">
<AU>Gaul C, Finken J, Biermann, J, Mostardt S, Diener HC, Müller O, et al</AU>
<TI>Treatment costs and indirect costs of cluster headache: A health economics analysis</TI>
<SO>Cephalalgia</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>16</NO>
<PG>1664-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goadsby-1997" NAME="Goadsby 1997" TYPE="JOURNAL_ARTICLE">
<AU>Goadsby PJ</AU>
<TI>Current concepts of the pathophysiology of migraine</TI>
<SO>Neurologic Clinics</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>1</NO>
<PG>27-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97211397"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goadsby-2012" MODIFIED="2015-01-06 15:20:59 +0000" MODIFIED_BY="[Empty name]" NAME="Goadsby 2012" TYPE="JOURNAL_ARTICLE">
<AU>Goadsby PJ</AU>
<TI>Pathophysiology of migraine</TI>
<SO>Annals of Indian Academy of Neurology</SO>
<YR>2012</YR>
<VL>15</VL>
<NO>Suppl 1</NO>
<PG>S15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gomez_x002d_Castillo-2005" NAME="Gomez-Castillo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gomez-Castillo JD, Bennett MH</AU>
<TI>The cost of hyperbaric therapy at the Prince of Wales Hospital, Sydney</TI>
<SO>South Pacific Underwater Medicine Journal</SO>
<YR>2005</YR>
<VL>35</VL>
<NO>4</NO>
<PG>194-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEPro-GDT-2015" MODIFIED="2015-11-10 09:55:50 +0000" MODIFIED_BY="Anna Hobson" NAME="GRADEPro GDT 2015" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro Guideline Development Tool [Software]</TI>
<YR>2015</YR>
<PB>McMaster University, 2015 (developed by Evidence Prime, Inc.)</PB>
<MD>Available from www.gradepro.org</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00e9_raud-2004" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Géraud 2004" TYPE="JOURNAL_ARTICLE">
<AU>Géraud G, Lanteri-Minet M, Lucas C, Valade D; French Society for the Study of Migraine Headache (SFEMC)</AU>
<TI>French guidelines for the diagnosis and management of migraine in adults and children</TI>
<SO>Clinical Therapeutics</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>8</NO>
<PG>1305-18</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15476911"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Higgins 2009" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<EN>5.1.0 [updated March 2011]</EN>
<PB>The Cochrane Collaboration</PB>
<MD>Available from www.cochrane-handbook.org</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holland-2012" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Holland 2012" TYPE="JOURNAL_ARTICLE">
<AU>Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E</AU>
<TI>Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society</TI>
<SO>Neurology </SO>
<YR>2012</YR>
<VL>78</VL>
<NO>17</NO>
<PG>1346-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horton-1956" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Horton 1956" TYPE="JOURNAL_ARTICLE">
<AU>Horton BT</AU>
<TI>Histaminic cephalgia: differential diagnosis and treatment</TI>
<SO>Proceedings of the Staff Meetings. Mayo Clinic</SO>
<YR>1956</YR>
<VL>31</VL>
<NO>11</NO>
<PG>325-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hu-1999" MODIFIED="2015-11-05 13:41:21 +0000" MODIFIED_BY="[Empty name]" NAME="Hu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML</AU>
<TI>Burden of migraine in the United States: disability and economic costs</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>8</NO>
<PG>813-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10219926"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-IHS-1988" MODIFIED="2015-11-05 13:41:48 +0000" MODIFIED_BY="[Empty name]" NAME="IHS 1988" TYPE="JOURNAL_ARTICLE">
<AU>Headache Classification Committee of the International Headache Society</AU>
<TI>Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain</TI>
<SO>Cephalalgia</SO>
<YR>1988</YR>
<VL>8 Suppl 7</VL>
<PG>1-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IHS-2014" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="IHS 2014" TYPE="OTHER">
<AU>Headache Classification Subcommittee of the International Headache Society</AU>
<TI>IHS Classification ICHD-II</TI>
<SO>http://ihs-classification.org/en/</SO>
<YR>(accessed dd Month yyyy)</YR>
<PB>International Headache Society</PB>
<MD>Web site</MD>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0022-3050  0022-3050"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Iversen-1990" MODIFIED="2015-11-05 13:43:08 +0000" MODIFIED_BY="[Empty name]" NAME="Iversen 1990" TYPE="JOURNAL_ARTICLE">
<AU>Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P</AU>
<TI>Arterial responses during migraine headache</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<NO>8719</NO>
<PG>837-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jain-2009" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Jain 2009" TYPE="BOOK">
<AU>Jain KK</AU>
<SO>Textbook of Hyperbaric Medicine</SO>
<YR>2009</YR>
<EN>5th</EN>
<PB>Hogrefe &amp; Huber</PB>
<CY>Seattle</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0-88937-203-9"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khan-2003" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Khan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Khan B, Evans AW, Easterbrook M</AU>
<TI>Refractive changes in patients undergoing hyperbaric oxygen therapy: a prospective study</TI>
<SO>Undersea &amp; Hyperbaric Medicine</SO>
<YR>2003</YR>
<VL>24 Suppl</VL>
<PG>9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kindwall-2008" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Kindwall 2008" TYPE="BOOK">
<AU>Kindwall EP, Whelan HT</AU>
<SO>Hyperbaric Medicine Practice</SO>
<YR>2008</YR>
<EN>3rd</EN>
<PB>Best Publishing Company</PB>
<CY>Flagstaff, AZ</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0-941332-78-0"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Law-2013a" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Law 2013a" TYPE="COCHRANE_REVIEW">
<AU>Law S, Derry S, Moore RA</AU>
<TI>Naproxen with or without an antiemetic for acute migraine headaches in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2015-11-05 13:47:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-05 13:47:25 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD009455.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Law-2013b" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Law 2013b" TYPE="COCHRANE_REVIEW">
<AU>Law S, Derry S, Moore RA</AU>
<TI>Sumatriptan plus naproxen for acute migraine attacks in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2015-11-05 13:48:34 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-05 13:48:34 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008541.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Law-2013c" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Law 2013c" TYPE="COCHRANE_REVIEW">
<AU>Law S, Derry S, Moore RA</AU>
<TI>Triptans for acute cluster headache</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2015-11-05 13:45:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-05 13:45:55 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008042.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Linde-2013a" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Linde 2013a" TYPE="COCHRANE_REVIEW">
<AU>Linde M, Mulleners WM, Chronicle EP, McCrory DC</AU>
<TI>Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2015-11-05 14:08:10 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-05 14:08:10 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010609"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Linde-2013b" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Linde 2013b" TYPE="COCHRANE_REVIEW">
<AU>Linde M, Mulleners WM, Chronicle EP, McCrory DC</AU>
<TI>Topiramate for the prophylaxis of episodic migraine in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2015-11-05 13:49:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-05 13:49:06 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010610"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mathew-2001" MODIFIED="2015-11-05 13:51:21 +0000" MODIFIED_BY="[Empty name]" NAME="Mathew 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mathew NT</AU>
<TI>Pathophysiology, epidemiology, and impact of migraine</TI>
<SO>Clinical Cornerstone</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>3</NO>
<PG>1-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mathieu-2006" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Mathieu 2006" TYPE="BOOK">
<AU>Mathieu D</AU>
<SO>Handbook on Hyperbaric Medicine</SO>
<YR>2006</YR>
<EN>2nd</EN>
<PB>Springer</PB>
<CY>Milan</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="3-540-75016-9"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-May-2006" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="May 2006" TYPE="JOURNAL_ARTICLE">
<AU>May A, Leone M, Afra J, Linde M, Sándor PS, Evers S, et al</AU>
<TI>EFNS guidelines on the treatment of cluster headache and other trigeminal&#8208;autonomic cephalalgias</TI>
<SO>European Journal of Neurology</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>10</NO>
<PG>1066-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Munakata-2009" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Munakata 2009" TYPE="JOURNAL_ARTICLE">
<AU>Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al</AU>
<TI>Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study</TI>
<SO>Headache: The Journal of Headache and Face Pain</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>4</NO>
<PG>498-508</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nesbitt-2012" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Nesbitt 2012" TYPE="JOURNAL_ARTICLE">
<AU>Nesbitt AD, Goadsby PJ</AU>
<TI>Cluster headache</TI>
<SO>BMJ</SO>
<YR>2012</YR>
<VL>344</VL>
<PG>e2407</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osterhaus-1992" MODIFIED="2015-11-05 13:54:40 +0000" MODIFIED_BY="[Empty name]" NAME="Osterhaus 1992" TYPE="JOURNAL_ARTICLE">
<AU>Osterhaus JT, Gutterman DL, Plachetka JR</AU>
<TI>Healthcare resource and lost labour costs of migraine headache in the US</TI>
<SO>Pharmacoeconomics</SO>
<YR>1992</YR>
<VL>2</VL>
<NO>1</NO>
<PG>67-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Piane-2007" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Piane 2007" TYPE="JOURNAL_ARTICLE">
<AU>Piane M, Lulli P, Farinelli I, Simeoni S, De Filippis S, Patacchioli FR, et al</AU>
<TI>Genetics of migraine and pharmacogenomics: some considerations</TI>
<SO>The Journal of Headache and Pain </SO>
<YR>2007</YR>
<VL>8</VL>
<NO>6</NO>
<PG>334-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-01-06 15:20:59 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Russell-2004" MODIFIED="2015-11-05 13:55:43 +0000" MODIFIED_BY="[Empty name]" NAME="Russell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Russell MB</AU>
<TI>Epidemiology and genetics of cluster headache</TI>
<SO>Lancet Neurology</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>5</NO>
<PG>279-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slotman-1998" MODIFIED="2015-11-05 13:56:53 +0000" MODIFIED_BY="[Empty name]" NAME="Slotman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Slotman GJ</AU>
<TI>Hyperbaric oxygen in systemic inflammation ... HBO is not just a movie channel anymore</TI>
<SO>Critical Care Medicine</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>12</NO>
<PG>1932-3</PG>
<IDENTIFIERS MODIFIED="2015-11-05 13:56:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-05 13:56:53 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9875888"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smitherman-2013" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Smitherman 2013" TYPE="JOURNAL_ARTICLE">
<AU>Smitherman TA, Burch R, Sheikh H, Loder E</AU>
<TI>The Prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies</TI>
<SO>Headache</SO>
<YR>2013</YR>
<VL>53</VL>
<NO>3</NO>
<PG>427-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stokes-2011" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Stokes 2011" TYPE="JOURNAL_ARTICLE">
<AU>Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, et al</AU>
<TI>Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS)</TI>
<SO>Headache: The Journal of Head and Face Pain</SO>
<YR>2011</YR>
<VL>51</VL>
<NO>7</NO>
<PG>1058-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-S_x00fc_men-2001" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Sümen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sümen G, Cim&#351;it M, Eroglu L</AU>
<TI>Hyperbaric oxygen treatment reduces carrageenan-induced acute inflammation in rats</TI>
<SO>European Journal of Pharmacology</SO>
<YR>2001</YR>
<VL>431</VL>
<NO>2</NO>
<PG>265-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11728435"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2011" MODIFIED="2015-11-05 13:59:02 +0000" MODIFIED_BY="[Empty name]" NAME="Taylor 2011" TYPE="JOURNAL_ARTICLE">
<AU>Taylor FR</AU>
<TI>Nutraceuticals and headache: the biological basis</TI>
<SO>Headache: The Journal of Head and Face Pain </SO>
<YR>2011</YR>
<VL>51</VL>
<NO>3</NO>
<PG>484-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vos-2013" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Vos 2013" TYPE="JOURNAL_ARTICLE">
<AU>Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al</AU>
<TI>Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990&#8211;2010: a systematic analysis for the Global Burden of Disease Study 2010</TI>
<SO>The Lancet</SO>
<YR>2013</YR>
<VL>380</VL>
<NO>9859</NO>
<PG>2163-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiss-1989" MODIFIED="2015-11-05 14:00:32 +0000" MODIFIED_BY="[Empty name]" NAME="Weiss 1989" TYPE="JOURNAL_ARTICLE">
<AU>Weiss LD, Ramasastry SS, Eidelman BH</AU>
<TI>Treatment of a cluster headache patient in a hyperbaric chamber</TI>
<SO>Headache</SO>
<YR>1989</YR>
<VL>29</VL>
<NO>2</NO>
<PG>109-10</PG>
<IDENTIFIERS MODIFIED="2015-11-05 14:00:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-05 14:00:32 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2708039"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wider-2015" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Wider 2015" TYPE="COCHRANE_REVIEW">
<AU>Wider B, Pittler MH, Ernst E</AU>
<TI>Feverfew for preventing migraine</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-11-05 14:01:31 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-05 14:01:31 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002286"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yusa-1987" MODIFIED="2015-11-05 14:01:36 +0000" MODIFIED_BY="[Empty name]" NAME="Yusa 1987" TYPE="JOURNAL_ARTICLE">
<AU>Yusa T, Beckman JS, Crapo JD, Freeman BA</AU>
<TI>Hyperoxia increases H2O2 production by brain in vivo</TI>
<SO>Journal of Applied Physiology</SO>
<YR>1987</YR>
<VL>63</VL>
<NO>1</NO>
<PG>353-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<REFERENCE ID="REF-Bennett-2005" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Bennett 2005" TYPE="COCHRANE_REVIEW">
<AU>Bennett MH, French C, Kranke P, Schnabel A, Wasiak J</AU>
<TI>Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-11-06 12:03:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-06 12:03:17 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005219"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bennett-2008" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NAME="Bennett 2008" TYPE="COCHRANE_REVIEW">
<AU>Bennett MH, French C, Schnabel A, Wasiak J, Kranke P</AU>
<TI>Normobaric and hyperbaric oxygen therapy for migraine and cluster headache</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2015-11-05 14:05:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-11-05 14:05:07 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005219.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Cohen-2009">
<CHAR_METHODS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Blinded, crossover randomised trial of normobaric oxygen versus air (placebo) for cluster headache. Each participant was treated for a total of four headaches during the study period.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-06 15:48:47 +0000" MODIFIED_BY="[Empty name]">
<P>109 patients with a diagnosis of chronic or episodic cluster headache as defined by the International Headache Society. Excluded if previously treated with oxygen or receiving preventative medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Control: Air breathing at 12 litres per minute for 15 minutes at the start of a cluster headache attack.</P>
<P>HBOT: 100% oxygen breathing at 12 litres per minute for 15 minutes at the start of a cluster headache attack.</P>
<P>Each gas was delivered alternately for four attacks. Random allocation to which gas was used first.</P>
<P>Final follow-up at 2 months. Total reports of 76 participants having 289 attacks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-11-05 14:15:10 +0000" MODIFIED_BY="[Empty name]">
<P>Pain relief from 15 minutes to 1 hour. </P>
<P>Requirement for rescue medication. </P>
<P>Functional state and effect on associated symptoms. </P>
<P>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Paper reports outcomes per attack treated rather than per participant. We contacted trial authors forfurther information that might allow inclusion in quantitative analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Di-Sabato-1993">
<CHAR_METHODS>
<P>Acute therapy and prophylaxis trial. RCT with randomisation not described. Assessor blinded. No power calculation recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>13 patients (1 female) with a diagnosis of episodic cluster headache according to the Ad Hoc Committee on Classification of Headache 1988. Excluded if any concomitant diseases or taking prophylactic therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Control: Air breathing at 2.5 ATA for 30 minutes.</P>
<P>HBOT: 100% oxygen breathing at 2.5 ATA for 30 minutes.</P>
<P>Final follow-up at 2 months: 1005 follow-up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Duration of the attack.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-30 03:04:22 +0000" MODIFIED_BY="Michael H Bennett"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Eftedal-2004">
<CHAR_METHODS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Prophylaxis trial. RCT with blinding of participants and investigators. Randomisation method not stated. No power calculation recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Forty patients (2 females) with a diagnosis of migraine with or without aura according to the IHS classification, on 2 to 8 occasions per month for the previous 3 months. Patients excluded if any contraindication to HBOT. Six participants did not complete the study and did not contribute to the outcome (1 HBO, 5 control).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Control: Air breathing at 2 ATA for 30 minutes on three consecutive days.</P>
<P>HBOT: 100% oxygen breathing on the same schedule.</P>
<P>Final follow-up at 8 weeks after therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Hours of headache per week.<BR/>Number of days with headache per week.<BR/>Doses of attack terminating medication per week.<BR/>Blood endothelin levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-30 03:55:53 +0000" MODIFIED_BY="Michael H Bennett"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Fife-1992">
<CHAR_METHODS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Acute therapy trial. Partial cross-over RCT with blinding of participants and investigators. Participants with no relief had the choice of undergoing the second arm of the study 30 minutes after completion of the first arm assigned. Randomisation by sealed envelopes. No power calculation recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Fourteen patients (23 to 67 years, 9 females) with a diagnosis of migraine documented by neurologist evaluation. Patients excluded if narcotic users, daily headaches or any contraindication to HBOT. Six patients did not complete the study and did not contribute to the outcome.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Control: 10% oxygen breathing via Scott mask at 2 ATA for 45 minutes.</P>
<P>HBOT: 100% oxygen at 2 ATA on the same schedule.</P>
<P>If initial exposure failed, participants could opt to undertake the alternative therapy after a 30-minute break. No other follow-up recorded.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Proportion of participants with significant pain relief using a Blanchard pain inventory from 0 to 5. Significant relief defined as reduction on this scale of 2 or more points.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-30 03:55:35 +0000" MODIFIED_BY="Michael H Bennett"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Fogan-1985">
<CHAR_METHODS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Acute therapy trial. Cross-over RCT with allocation concealment and blinding of participants and investigator. Cross-over was made after six episodes were treated with the first assigned gas. Randomisation method not stated. No power calculation recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Nineteen patients (20 to 50 years, all male) with a diagnosis of cluster headache according to <LINK REF="REF-AHC-1962" TYPE="REFERENCE">AHC 1962</LINK>. No indication of any exclusions, but participants were instructed not to take prophylactic or pain relief medication. Eleven of 19 were successfully crossed to receive both gases, but the remaining 8 received only one of the gases (3 air, 5 oxygen).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Control: Air breathing from masked cylinder using a non-rebreathing face mask for 15 minutes on at least six occasions.</P>
<P>Oxygen: 100% oxygen breathing on the same schedule.</P>
<P>No follow-up after treatment period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Subjective score of pain relief after 15 minutes of oxygen breathing: 0 = no relief, 1= slight relief, 2 = substantial relief, 3 = no relief.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-30 04:08:55 +0000" MODIFIED_BY="Michael H Bennett"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Hill-1992">
<CHAR_METHODS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Acute therapy trial. Cross-over RCT with blinding of participants and investigators. Cross-over was made 5 minutes after completing the first assigned treatment. Randomisation method not stated. No power calculation recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Nineteen patients with a diagnosis of migraine according to <LINK REF="REF-AHC-1962" TYPE="REFERENCE">AHC 1962</LINK>. Migraine needed to be stable with regular headaches. Patients excluded if narcotic used to treat the headache on the occasion under study or with any contraindication to HBOT.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: Air breathing at 2.0 ATA for 45 minutes.</P>
<P>HBOT: 100% oxygen breathing on the same schedule.</P>
<P>These two periods were separated by a 5-minute air break period before the alternative arm was instituted.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Pain relief.</P>
<P>No follow-up after therapy period.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-11-07 06:05:29 +0000" MODIFIED_BY="Michael H Bennett">
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Kudrow-1981">
<CHAR_METHODS>
<P>Acute therapy trial. Cross-over RCT with randomisation not described. Cross-over was made after 10 attacks were treated in the first assigned group. No blinding employed. No power calculation recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Fifty patients (8 females) with a diagnosis of episodic (36) or chronic (14) cluster headache. No exclusion criteria recorded. No losses to follow-up.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Control: Sublingual ergotamine tartrate, three tablets allowed at intervals of 15 minutes.</P>
<P>Oxygen: 100% oxygen by mask at 7 litres per minute for 15 minutes. Ten attacks treated.</P>
<P>Final follow-up at end of therapy period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Proportion with successfully aborted attacks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-30 04:14:39 +0000" MODIFIED_BY="Michael H Bennett"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Myers-1995">
<CHAR_METHODS>
<P>Acute therapy trial. RCT with randomisation not described. Assessor blinded. No power calculation recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Twenty patients (14 female) with a diagnosis of migraine confirmed by a physician. Patients were evaluated for inclusion while experiencing an acute episode. Exclusion criteria not recorded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Control: Sham treatment breathing 100% oxygen at 1 ATA for 40 minutes.</P>
<P>HBOT: 100% oxygen breathing using a hood at 2.0 ATA.</P>
<P>Final follow-up following therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Proportion with significant headache relief measured by improvement on a six category scale from 'none' to 'most severe ever'.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-30 04:15:12 +0000" MODIFIED_BY="Michael H Bennett"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Nilsson-Remahl-2002">
<CHAR_METHODS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Acute therapy and prophylaxis trial. RCT with randomisation not described. Participant, operator and assessor blinded with cross-over. Cross-over was made 1 week after treatment with the first assigned breathing gas. No power calculation recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Sixteen patients (20 to 62 years, 3 females) with a diagnosis of episodic (12) or chronic (4) cluster headache according to IHS criteria and who had suffered at least six headaches during the previous week. Excluded if taking prophylactic therapy. Two patients had sham only and did not cross to receive HBOT.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control: Sham therapy breathing 10% oxygen for 70 minutes at 2.5 ATA for two sessions 24 hours apart. Rescue simple analgesia if required.</P>
<P>HBOT: 100% oxygen at 2.5 ATA for 70 minutes on the same schedule as control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Headache index improved by more than 50%. (HI = sum of (number of attacks multiplied by degree of severity)). Severity measured on a scale of 0 (no headache) to 4 (very severe headache).<BR/>Jugular venous plasma calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP), and neuropeptide Y (NPY)</P>
<P>Final follow-up 1 week after therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-30 04:19:05 +0000" MODIFIED_BY="Michael H Bennett"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Ozkurt-2012">
<CHAR_METHODS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Acute therapy trial enrolled all primary headache patients. Migraine headaches reported separately. RCT with blinding of participants and investigators. Randomisation by computer generated numbers.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-13 08:35:10 +0100" MODIFIED_BY="Michael H Bennett">
<P>56 adult migraineurs presenting to an emergency department for the treatment of acute migraine.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-03 06:45:57 +0000" MODIFIED_BY="Michael H Bennett">
<P>100% NBOT using 15 litres per minute flow through non-rebreather mask for 15 minutes. Sham the same using air.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Reduction of pain intensity using a VAS (0 to 100) up to one hour after administration.</P>
<P>Rescue analgesia.</P>
<P>Emergency Department length of stay.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>A total of 204 participants enrolled with mixed headache aetiology. One cluster headache in each group was not reported separately. Communication with editor did not provide further data concerning the migraine participants. Outcome only available for VAS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Wilson-1998">
<CHAR_METHODS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Acute therapy trial. Cross-over RCT with blinding of participants and investigators. Randomisation method not stated. Cross-over was done when presenting for treatment of the second migraine after initial entry into trial. No power calculation recorded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Eight female patients (mean age 38.8) with a diagnosis of migraine with aura confirmed by a neurologist at 18 months prior to entry into the study. Migraine needed to be stable with regular headaches. Patients excluded if severe migraine lasting longer than 4 days, fewer than two attacks per month, if fully responsive to standard therapy, with existing neurological deficit or with any contraindication to HBOT. Six participants did not complete the study and did not contribute to the outcome.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Control: Sham hyperbaric therapy using brief compressions to 0.1 ATA to simulate descent, then 1.1 ATA 100% oxygen until pain cessation plus 20 minutes or 60 minutes.</P>
<P>HBOT: 100% oxygen inhalation in a monoplace chamber at 2.4 ATA to pain cessation plus 20 minutes or a maximum of 60 minutes.</P>
<P>Final follow-up at end of second treatment session.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Headache severity on a VAS 0 = no headache, 10 = intolerable headache.<BR/>Pericranial tenderness on palpation.<BR/>Algometry using a dolorimeter at points of pericranial tenderness.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-30 04:28:36 +0000" MODIFIED_BY="Michael H Bennett"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ATA: atmospheres absolute; CGRP: calcitonin gene-related peptide; HBOT: hyperbaric oxygen therapy; HI: headache index; IHS: International Headache Society; NPY: neuropeptide Y; RCT: randomised controlled trial; VAS: visual analogue scale; VIP: vasoactive intestinal peptide.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Capobianco-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Chu-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Third party report of included trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Di-Sabato-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Non-randomised comparative trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Di-Sabato-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Non-randomised comparative trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Drummond-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Non-randomised comparative trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Ekbom-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Evers-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Non-randomised comparative trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Fife-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Fife-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Francis-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Green-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Leone-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Mendizabal-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Nilsson-Remahl-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Nwosu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Pascual-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Rozen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Rozen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<P>Review - no new data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-10-30 02:06:00 +0000" MODIFIED_BY="Michael H Bennett" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Cohen-2009">
<DESCRIPTION>
<P>"Randomization...was performed using opaque sealed envelopes, inside of which was a card labelled &#8220;A&#8221; or &#8220;B,&#8221; which determined the order the patient received active treatment or placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Di-Sabato-1993">
<DESCRIPTION>
<P>Only a vague description of the method of allocation; "Five minutes after the onset of the attack, the patients were placed into a...hyperbaric chamber...the patients chosen for the placebo treatment were placed in the same environment".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 03:51:30 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Eftedal-2004">
<DESCRIPTION>
<P>No details given of the randomisation procedure: "the patients were randomly assigned to the treatment or control group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 06:02:17 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Fife-1992">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 04:06:05 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Fogan-1985">
<DESCRIPTION>
<P>Little detail of method: "That department randomly assigned each patient a special study-coded "E"-size portable gas cylinder."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Hill-1992">
<DESCRIPTION>
<P>Randomisation method not clearly described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Kudrow-1981">
<DESCRIPTION>
<P>Randomisation method not defined: "Twenty-five randomly selected patients".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Myers-1995">
<DESCRIPTION>
<P>Method not clearly described: "The patients were initially assigned at random".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Nilsson-Remahl-2002">
<DESCRIPTION>
<P>Method not described: "If the patients fulfilled the inclusion criteria, they were randomly given one of the two breathing gases by mask".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-13 08:45:28 +0100" MODIFIED_BY="Michael H Bennett" RESULT="YES" STUDY_ID="STD-Ozkurt-2012">
<DESCRIPTION>
<P>"Patients were randomly assigned to the treatment or placebo group according to a computer-generated randomization table."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1998">
<DESCRIPTION>
<P>No specific description of randomisation method: "Subjects were randomly assigned to either treatment group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-2009">
<DESCRIPTION>
<P>No clear statement that participants were allocated prior to inclusion in the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 03:45:10 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Di-Sabato-1993">
<DESCRIPTION>
<P>No specific statement regarding concealment of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-06 15:48:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eftedal-2004">
<DESCRIPTION>
<P>No specific statement concerning allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 06:02:40 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Fife-1992">
<DESCRIPTION>
<P>No clear statement of concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-06 15:49:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fogan-1985">
<DESCRIPTION>
<P>Principle investigator enrolled then sent to another location for allocation: "I examined each man and then they were immediately directed to the inhalation department of our medical facility."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-07 06:05:14 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Hill-1992">
<DESCRIPTION>
<P>No specific account of methods.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 04:13:30 +0000" MODIFIED_BY="Michael H Bennett" RESULT="NO" STUDY_ID="STD-Kudrow-1981">
<DESCRIPTION>
<P>No allocation concealment indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 04:17:16 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Myers-1995">
<DESCRIPTION>
<P>No specific mention of concealment of allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-30 16:23:21 +0100" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Nilsson-Remahl-2002">
<DESCRIPTION>
<P>No clear statement of allocation concealment, but likely to be so given cross-over nature of trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Ozkurt-2012">
<DESCRIPTION>
<P>Likely entered into trial before randomisation "After the treating physician decided the patient's eligibility for the study, a study nurse applied oxygen or room air according to the randomization scheme".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-04 06:34:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilson-1998">
<DESCRIPTION>
<P>"After obtaining informed consent, each subject underwent a history and physical examination and an explanation of HBO, therapy by the study physician and were shown a picture of a monoplace hyperbaric chamber. Subjects were randomly assigned to either treatment group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-10-13 08:46:52 +0100" MODIFIED_BY="Michael H Bennett" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Cohen-2009">
<DESCRIPTION>
<P>"A face mask and 2 standard CD-sized, 2-liter cylinders with integral valve, regulator, flowmeter, and operating instructions were delivered to each participant&#8217;s home, one labelled &#8220;treatment 1&#8221;; the other, &#8220;treatment 2". Copies of the randomization code were locked in the office of the principal investigator and the manufacturer, where they remained unbroken until the end of the trial."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Di-Sabato-1993">
<DESCRIPTION>
<P>No specific account of blinding methods for personnel, but participants were clearly intended to be blinded because or the use of the sham therapy described (air at 2.4 ATA).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Eftedal-2004">
<DESCRIPTION>
<P>"Only the chamber operator had knowledge of which treatment was given, the participants and all<BR/>medical personnel were blinded."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-07 06:03:14 +0000" MODIFIED_BY="Michael H Bennett" RESULT="YES" STUDY_ID="STD-Fife-1992">
<DESCRIPTION>
<P>Participants and assessors blinded by sham therapy.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-11-10 10:16:07 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Fogan-1985">
<DESCRIPTION>
<P>"The type of cylinder assigned was recorded and known only to the inhalation department. The patients and I were unaware of the cylinder contents until the conclusion of the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Hill-1992">
<DESCRIPTION>
<P>"Neither the patient, the neurologist nor the inside observer knew which gas the patient received".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-30 04:13:35 +0000" MODIFIED_BY="Michael H Bennett" RESULT="NO" STUDY_ID="STD-Kudrow-1981">
<DESCRIPTION>
<P>No blinding described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Myers-1995">
<DESCRIPTION>
<P>Participants were blinded: "Patients were blinded to the level of pressure".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-30 04:25:14 +0000" MODIFIED_BY="Michael H Bennett" RESULT="YES" STUDY_ID="STD-Nilsson-Remahl-2002">
<DESCRIPTION>
<P>"The study used a double-blind, placebo-controlled, cross-over protocol."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-11-05 14:20:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozkurt-2012">
<DESCRIPTION>
<P>"Patients and the treating physicians were blinded to the treatment." "We used this special room and wall outlet system for all patients who were enrolled. Patients in the placebo group were connected to the wall outlet system that appeared to be oxygen but was actually room air."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Wilson-1998">
<DESCRIPTION>
<P>"All physicians, personnel, and subjects associated with the study were blinded to the groupings and previous results, except for the individual in charge of administering the treatments."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-30 16:30:21 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Cohen-2009">
<DESCRIPTION>
<P>Assessors and participants unaware of allocation (see above).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-30 16:30:21 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Di-Sabato-1993">
<DESCRIPTION>
<P>"An observer who did not know the nature of the administration registered the duration of the attack" and participant assessors blinded as above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-30 03:53:21 +0000" MODIFIED_BY="Michael H Bennett" RESULT="YES" STUDY_ID="STD-Eftedal-2004">
<DESCRIPTION>
<P>See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-30 16:30:21 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Fife-1992">
<DESCRIPTION>
<P>Participants and assessor unaware.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-30 04:08:19 +0000" MODIFIED_BY="Michael H Bennett" RESULT="YES" STUDY_ID="STD-Fogan-1985">
<DESCRIPTION>
<P>See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Hill-1992">
<DESCRIPTION>
<P>See above - participant blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-30 04:14:10 +0000" MODIFIED_BY="Michael H Bennett" RESULT="NO" STUDY_ID="STD-Kudrow-1981">
<DESCRIPTION>
<P>No blinding described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Myers-1995">
<DESCRIPTION>
<P>No specific mention of this, but blinding for participant as assessor of pain relief.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-30 04:25:32 +0000" MODIFIED_BY="Michael H Bennett" RESULT="YES" STUDY_ID="STD-Nilsson-Remahl-2002">
<DESCRIPTION>
<P>Outcome assessor included in the statement above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Ozkurt-2012">
<DESCRIPTION>
<P>Participant as assessor of pain was blinded, but no specific mention of other outcome assessor blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-10-30 04:31:39 +0000" MODIFIED_BY="Michael H Bennett" RESULT="YES" STUDY_ID="STD-Wilson-1998">
<DESCRIPTION>
<P>See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Cohen-2009">
<DESCRIPTION>
<P>109 participants were randomised, but only 76 received treatment and were analysed. Dropouts were reported to have done so because they did not receive treatment (33): came out of bout (17); lost to follow-up (9); withdrew from study (6); died (1). All 76 remaining participants accounted for with little loss of data. See figure in the trial report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Di-Sabato-1993">
<DESCRIPTION>
<P>All enrolled participants reached final follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="UNKNOWN" STUDY_ID="STD-Eftedal-2004">
<DESCRIPTION>
<P>Six of 40 participants enrolled did not reach final follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Fife-1992">
<DESCRIPTION>
<P>Ten participants did not progress to the second arm of this study because of headache relief in first treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-Fogan-1985">
<DESCRIPTION>
<P>All enrolled participants are reported, but 3 of 19 participants did not receive NBOT for any headaches, while a different 5 of 19 did not receive air for any headaches. Furthermore, participants received treatment for between 1 and 10 headaches.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Hill-1992">
<DESCRIPTION>
<P>All reported participants reached assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Kudrow-1981">
<DESCRIPTION>
<P>All enrolled participants were reported upon.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Myers-1995">
<DESCRIPTION>
<P>All enrolled participants were included in the analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Nilsson-Remahl-2002">
<DESCRIPTION>
<P>All enrolled participants were in final follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Ozkurt-2012">
<DESCRIPTION>
<P>All enrolled migraine participants were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-10-30 04:32:20 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1998">
<DESCRIPTION>
<P>Unclear if all subjects reached follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Cohen-2009">
<DESCRIPTION>
<P>The report gives data for all outcomes indicated in the trial registration at isrctn.org. However, rather than reporting the primary outcome as "Proportion of patients pain free after 15 minutes of treatment comparing oxygen and air" as indicated, the trial authors reported the proportion of attacks treated that responded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 03:49:41 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Di-Sabato-1993">
<DESCRIPTION>
<P>No pre-registration of trial by which to judge selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-06 15:49:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eftedal-2004">
<DESCRIPTION>
<P>No trial pre-registration with which to compare.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-06 15:49:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fife-1992">
<DESCRIPTION>
<P>No indication of missed outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 04:09:06 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Fogan-1985">
<DESCRIPTION>
<P>No pre-registration with which to compare.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-20 08:03:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hill-1992">
<DESCRIPTION>
<P>No preregistration with which to compare.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 04:15:03 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Kudrow-1981">
<DESCRIPTION>
<P>No pre-registration report with which to compare.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 04:18:54 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Myers-1995">
<DESCRIPTION>
<P>No pre-registration of trial with which to compare.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-30 04:28:29 +0000" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Nilsson-Remahl-2002">
<DESCRIPTION>
<P>No pre-registration of trial with which to compare.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-13 08:48:56 +0100" MODIFIED_BY="Michael H Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Ozkurt-2012">
<DESCRIPTION>
<P>Trial was not registered on a trial database so it is unclear all outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-06 15:20:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wilson-1998">
<DESCRIPTION>
<P>No pre-registration of trial with which to compare.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-12-18 13:45:49 +0000" MODIFIED_BY="Anna Hobson">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-12-18 11:38:49 +0000" MODIFIED_BY="Anna Hobson" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-07-22 10:17:59 +0100" MODIFIED_BY="[Empty name]">Hyperbaric oxygen therapy for acute migraine</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Hyperbaric oxygen therapy for the relief of acute migraine</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>Acute migraine<BR/>
<B>Setting: </B>Hospital care<BR/>
<B>Intervention: </B>HBOT (2.0 to 2.4 ATA for 40 to 45 minutes)<BR/>
<B>Comparison: </B>Sham therapy (air at pressure or 100% oxygen at 1 ATA)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="BOTTOM">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Number of participants<BR/>(trials)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="BOTTOM">
<P>Risk with sham therapy</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="BOTTOM">
<P>Risk with HBOT</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Chance of obtaining substantial headache relief (Relief).<BR/>Assessed with: Patient self-assessment</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 6.21<BR/>(2.41 to 16.00)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>58<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Low¹</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>We included 3 small RCTs but all showed large effect size with HBOT compared to either air or 100% oxygen sham.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>111 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>663 per 1000<BR/>(162 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>Abbreviations: </B>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>OR:</B> odds ratio; <B>ATA:</B> atmospheres absolute; <B>HBOT: </B>hyperbaric oxygen therapy.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect.<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>¹The evidence has been downgraded from moderate to low due to two of these trials being incompletely reported crossover trials reported only in abstract. [Two of the three included studies were planned as crossover trials. In those two, many patients obtained relief during the first treatment period and were not crossed to the second period. For <LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>, where all patients are not clearly accounted for we have included the results only from the first treatment period.]</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-08-23 07:12:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;b&gt;AH July 15: EDITOR please advise:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;PR Sheena Derry: My main problem with these results as presented is the amount of statistical analysis and quoting of RRs and P values. I don&amp;#8217;t pool data unless there are at least two studies and at least 200 participants. Anything less is likely to be misleading (see PaPaS guide). My recommendation would be to take out both analyses and present the data in a narrative form only &amp;#8211; perhaps with results from individual trials in a table, but with no statistical analysis.&lt;/p&gt;&lt;p&gt;Author response: Analysis 1.1. We acknowledge your advice and have removed the P-values here. but would prefer to keep this analysis. We will, of course, revert to narrative reporting or individual results if instructed to do so.&lt;/p&gt;&lt;p&gt;&lt;b&gt;EDITOR Aug 15: &lt;/b&gt;see comment above in SOF table. [AH: I have added a Figure as suggested]&lt;/p&gt;&lt;p&gt;Re. Analysis 1.1: I would keep it in, but it is opaque, because there is no figure, which is a shame. We need a figure for Analysis 1.1 in order to make some judgements of our own about these data. The RR of 6.7 is very large, and that might be important even when numbers are small. We need to see the raw data, not have it hidden for this key finding.&lt;/p&gt;" NOTES_MODIFIED="2015-08-23 07:12:19 +0100" NOTES_MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-08-23 07:12:19 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>HBOT versus control for acute migraine attack</NAME>
<DICH_OUTCOME CHI2="3.322087569013593" CI_END="16.001861883760135" CI_START="2.408338227543762" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="6.207889793362555" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" I2="39.796891007486366" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.2041705175808501" LOG_CI_START="0.381717479280448" LOG_EFFECT_SIZE="0.7929439984306492" METHOD="MH" MODIFIED="2015-08-23 07:12:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1899408197765703" P_Q="0.6298968553391101" P_Z="1.5728015187494484E-4" Q="0.23220068567500163" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="27" WEIGHT="100.0" Z="3.7792836947697066">
<NAME>Substantial acute relief of headache</NAME>
<GROUP_LABEL_1>HBOT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours HBOT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.659943243366567" CI_END="15.870030095869636" CI_START="1.7553146486533664" DF="1" EFFECT_SIZE="5.2779632721202" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="62.405212874604565" ID="CMP-001.01.01" LOG_CI_END="1.2005777503501676" LOG_CI_START="0.2443549771696837" LOG_EFFECT_SIZE="0.7224663637599257" MODIFIED="2015-08-23 07:12:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10290446372689299" P_Z="0.0030597573194904824" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="17" WEIGHT="75.01565435190983" Z="2.9616697964665635">
<NAME>HBOT versus air sham therapy</NAME>
<DICH_DATA CI_END="8.044928737241554" CI_START="0.6767548380187687" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.9055222014294756" LOG_CI_START="-0.16956863084028678" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2015-08-23 07:12:19 +0100" MODIFIED_BY="[Empty name]" ORDER="33207" O_E="0.0" SE="0.6315136766607068" STUDY_ID="STD-Fife-1992" TOTAL_1="12" TOTAL_2="7" VAR="0.3988095238095238" WEIGHT="63.11834690043832"/>
<DICH_DATA CI_END="314.68084828844803" CI_START="1.3881048127835338" EFFECT_SIZE="20.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.49787031223084" LOG_CI_START="0.14242225999126748" LOG_EFFECT_SIZE="1.320146286111054" MODIFIED="2015-07-22 09:46:58 +0100" MODIFIED_BY="[Empty name]" ORDER="33208" O_E="0.0" SE="1.383601845541428" STUDY_ID="STD-Hill-1992" TOTAL_1="9" TOTAL_2="10" VAR="1.9143540669856458" WEIGHT="11.897307451471509"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="58.4430135476589" CI_START="1.3859654915629298" DF="0" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="1.7667326017416582" LOG_CI_START="0.1417524171369916" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2015-07-27 08:01:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.02134011745957018" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="24.98434564809017" Z="2.3019123171316838">
<NAME>HBOT versus 100% oxygen at 1 ATA</NAME>
<DICH_DATA CI_END="58.4430135476589" CI_START="1.3859654915629296" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.7667326017416582" LOG_CI_START="0.14175241713699152" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="33209" O_E="0.0" SE="0.9545214042184236" STUDY_ID="STD-Myers-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.9111111111111111" WEIGHT="24.98434564809017"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-12-18 10:48:17 +0000" MODIFIED_BY="Anna Hobson">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApkAAALvCAYAAAAu1N6OAABqcklEQVR42uzdAeQV2f//8R9ZK0ki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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-12-18 10:48:17 +0000" MODIFIED_BY="Anna Hobson" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: each 'Risk of bias' item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADnCAMAAAD4paggAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-12-18 10:48:17 +0000" MODIFIED_BY="Anna Hobson" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUYAAAKfCAIAAACdbPbdAAAfq0lEQVR42u3dv24dxxnGYQIBghQs
VOgKcg2sAiJVUuWeopKFgbjUXQS5BCOyS0VVuiCOZNgqVMhJZzvG5igE7CNy/5+db+ebfV6wsGn6
5XLO/PabmZ2d9+qKiBpTR0RNCNJEkCYiSBMRpIkI0kSQ1hBEkCYiSBMRpIkI0lR9t7N5EdLURoeb
802CNCXobav/K0GaCNJEseVa94M0NcWzITekCdIEaYI0pIlKdzs8Q5qIIE0EaaKIbmdPKKSpjT53
/g+6H6SpKaRRDWmCNEGaaqVa94M0EUGaCNJEJcbbUtkgTUSQJoI0UWi3M+qGNDUzox7/DkGaIE2Q
pgqo1v0gTY1MoU2nIU1EkCaCNBFBmoggTUSQpka6nYOKIE1t9LmhfyBIE6QJ0gRpSBOVmEvrfpAm
IkgTQZooYDptIg1paopnVEOaIE2Qpjq7nRVvSBMRpIkgTRQ48NYDIU25+5xGgDRBek39hzRRVqp7
e/IBuzekaf+J9OU9cNzhUD0c0kSQJqp+SG8uTbTn2Htzng845IY07V9It6UO0pCm/ZHeEDxIQ5qa
QvrBFNpcmmgHqnU/SBMRpOlQHfrAe0IhTe2AV24tHdJE0+AVnaKX/l2QpqCKB2lIQzr3hzfnm8ek
2sCb2hm+Vv6ZWsSCNJlLE6QPRsiR59I/LXGr/5Buh+dENVCXgzS1g7RaCmlqrUqH3S8gTVk/QqPu
TtoWpKkxqiENaWptLi25GtINEqIRPMSCdPoR7JHfPSJIN4t0l2eFzBMsSFMjSFvEgjTNpTrpQyw9
ENLUwj0I0pCmtrpdgbm0FW9I5651uR7blL42PRnStM9tCNKQpjaH3EV3j0GazEtzD7/tHoN0I0PZ
XGVKf4M0NYU0qiFNc/HIuBt087m0N1gg3cIU2pbpziYWSBOkIU205RCj2zovHtKQpt1qaYm3x8xB
IE1NIU2QJkhDmqqcl+baQLbtBQvQgXRrFY8I0pBuvzVUaUJ11oG3jTeQbnMifeTjBPVkSJPhMaSJ
NqV687PHDn6ngHRrY++kk4VNLl79h7RBrNZo7dYJaZ14z6vd/MpLgNdrVS04kIY0PHa+DUGa0oPn
fSlIk7q07GbRFVtLN5cmir4Zbf6OV6K3xyCdu/vGHHOf7oRwSEOaEndiSEO65XnvATtx71y6UCZm
/U0B6cQwF333qATS3peCNC2u0gesSwFjFkgTNTVm6fIcCAXppgp1lo8y7BzvzZ1LR2RDGs9xG0KP
vPBmxZvSI12uLsUczZ/omiFNY7W0/k6c9OmxDaHUSP1PFHPj0H9IUwt1CdKQbnPg3TmXT44HpA2P
awBPD4Q0FUS6dF3S3yBNTVXpElcYv3sM0pRm9piU6sfORfelmUuTm8VYRa0cPEhTO0P6RHPg0ttj
UzQFpBspoYkqXq6RRbp3vCFNO9QlD7EgTS3X/9Keh+rhkG6HwC7t2SMbtsOcb0KaEuCR/UShaufS
6eb/kIZ0FQP7I4+wth1ZQBrStPJOVOf8H9KtdTUNkmumYC5NietS3ttQ6cOVNxlyQ5r26cRJt22W
W6jfduoE6aam07kO0N3wdwU8S89yXiqk2+E5XV0KqNIH/AQhDenoutRZ0utrjY0HLNiAdEt4OAIB
0u7xTd3gEk0WIE27VbxCg4vDLukVGllAus2KVGJvU65MjCxIbx5UBOlGhtzj3zwI0hmX9Kx4U3RX
y1Wl8462IE2559J4LrSyAGlq8za01c1CgA7R4iF9tYPYxDc1/Ywi61KWVyCKriwUamdI085T9Jpf
gegc+ks1EFJtXYpvjfonC5Cm4l0tXV1q7KYMaUgnc+5SHVQcH81rLo3qq6QXXGhDaK6RBaRpepBc
orfVvAWygTHLhr8I0hRUPVIjXcK80JoFpCka6S7ktc1Eo6Eil6oHNzP2TuEcORM5aH8AhlraZGsc
sJ0hDel2Rhae0kMa0rN6c1f44JGMp5oYeFPWipfiFYiRiprxmiVXUsG6VPqEsPp3j5UeePe2huRK
SoN0xj3k8QtvkD4ocjIxRu5ESTMxIU0UNFmIvHVC+uidOMvUNO9kYZMSGjf5x0bG7ltoRpr3fekw
pDtbTSisSmuQokv09Q/pIU0tjCyChwA1742BdIOcbO68ec9L9Fw63TgL0o10iHLbNhPtHitRS0vH
CZa4XUK6HaS7nAcVVH7NpeMEzaUpN9Jdwn3pXZ6NN5BuiuqDH4EgQAfS1GaHTsGzAB2aNS/NVEkc
+q9KUyTVWZ7ENvbxqdJuyWki4wKQzpXj4dBf2qF6lD4CIdE1x5yXYuBNyZBOPbIIOIkN0tgruG0z
19OgvE/pIU0RXa2BxYUDjlkgDellRaPQLshcTW33GCWr0qV3NRealxKkDTWbGsR2gc/Sq909Dmlq
Z/5faBpS9NgGW02oNaqF0UOaJsqIO0Wi9X9IU1D1SH2DK9E4WSIQIA3poOrRUv33EIsyUZ36HE9D
eki3NpFO8b5UDHvHPAIJ0gS8Kq55q5sppGnBEKBy8Kx4Q7op8LoMrzRDerypDbzxnHhzRbl56Ya2
AbvHtvWHNKT3oTrd26BZQn8gDekF1UM71081pNuZS6d78bgEHllerii3GgJp2u3uU3ot/ZivmkKa
gqpHzBS93MpClmuGdJt1Dx6QpsRUj/SPOvEo+lbT+a844GoIpNvhedtpZNK0DYI0pIOqB6RjWgPS
rU2nU2CTscsVjUCANLVzD0rRAx3NT22yZ3jsCAQyx2theJwo1QTStAPS6d7E7sosFpZINYE0RVMd
EOya7n1pz6Wp+FCzc6pJ6v4AjOyF1BEI5YbHRW9wkKb0SHcJt20mYgTSkG6hH0Ma0g3OpYumuiQq
pwffxwppauo2lO5msfnrsZCm/QexGSNjC5lfPoGCdFOEZDnmthwwpZ+lh93gII3nTFO+cgfopptL
Q5rSI11uFFD64PHIfGlIH5rqg2+uyDVCCeoPGoKG8Kg/JB3VkKbFSHfbvU4YnC91tNEQpFsbeHsF
IteahbPHKG6cmfEAXUhDGtI7X3aumJsSl+04QcpNdWTFq38u7ThBKtshes1LF6UUSCfrEtigkYl0
oooHaUjTDkiHDVtqnv8XeqQH6XbG3p2j+RLO/1VpSjw8Lr3VJCPSmztDGtLNltPKH48Ven0F0pBW
8epqDQNvVGdaEEp6uILdY9TUCLbyTpxxeFyuQSBNTSGdZXg8fsuAtFF3vtcJc92G8nUJbLRaWg9y
GwqYpQvQIVQ3+7fX/HgM0rr1gtKkeQNWFsylzaUlV+wwPIY0GcQ+dC59UGGKAQukKT3VkTveDvj2
GKRbG3gXXUOGdJougY02amm607ZLH/pTbS2FNAXNxCi+nQ28KWVX084xzj6t1qbTB79ZpGsNSJO6
1OBtaMMLhjRBuqJB1uV3DUi3M/DukiRXdMVW6S0WQrqdWprroKJyb01Z0oM0pKmpcRakIR09PKai
nyCk27nHC6PJuGYBaYquHhsinXcvd7nREKQpcf0v9zZl2Hua9aeaQLqpyVje5e6anbtUy5CQbofn
LDPepMPvLKfHQBrS1NQ9DtKQbmGWHl9Lqz0vDdItUJ2O53J4bO4cEKBj4E371FJhdJk+Nd2Xwjqx
N7EgTU0hnXEu3ZV84w3S1ALVSZvCc2lqZyItbasrvHus8yYWdZKrkiNtjzcZG1dx66z2ZgFpSEd3
YoI07UB18H6p+t/cyHLrhLS5dDTS3cB5KRu+v7mhs91j1MjAO35DSIkjFrI8RoY0JZ5LQ3qkqSFN
KRe9e28W5Q79TXScsDex8GxDyD73zXK7TVVpKtJ93SzCVhbMpanBwUUK5xSTHUi3hkeKupRuWaHE
o6xCoyFIGxBGdN/sSOe7xWsISEfigepynyCkIb3/RLrao/mKztILjYYgbS4d14lbunVW6wxpmuhq
WTZgJUXaXJr2QbrbbsNmieFxwLP0mELtTSzjbSlQuzV4nashkG5qTLj5XPq8l2jkGGdI4znNrK/c
yCLvs/TOEQiUF+nIkUVR5wQTBGw0M8erH4+kATpONSH1vx3nmJtyZ8Wbkg7pMwbolG5nJ4TS4Jjw
sHhknOBAmvINLI1ZIE2NI53uCIRE0xBIo3q3oWaupshyM4V0axPpjOvSKcYsWVYWIE37DDXNRLwv
TY0gnfQIhGR3Cj24pbH30Yaa8fc4A28q3s8cVJB6GmL3GPUjXX8B6XIegeC5NCVGOl386i4TnGo/
QR9VU1T7KN2UIU27FbpERyAkqv+QJgPvlc1S9XXqx6k7We9AjkoMj9P0Cp9Z6k52vt5btKNsexsq
tM9kc+dySD/ItTfwhvTGvM0cCGx4G9oKmHLO5agudM2QbqdKFyI5IKK5fqTLPUuHNBVHutzkPHWV
DvsEIQ1pVRrSkG4C6YBHTQFvSlX+XLpoOz+wsjxG0XcQ7ZDmXq8hiCBNRJAmIkgTEaSJIE0VfjZE
Sx6hQbpqpDlzXuoMaUhzhjRBmjOkSSfmDGlIc+YMaUhzhjR+MiL9/of3d6/vbl/dPvn8ydVnV9cv
rm9e3jz78tm7799d6Pzjj++//fbu7dvbN2+e/OtfV69fX3/zzc37989+/PFdtdesNSCdG+nnXz9/
+sXTUz94/HXqH59+9elq5//85/mbN09Pfffx16lP//vfn1Z4zVoD0rmRPt3Ie7vC+dfpZ1Y4n4pP
b/c9/zr9TFXXrDUgnRvp0919sjfcfw3d6YecTxVpsgfffw1Vp/hr1hrNIj3/rIlCmYNbfXP8Ok+z
r6HRWu/47e13b2c6n2aM5yPMv/716re/vfrVrz58/eEPV3/728Mx53//+3b3a9YazSK96OimokfY
XvjNyeu8e303szeMDN56nb/99u68m/761x86xl/+cvXnP3/4h9/8ZtaAM/iatUabSI8HhT6uhEMH
2c//yZFrKI307avbng/+Xn0d4ublzUznt29ve0eV//jHB+9f/vLh97/55mb3a9YaR0F6spCOxwWO
/+S+SN8/7ZjfIa5fXM90vn9C8+Dr73+/+t3vPnj/6U8P/9Pr19e7X7PWgPTG1I3/2EzzoY+g/5u9
XeFcj/rETOfeovT733+w/OMf+5eFdr9mrQHpiYL8+BDWckifw1xtlf7FLz4Y//OfPT34gFW68tY4
xFx6XUFetOo2kk1x4Ri7ktnj0Ncx59I1t8YhVrzjF6WbWfG+/7rX/C0Wra54p2iNppDuhp/xDq1j
z18bH6G39+CYNp5Lj3fioz2XTtEarSHdnuyX0hqH3j12HKQ7u5q1BqQbQ/r+Tt+/dvr/0donbz5Z
7fz/d4+eDL979EmF16w1IJ0e6W74bdve2dci56E3hHtnjJVcs9aAdHqkOXOGNKQ5Q5ogzRnSpKtx
hjTpxJwhDWnOnCGdBWkiyZWqNGdVGtKQ5gxpgjRnSJNOzBnSkObMGdKQ5gxpSob0D+/fv767e3V7
+/mTJ59dXb24vn55c/Pls2ffv6s3q1EmZunWgHRWpL9+/vyLp097X54/Ef7VpzVmNcrEDGgNSKdE
+lSKJ0+5Of3MCudy53g4LyWmNSCdD+lTfZ55vORQrY4/bcupZjGtUSPSI7vehk7GnZlZOf/PXNQg
c84k7bY7IfQ0fx4ab/eOwL97u39Wo0zMmNaoF+n5dF3yw1v95Oqj+ded4/367m7JIdD9w+/grEaZ
mDGtkQPpbjQQYxyndYGV4//6+NcFp228ur1dhPTLm/2zGmVixrRGg0hPcjU/sHImivFI3z+vmv/1
4nr/rEaZmDGt0QLSc+bSK7jaBOmhO0jvGGH++P9xd3o6EXu4f1ajTMyY1mgE6cmB98z4yPk1fOby
WHdxSGUNVXqTrEaZmDGt0fJceqt0u3VIbzXGrmQufXlWo0zMmNbIt+K9AunHC10zfzJgLl35iveG
WY0yMWNao16kN3ku/XigO77iPX4jWFSK23guvWFWo0zMmNaoFGma/NjsHjuX3WOQTo90Z4/3x7LH
G9Lpkb6v1UOr36fvv/mkxqxGmZgBrQHprEh3w+9L986fFzmXy2qUiVm6NSCdGGnOnCENac6QJkhz
hjTpapwhTToxZ0hDmjNnSGdBmkhypSrNWZWGNKQ5Q5ogzRnSpBNzhjSkOXOGNKQ5Q5qSIS1fMsY5
VztDOivS8iVjnNO1M6RTIu3skRjnjO0M6XxIOyEsxjljO7eA9MhGuZmJljOHSePnk6775vjvlS+5
o3PGdm4H6fHvl0N6kyO7lx76K18yxjljO7eM9FDpnnnidzccfDl5GaWRli8Z45yxnQ9XpSezcuZj
uRXSIylZnXzJXZ0ztnPjc+mlSHez4yzH27c00vIlY5wztvMRq/QmcZZbIT3pLF+ytipdeTsfeuB9
4RLXyAUsMhx/o12+ZIVz6Zrb2Vx6ei49WaUvWQZf9xBLvuQuK94p2vlAc+nVK97dVLr1/OfhhZ5L
y5dMly8pufK4sntsX2e7xygI6c4e7yhne7wpCOlOvmSUc7p2hnRWpDv5klHOudoZ0omR5swZ0pDm
DGmCNGdIk67GGdKkE3OGNKQ5c4Z0FqSJJFeq0pxVaUhDmjOkCdKcIU06MWdIQ5ozZ0hDmjOkKRnS
kitjnH94//713d2r29vPnzz57OrqxfX1y5ubL589+/6d5EraDmnJlTHOXz9//sXTp70HK5wI/+pT
yZW0BdJONYlxPpXiyROQTj9TVTtDOh/Szh6LcT7V55lHjw7VamePhdIyeUz/zGYZOTl03TfHPzbJ
lTHOp/nz0Hi7dwT+3VvJlRVPUxeFXV5yNP/4b5RcuaPz67u7Jcb9w2/JlTsj/dPB3ZNHfz/4+XVI
z7yeB5JcGeP86vZ2EdIvbyRX1or0IhTjkZZcGeN8/7xq/teLa8mV1cylCyE9Gf2x1PlekitjnB9D
+3TCWHJlkio9+Ybq0PJYN5XIsw5pyZVNVmnJlTsMvFespc0ZTi/93yVXtjqXllzZwlx6xcK75MrG
VrwlV4Yi3U09Ou4ueC69Ll9acmWMc9hzacmVR7/vdHaPRTnbPUZBSHf2eEc52+NNQUh3kiujnE+1
emj1+/T9N59IrqSNkO4kV0Y5D70v3Tt/3r2dIZ0Yac6cIQ1pzpAmSHOGNOlqnCFNOjFnSEOaM2dI
Z0GaSHKlKs1ZlYY0pDlDmiDNGdKkE3OGNKQ5c4Y0pDlDmpIhLV8yxllyJUUgLV8yxllyJUUg7eyR
GGenmlAE0k4Ii3F29tj+AMzZLhcA3orkytUnhB48X1JyZeNI73UfGbqMgHO8D54vKbnyiEiPlMdu
6sju8yzLod+4SRjt/L9IvmSMs+TKSpGeTLGbpG6SwEuQXhEZL18yxllyZV1z6XXD4BU/2c1LrhwZ
Asy8H/0k+ZIxzpIrU1bpoYH3JUj3jupL50sfNl9SciWkN/jmosbdHGn5kq3OpSVXlppLX1ilN7xf
yJc8woq35MriK96XV+kVz6Xn/0XyJWOcJVe2diOo+drsHotxtnss99p4rtuNPd4xzvZ4U9wIQr5k
jLPkSoqbFMiXjHGWXEm1z/M5N+wMaUhzhjRBmjOkSSfmDGlIc+YMaUhzhjR+6kSaSHKlKs1ZlYY0
pDlDmiDNGdKkE3OGNKQ5c4Y0pDlDmpIhXS65UiZmjLPkSkj/rHLJlTIxY5wlV0L6rG4UOxPDeSkx
zk41gfRHd/dCJ1c51SzG2dljccz0ngE83oj7nhC6Ye6hTMwYZ8mV+yA9Avnj5htyCDjHe8PcQ5mY
Mc6SK+ut0hcmV05+QsG5hzIxY5wlVyYbeJdGulzuoUzMGGfJlWWRHnpn7XKkJ9N5Jj+e4NxDmZgx
zpIrsy6PdVPpPOuQLpd7KBNzxyotubJqpBcNp5f+7+VyD2Vi7juXllzZwlx6vOWDcw9lYu6y4i25
Ms3Ae/IR9OS5M8G5hzIxY5wlVx5Xdo+16mz3GKQf1RB7vJM72+MN6Z47faHkSpmYMc6SKyHdMysr
lFwpEzPGWXIlpDlzhjSkOUOaIM0Z0qSrcYY06cScIQ1pzpwhnRJpIsmVqjRnVRrSkOYMaYI0Z0iT
TswZ0pDmzBnSkOYMaUqGdLl8yR/ev399d/fq9vbzJ08+u7p6cX398ubmy2fPvn93RGfJlRSBdLl8
ya+fP//i6dPeF/5PtHz16bGcJVdSBNLlzsQ4lbXJk3lOP3MQZ6eaUATS5U6uOtW6mUdiDtW9lpyd
PbZnX5/5J5T4Sy9JruyWn+NdLvfwNBcdGrv2jma/e9uys+TKPZGef/2b/6WXJFd2A3k641dbLvfw
9d3dkoOr+4eyzThLrtwN6Zn//CC85vG/9kZYdaMn6V+YXDmUpzP+sZXLPXx1e7sIj5c3LTtLrtwH
6UU4PYB2hLdF4RgXJlcuRbpc7uH9s5/5Xy+uW3aWXLkD0uPz0nVx7b0ldLyczkmu3HAuXS738HFH
fToR1diys+TKaKQ3GfSWQHpknF+uSm+Se6hK71ilj55cuWguHY900YF3udxDc+l959KHTq4cGeuO
TJWXLoDNjJgMnkuXyz204r3Lirfkyq6bSpycE9c+56HxOqS72OfSG+Yeei59LsmVFHHnupfdYzHO
do9RENKdPd5RzvZ4UxDSXcl8yVPdG1pJPn3/zSfHcpZcSUFIdyXzJYfePe6dizbvLLmSgpDmzBnS
kOYMaYI0Z0iTrsYZ0qQTc4Y0pDlzhnQWpIkkV6rSnFVpSEOaM6QJ0pwhTToxZ0hDmjNnSEOaM6Qp
GdLlkivLOZdLgczoLLkS0j+rXHJlOedyKZAZnSVXQvqsbhQ7E6Occ7kTQjI6O9UE0h/d3QudXFXO
udw5XhmdnT12KQlF/8BLTggd398XnHtYzrncaZsZnSVXrmFsfjrktr+rW5sEMP9OXC73sJxzuTOx
MzpLrtwM6SHYHv/8+A8M/eRSpCebPTj3sJxzueSKjM6SK1eOhMcTcCYhn19RL0F6/K2a4NzDcs7l
8qUyOkuu3AzpoX+dOUieWUsvD/EZ/2a53MNyzuVSIDM6S64si/TjUjkz+GZyeaybCvGZ7lWxuYfl
nFXpmHaG9AKQusuSKzf8Zrncw3LO5tIx7dz+Q6x1OZVLV6c3z7hetF66Ye5hOWcr3jHtDOmxFe/L
B96LnkvPL/Llcg/LOXsuHdPOzSK94slQrku1eyy7s91jR+S5s8e7aWd7vI+ovZIryzmXS4HM6Cy5
EtI9s7JCyZXlnMulQGZ0llwJac6cIQ1pzpAmSHOGNOlqnCFNOjFnSEOaM2dIp0SaSHKlKs1ZlYY0
pDlDmiDNGdKkE3OGNKQ5c4Y0pDlDmpIhLbkyu7PkSkj/LMmV2Z0lV0L6rG441SS5s1NNIP3R3d3Z
Y6md9z97bCQLcn7C01a9fOa2uM1ZGvrmJYeBXn5CqORKyZUrkR45rToY6YDfOxPpC4/s3uQcb8mV
kivXV+nxfvk4LGZdmfrpd63jatJt9TXMDI7dkF7JlU06V5FcuQjpy2vXyGB+zhRgxG3+1S6dWYQh
Lbkyu3MVyZVzAF4RNLWi94/MpS9Pw1kdB736MsadJVc26VxFcuV4ovrqgfeFvX/If07ga+/VpkBa
cmWTVTo6uXIp0lsVw8nev2hAu+Fq1tJLGr8TLVqlk1zZ6lw6NLmytx6Wm0tfjvT8Kj0/zH3zZfD5
8/OR9VLJlZIrI55LX77ivWJ5bJHbeJj7TKRHZvUz/9LxB+ySK4/wXFpy5YFk91irzpIrIf2ohtjj
ndzZHm9I99zpJVemdpZcCemeWZnkytTOkishzZkzpCHNGdIEac6QJl2NM6RJJ+YMaUhz5gzplEgT
Sa5UpTmr0pCGNGdIE6Q5Q5p0Ys6QhjRnzpCGNGdIUzKkpUCeK2PapuRKSP8sKZDnypi2KbkS0j/L
CSEfVdGEJ7E41QTSH9UN53id17p056U5e2wxCZN/1Io/+cLkym70jNH5v9Fpmw/mounSNqtIrkxa
2Zaeer8U6aVHdl+SK/CTnIl9roxpm1UkV+YdqZ5nUJ6XxJH8kMd8ztwrP8n50luM5IpJ54xpm1Uk
V2ZHegS8S2I05yO9btQgX2rSOWPaZhXJla0ifWE83eQQeibSi74vBfJcGdM2q0iubAPpFVE7FSKt
Sk9WvMrTNqtIrmwA6fkj8KVIz1/0mj+6Npe+cF5ac9pmFcmVDax4L5pUz0d6aQL2ooV3K95LV49T
pG1WkVyZjurJjMjxxbCROM7eXzQnubKbl3E/+bF5Ln2ujGmbkiuPK7vH5jjbPQbp9Eh39ng/qKj2
eEM6O9KdFMhHdS9d2qbkSkj3zPekQJ7PUdOlbUquhDRnzpCGNGdIE6Q5Q5p0Nc6QJp2YM6QhzZkz
pFMiTSS5UpXmrEpDGtKcIU2Q5gxp0ok5QxrSnDlDGtKcIU3JkM6Y1SgTs7QzpLMinTGrUSZmgDOk
UyKd8RwP56XEOEM6H9IZT9tyqlmMc3qkx0/VHTnusyh48+MsVyRXZsxqlIkZ49wa0uOZOIWQnplH
ue7c/2ayGmVixjg3jvRknsacmnmeXDn024ORzpjVKBMzxrmRufRQct2KkMreb06O24ORzpjVKBMz
xrkppFeX6xUozkS693YwM5dj5DdmzGqUiRnjfFyku02TK4eWx7qB/J0SVbryrEaZmDHOh0Z6q7Fx
d0EQ/LZz6ZqzGmVixjg3gnQ3Oz5y3Vx69cA7ZsU7RVajTMwY5+MivXTFe93AO+a5dIqsRpmYMc7t
IN2q7B7b19nuMQpCurPHO8rZHm8KQrrLmdUoEzPAGdJZke5yZjXKxCztDOnESHPmDGlIc4Y0QZoz
pElX4wxp0ok5QxrSnDlDOgvSRJIriVQCSBNBmoggTUSQJiJIE0GaiCBNRBUiTUTN6H8yMHpJNxuT
NAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-12-18 10:48:17 +0000" MODIFIED_BY="Anna Hobson" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 HBOT versus control for acute migraine attack, outcome: 1.1 Substantial acute relief of headache.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvAAAAFgCAMAAADq9r2WAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAA8s0lEQVR42u19C3Rj1XnuL8vnSEfSyD6yDOOBgfF4AimL0GZmGD8n
BM0ApdOUNk2y7m1vCMldi6SrueF2lZU09EFI85qm3CZdIQS4q1zKomm4NIGESUjC+EJsebAyGEpI
Wog98jw9YPsc2yNZlo9t3X3eT0lHsqSR7P+bsc5j7/2f/fj2f/6z9es/HhYQiM2DJuwCBBIegUDC
IxCNDy9TpxWLdSalj1hn5xnKt+iFqMfT7GtdJOdEJMsQOXT+1Hunhx8xn4yCYL9ujVrYedZLv/BP
+hWNe2JaxqvW/DtCDStWTkvOUDS7mKclUprakicvcksaQMMPCs/3hKH9wtr5FMwLMDgI0l/JmDo4
dP6Vfe+1nL2u5yK2bHm+92CexohpW9SDe3vKbHMNx6g3la8lUpraku6L3JKGMGn2wxq83R+MULMD
61hU2trPRLhBomrCPrqFqJ5YJOB7lCY7ZDdEbnR3+3zhWreMIS2LxWAoSNNMQjwh+O9MGNISAZoK
ZJRKAuR8dLiOx4hUMRqgfAHpntl+q08wpAmMj2YiPrUl8hgg4Z2RAT98HN4Ud4TypfjhDWnbsvdI
cE8r2Vmd6P+TZaJwyO70WWgZCxzZW+tBGALJarmp+/zJ3htEvm+5/YF9hrQbZpcXe1ilktBy4Ehw
b0u9jpFEpet73trSI07K2QuDKcqQFuay6d7FrNoSdQyQ8AbLUNQE0vbQsRl4DCJA/ufKl9cvSiDI
QniCjAFAsoNoHmVIIuT0RJh81LaF9770orizBtuee0qs0pa+XsqYljl+dxhW1fx7YfcELNXnWB0a
XRB3jsJlq1JLPtQXoIxpme3hLVp362OAhDfYfoqtNzj4am+IbDnxv6d8ecOiBFGxwz6Z+eRzQEkj
uzmI7NO5VZsW3jcEu8Sd+eG+x7eJ1trayJ+qaa+Jac/f+2CIWASazo9E6nSs7huWd0Lx3nd3iC0Z
HlkypbVet7pF6259DJDwThCJugS/BMIAqnwpNFwtbQ8C5zxxyOmDNTZ8Qz07JHP9/KtH+8SFjLCv
Z0hJmxHTDsHpN4yDxXH1asIHuj8r9eHUq7v7xZY8T/cOGdMWTS3x5hsDJLxqA56P38QJmV38Oh4Q
6b/iIrEAxGGsixj0Fr1PznSNwUiNW8Yfy4hPJYEPeFek8Z+ZGbrFnJbtIrtxuZK0qeb1hblj/yi3
pOnL8BGR5bPDv21MuwOurouWNADhY1TrSwvQscW7NeT53jo0/PT3ntuaTrwAk8cPpV+eU88+NHy5
vJM8nj50fL7WjaP3i49u89fOh16SFiEpX0/UkDYX3yFaWcHhy8QTk8e/nH55vk6HyTcgtSSxEDz2
gNQSqjtqSOuNXydSPRC/XG7JofTxuYtRTQ86jyE2E9C1AIGERyCQ8AgEEh6BQMIjEEh4BKLOCM+F
fPSBYAKiZhd5xaPFCYncAdoXFFzkLIqYBMekKFM0/1DAubqFpAaKSw3mkZoAjo7RHCRiflu6smco
axIvwJDuI2QsKF/ZsbLayUSIpu8WQJDztlIPAQSVrzOHbqUPhBLrGgKXw7SuFnBBHx3WWsDSrQCh
jDqGlK8GLTD8AGRbau7Cr278/ErPdpN/fifkddf/l/1P/F3qxt9+uXjOouiEwWTSubilPjKSSbGE
enTy8qRjdQtJvbx8qV9d+txBuOIj1FMdn3xOLWjJedJJfCdAKvN0B8hZpJyaYKmq4FhZLc+39/0i
mpvLLl91dJJkvH3k6OrU1x6WUqZ2nz53z54vCOsZAnfDBG9Q62jBA92/iO4WW5B4g2TMpT/6skAr
Cuh/e8/99Y1/u1LtFhg0/KdhBZjBJUp1WSZ/QtDPAjCxdjInJWUm+4zL/uMAAlxDSjys5gZouZUR
IBHwt0pTPRDQfc+lv1jsUcVZ2hnRmOgkFopFRb9vjmRng76MVJ92hqaDTiUl+ZK/eHuQpv1RR6mi
tg3GoiTv3ZzRD76d8dHBKYcikt+55LstBGkfM2RJ5qADhskfB/dxYdonVZXk9LVKnRBl/LLftwN8
y7DsK6hBBSoAnN/Xzsl9IAR8+leDy8CMQxa2gnTqMSoH71SEbe0PyL7+VccI4cJI4RbQDHAMHeXk
/pY5pEAQW7AMl8o+UTnqMWhTWrDUPxdhBqvvQNlk3N0tDq2guCyLaO4OcKLjgwCPi+Ov+4xPn5Vu
D/BuMxlyL/V+E67veXZFOpo9bfN7vivY05y/MjPH9pHb3b5jywcC83uJMoG1QP9dUn0u9E61dDt4
gsvyJX/xlG/5ZN8FR6ndRGr3MWHvT0NjolTND35BlLrTQarkdy75brf8aDnV+7glnSFj9lXy9z/A
27k3GNy7Q+6r4H1S6vRCXyZr6EQjhlZhdajggFCBHrazzz+9Q+6D5p6A7sF5h+yIsgIZafYLd3DZ
E3KK6utffRxehZXDhVvA9LI7e/0znXJ/yxxSCSK2IAdrsHhncBbuEID7L0oL/ggu1NqGXxiB3nuD
CZNCgvGfA5wnY/tJUY3CkuoznpGcO1+0lpicgO+Tzg/LLl6ZNpvf8+Q4+ApY8X5oI/9818NERrpM
choekxL74b+tPOWgwAzyM03hj9nd5UWpPllqFvzjkje5wQ/+MuErDkrF4He+2BQOK3XQEO8TVoZ7
h1eEXw1Pkx4ZJ7WT+6pXSuap/F7GVK/QRxkrZ66qZB2NLC6NJEHpAx9MTGo5/LBrl9hETyrU/efA
BPfs9HX6WuX+qZW3bbi3vS9cpAW+xT0jz4PS3zKHFNDwjPhDrlw83Nt9H+wJMp3f2UlLLRivUQsM
Nrz37b9Ibr9ctqKUvxvgE490wplza2f+1xnRv997BTmeXOuET0glHnn7M5OGEuT04c7h1aYr7/HK
R2RorrzncOfpVWOG06v5bfhzYy8veWM/+NQVTz4JJ1dFCZ1XJMXCj3xlW8dYMmOzCw3y2d868/al
cm6r1LtWl7ynT//dlc8/CaeMUsMn+jruS1E2qWev+IQm9T/PTHzXIpW57OR7zz/A9J7ceX7ZK1b1
RTGr1DdyszstBQzV+e7s5YPfVS3gwWTSYgGTw8PB7ive/jypg9QHN4hdpuYZ5hbhpGdVSHrPPvnd
1aXVfz485w0virfTs1e8fHi9j1HubPgnLr3zjScuLdyC6W54+xtkbKT+ljmk5Elzz4STTavC6uKj
pAXPrp77Ku+dvF9swbkatcC4LBmZO/eKopzikmkj+s6KtyNq4B0DtHJPNfmMR+bPjZEJOwyKj63k
5OwFTrO2Fb/nITVDorA/d+TJ/tb+JyNN8NTg4LIx4eDUkdHxlMN81f2q03DqzTxS/USqP+K1SeWn
7kv0tzh1iuZ3TqTabknNRGs1k0v7yZ9HE+px46zeERfiHTbNaIKQHYlnEqD0QdwolUoJ6ZwSyUBs
9K5mqm96VdacV9dIw0/HPx2fLtKCpfhIRgCvYwuWUx5jCxapvg7pdkvBllqbNP5YJPJ9MpK7pB8W
TUUli2GXaJ/+EPbJNuJ3zD7j/lgm8gNS4g6I7pAneRepeAbGmvVbmOT37IV2OcPBXVDomQ0m4t3x
CVJqpxDTlg3F+jAfmDsNXnt+Rb7oZd0EW8byPRsMd8dnxLztMW21cFiS+genikq92iaVggGYhhli
R1CkNV1TMUY2aXYZbP04OLOfGpBuKIOGX+5bmNPWFzgyEFP7gMjfoeVhfO2RAT8E7ozK3ZhhYGRK
GkF/XPb1rwGo/qIt6A8+O/BNtb+XZA6pLZiK9M8CQ7e/LrdgBeLtUgt+HW/lflaDFhgIf2E0TX8u
8QI8Nbwd+PjHxGatvJT6utidwzDSIVlnZp/xnyV+lzqYmIPeeEpeXPIujgwCf+x+FpRffCl+z/zI
hR/Kl0uNzhaw4aFtCag2UmpPMKFdRqzPi6M7tr7ksLStyBf9xQPx4HN5pFJZaKZg8uih+VGTH/yL
owtbR0NOUiW/c9F3OzAy/367kgMfBdQIxN+Eyd3pK+Xfpc6+lParzdb8vsF+d7A/tJueYoW9x7iD
x/ZFlT6YFUPyqHmCTfPpD3MQeGLh3UeJZT/knQb/Dmm2zcx9VvL1rwGcWjBsPGjf6+MOjjwTVfpb
4ZCcJ+jZsfgKAyFq/qbjYguaKGDmJRXY8fzapfcdPVP16rvxh+dgW99rM65F0oET438xmnbiNNRz
bJV1wudPbrnlWBnralM7MxXJc/EQTWcqkqcWcEN4X64pUMJvKYduXgUqMO00FWB54xI+srQC3hf3
lV4w9KP9Fclz8RCcYSqSp14Ij0AgEAg3+MM6q08zanhEVVFnBEP3YMSmAhIesalgXlMNdqvrhoGe
QfM5aUmRfMTE1VPvPAXRjODxBqcVr8Cy1hvty5SFFi7Fha0NvbCJqLGGFwLd2l6P7ZyGSsVrL7XY
db04XIhKEv6WgnsGOMZrzyhu5+zdtC/HyT7zStxzxR3eEDtc9F0fAs1rHvS0KHNrRE+PML4w6/OL
jnSU7GIupXOGayh+8LKvfSAmQCLG4LgiXBA+cVrbO2M/Z4BjvHZmpHsKhO5r1sZCgQM7QPKZ1+Ke
S0j1vBXukVyEUjPLJ/sUJ7RZyYdAiyv+16Hsop6+stC/dzUlxRlV/PSl9M6x0E/Va2h+8KKvPQUv
ws3ribiK2ESET7VpexH7uaLx2hm4H9pgzxKMT0jfqGYietxzCWtw2cpTkpt5Zrvuu56R6KnFFf/w
NMmnpU9S0t+afhUpnVzjWvUamh+86Gv/LNxGZsYsjiti/as0xeK1T4z8Y2IpflsOPvAByck4Yoh7
LkGLHQ7sdWs/V4OFR8xpUtB2LT0CpjDu6pHxGnpecrA/LiSWj6GGR1SA8Dqc47VHfAM3DPgjkoe4
Yukocc8Vf3lu6pWjUuxwSNl817W44uCcbobxGpoffEKcftTAjfuR74gSCG+LOOFkwzvGa08O9Q4n
xTjrU6pfsxL3XPGXJ0ecFDscvDYvcy2uODing+wXr8B4Dc0P/uAuMgtp6C7scY9AwpeIvPHaI3cB
HRF95neMviCfUeKeK/7y84mFDjl2eCA+b/Fd1+OKO6eD7BevTi3xGvNqXsUPvik1ugJvxWFkGocV
kdc42Ci+NPJXUqLr/hFclayncRlEwlcFdE606f1rTf45ZBkSPi+aN0rHyj8tWYL6fK0jooFteAQC
CY9AIOERiHpDM3YBorZYMOyHUcMjEEh4BKIKJo3kJsACz4q7xvV5nlWSWdumZih2PVMdKybV2C95
yhpEqHVg1V3XV7fKEmXkT3UsK12TB/xRfgk2PKt+moeL10aTZy2b2vG9yPV4V7lKlap3C5+vrEGE
Vgeedcd3rahdFlsw1aGsfHmWR0qX/NBKhktWFpri4J1JUEdQ6lhqrdhSZoZzedZah3KuzhatTkMp
7ljeAxFPF0o0Y7AmhBf1hFGfNEJfs9WeT853FTZPHSp973NjqfD1o92NPC3sWlB7v4Pmkuxk86aW
M4F1a52XWqvyW6FoBRvvefE/X2JtlfzOxeQrmbqA5QHN9QrZ8GZ2WwZS3dTeZqnxDHN/V2EtFWMN
k6EEYVJ+52KsvQts/cEj/cs3aZytBIuhWZ89XBUFX7pQvjq1LXL7RdIXR5MLE8bJntlMfAfXfVRu
bfn1y2JZFm2c9Wh4m5GonFA2fI0X4lmXK+al1Wo9rbD0h/mRleXd11Y3z52sdFuqspJgTUW4A8aH
r0sUuPPwbJkFLw7q7Qcg6FpQp4yvvYG12R9aERcR5X4Fhfdr1PAIBBIegYRHIDYiQkh4xGbC6a/n
fWjV3E21/8bTF9Ub3u0VK+0PX9DLnmeNG0PfOLhB2PrNyQPeQZSDB7x5XMx50R/ejj8LpfIQ3vlZ
vx684d360lTaH76gl73161G9b+z+8LZ+c/KAdxJl957hzZc3590s/vALJfwcdnb2n+8qQnjz14b1
7w1fvVnGF0105zfDlnY5Nr+Ihh2Pik5Fb0nybjd0UHNFhmqDws2SN1tMY1ToctZMBuLzm+8nCwvu
5TXNtnrymTS8myl6MbzhS1ARF/WervzKztEf3tZhfGFJrC0Tn3d2oUtNAYvGxHcHf3jncbi43vBu
L3zRqme8uCt/+GI1VUlszGSUyVt/H1iHPxioIkqIZ2Pmu3vXgovtDc9WMFe1q+hkZ1s7jF1nc9D9
3SU8FgunNHvionnDN4g9U+CBtJSaOvnHm0ug+3uZcKvhL643vFt/+FIN2cpJNVrRDv7wSofl83HP
I8rJA75IXkQxhY+dVB8o2wO+/Lw1AfrDI6pojqE/PBK+QcCylXgSZxv5hs1Fwv5mbzCX4dCkQTQq
XJo07UI2NyXvts22UVTzdJXetosaHnGxFXvm637vm8lzCt9hFmbPn06mKH/LUBVUvVd/xyP3gMf7
3rfjj6hTszMpbqIgqBmGntR2lcQIrCS+Dd4/e9Er3NRJkGxd++az8PW/fFTOf/7Ue6eHHyF5/eFM
Vfss6vE0+xe9ZC+wP1lJwUEiLtYpNc2uu+TzSsvJCeEzx73M8COtqw8+C8HBR/OI1PMPPenx+uOP
CFuavHLlY/J5pQ3qddlcM926aKqS4ZotIMpQ8sac6nlxUbhCQiQ2efjC91KL9qR0au6bD9DMQ48e
rhbht6XmLvzqxs+vqDUFqao9l2s1Pqnvyonc6Nnst/dxFMxll686OplMwu3xo6tT73tYyjO1+8zZ
e/Z8QSB5gx/66eFq9mpuJd22Z0YAYUsPVHDE25u6ibhkMnnh0sSyLVU5v3xV4o2kdFHWwz194rOe
20dIH3zt4XxC9fz/upKeGv2iEOp99Gmx8mKvkvs/OZbboMjPvIdjllbUUZFbqMvY0j339o1/uyLl
HRWSndAwhBeiGT/Mzf1ikejCNkUfWrfM9MK/3ndwNhA+UzH6GEyaT8MKMINL0hvnpbfOt/qZBC1F
eM356LD4RvcYCEHaxwwpJbqyR2AZuAnysVV+tHqMysE7lVe/b+1nItygNHe94zur2quZZepNWAW4
pbJi36XQjLsQd3zZsXT+UlCtzWUY3w2MqQ8coOcntfaR++ca7J+BFS39Fo9Zflucm85qN8hbLDJW
YIYRWy7mDTTO02kr05yanzs/0yaym1gxhbbHzk6+eY0/zCYqTfgm2K1RWcLaT3pjy2KE15YDR4J7
W7LS7o+WU72PKxmycA3cAcTQypGOz9DBWTJv7+CyJ+RUP7yhShrX7aJqYUz8DjlxpqIyR88pWqrf
7/g6e+n8KizeGZSal4NIBG439YED9PwEO0n/UZAZIl2pIjFvkf+RoJ4fEqelkRFlzMpDMDQEX5Xy
+qYbgexTrSHf+yaS56ZhVrLX3f39x9TJE++gg63tlST8wgj03hs0zKNJP3RLO3th94Tywt/FpnAY
HtPGro3QmtlFhho8qVD3lcAE9+z0dfpaxdR+YuLrN7Aq92PmEBAFl4pUVGhaFsftjTvel5Xz8VRv
95/LDRbvcaY+cIKWn1jxi9ALp0YO3RvXNXyKMsvvH/f1dmvCUm3S1IqHe7vvE/d43733DvdKeScb
QrufzkHuWJmGqydXUQ1PnRsbge4b9BORffAzeVxE1SWD/Zu1E/LISioN4P5EOBv3QPooNU7u6XPL
H1yayYalyTEM2kN2xOrCU3m90f9K1VZvmZwvkv98OkvdBg9KTJb7xNgHTrNIyw9DBwde+Sg83nff
a/1sgeuO3wbLVhnTt8G3xL0rsq8dGbgxfx3rDvvmU8sz/isviypWi7u/3+1o7QoJqfnpShIeInPn
XiFaO67qY45TkpvEXaWr4ZRunnoIpamUkM41qccAu5qpvmnRqAQartZ0VZV7kTwY31e9LxnbxR/Y
FD7fpHVTk6kPCna7cFPuNV58diI2/HJe+cPWYdJ7X3puIDa8IOZtoJBaEWZhcTXStX2rZLG0KZZL
vu1vXtaZ/sGSh6vMwryhJ/2xSOT7pN88MBWVTux4ndgxop6mYayL2C5xEMfz6jGtRDPRZ4yvPTLA
QODO6C7xsRYyPIxMSVIZ+q+4SEx6ktoCVFV7sC2X2l896aswUeA8Q492kZaTx3waurrgH8Q+YNQ+
cNLbWv6221tmpCEgNry1f8RVA0U+dO0CeSnBIKP9dVlGs2jDe8W849BYmOFS2dw7Ore1zyonnLZb
W38ROrU4x1Tu7mUYlgujafpziReAj39M7n7vzcd+Dg8NXw6Tx7+cfnkeAvHLITAy/36txDeI3Rxs
mk9/mIPgEwvvPkqsyCEvBb4d0prG9Pee25om8qS1hOrqn2z/LbFYrFrSVyBS4HyI2r94XLKfZ3an
04k9Yh9Mg38Hk0eanj87/i6x1gujrQdG5/LKnz9OpPKKptdkzN8ky5i/9sCB0RdFwkeg8RCZmcus
5HZ+cWvUnhb9oyuvymU976mwqlyXawG3jV5wlbE1M9WI41FrxAq88yiazqxTwkVqk7sKCVFBWJ1t
k7V7G9Xkf7tKNoGXWUfhw+Fll6sv3+pDOhfH2VPNeS1/z6wLBtCnT63WWZtcfvXrzQprs4dbfvd8
sKUteuZLK0veKtUHnccQ9aDhawZ0HkNsKiDhEUh4BAIJj0Ag4REIJDwCUbcwfAOqOKPYY4sVC/1Q
5dAQPKtWrvLXwWAum5jwdRqckNemIV+VuYQB6za9ScPzvBIrS9qznAY9geRxzFlx/V6tGwlyfTNr
eLPaY/O9gcK4L+Vhq/pKkGryHYEavpgCFEOfs84ZGpOQOI82vYa32c8OB7x9HqB9gGh0whvfoWUm
NOtwM6iurqySdFTwaNLk1/HSKp7hbYn5NT4aNIiG0fCqeSK9BFF/l4XRarFYMPLrEhuQOzwuxG82
oD88oqpAf3gEAgmPQCDhEQgkPAKBhEcgkPAIhB3GdXie1T/Ney7h8MJ1bU1fyaC+m92exZDZkkX+
wpe1XUvbc3aW562+/bz57e0Fa6Nt0IF44xJ+3WCdpoDZ2Yy1fSurZ9H8Lx1eXM3a2WxIYsG5iDrP
DCdYY768tdE3PIt83/gmjdUj3ujyzvOyU7zBI96YTc+vkpBViyme9GyhWcJaT5rkQVk3H95J+avS
Wcd5ixzfVBre7hFvVnpg8YjXtSmr2Bc2TzPV2uGNLmkORGQNG9VKUh14DIXYPGx2lGuZUjyrmzoO
tbEaT6jgNy7heXfGCssXsmJYRyOAzafBjZwyTSv75Qq8nN0+EUqxwVin5xDJVJKciXhU+BuU8Oqj
ndFCLsQxN1Nlnfwr9+GhQs8hrPOjOGKDPbSyxanEumecA13MRoRLOvEuLlUW//mCdx0eWbIZVmkK
rE7yzuYzazCSjbt5ngtdG8l8CXq8PE3MupqkiA1LeJNHvGZoyLuKj7zZAd5wpK24WxPy81ldH9ev
oK9+m1zynevK5kuw/A7LcCI/ndVMhi8QWLThNxDK8ocvov4qox1dGzps6XJRf9cM9eYPX/IXT3xR
w6HGbCrxiyHkOpo0FV4QqRCj2Ipn1HMj6Tct0HkMgYRHIJDwCAQSHoFo2IdW3vEZUPOwLdE/0erU
ZV3N5lnTZUvwkS/u/271aQd0DkDYCV9ofXqdfCnkjlLYl93uI1/c/93m3ml1g0egSWOijsHHXXF+
t7jGQ55o8fY48aoQi0e97Dqfdzqx+WZGGUCiI5w1vEVVGjWjxTUeCkSLN9PX5Flv9J83eqUXsm2M
RpHD5HDvLIYqHpGH8EW0I2tmkTlavEtSOTom5vvdBW83ikrzf0dfGERBwitq032cUd5x137Ml/58
oDqPleCN7DC9ULsjChCeLf4Qm09h89afRZfwjhBnH/kSyiAQ5Zo0bn/lw/KsowWSV4NbQ4HkoTbP
ulH/rqiO2h1RmPBmt3SNMHk94MHsNG9yXzcVMnjUS3KVX2Y7rKrn85EHV/7v5jI2v3jEZkbjxYcv
k7lI+IsDjA+/XpT3G1PkO6JBCV/eIyryHdGohEcgkPAIBBIegUDCI5DwCAQSHoFAwiMQSHgEAgmP
QCDhEQgkPAKBhEcgkPAIBBIegUDCIxBIeAQCCY9AwiMQm4TwwZi6F5D3ogEf/SlB3IvF5I9YLEb5
AuRUNEj7Au3iORElXzhEiiRCB+i7BRDupulQAlqph0gNhsptyVDAUndoJ/WK6hUUyGc7jjgSXoMQ
6Nb2euSd1Go4/brl96CDwvM9YWi/sHY+BfMCDA6C9FcSpoL7yOf1+z4bGmuDtrHQD/ddDx9a/BRM
re0vtyX3KlUWGGUHVuU/tYIvksNv44gj4TXcYt9byk5fgGVrof2wBm/3ByPU7IA+GTKxoHSPYO+m
fTmO6NUQA0NBmmYS0t2B/EUD8r2B4I/XxE8Gdo9Dlsgf3032H6Ny8E6fIi3so1tAoALA+X1+opiF
mD8R8LcSKZwq/1HGL109EaCpQIYml5Dr7lFrtAyjIOi1fj85PIAjjoTXkDit7Z3Rz3bZ7fwM+OHj
8Ka4oxOKGemeAqH7mrWxUODADnJi+izc1H3+ZO8Nao5Uz1vhni3S7m1nxc/bIRIhm5y4uZ3o5ju4
7Ak5a8veI8E9rVSgh+3s8/vIVR4H3/U9z66QpE5V/v8M9WXEvDfMLi/2sGRWyreZxDxoGn4GVvRa
L4OPTCsEEl4jZJu2F9FORtMqS1RLPRY7dGwGHgOSJ0LIqjMe7oc22LME4xPSTSETITeCbc89lVEz
rMFlK08tSbt3SRcYB4nu/eLmMWCCe3b6On2t4lEWwhNkOiVHFpdGkueJuE8C7YewGJJGk5+cBuk+
kTl+d1gyX5S6U8oO1xtn4n0J9TzXN8zF+wQcciR8IUQvDNyjRD4aVCz1wcFXe0Mig8T/Hj3rxMg/
Jpbit+XgAx+Q+Ec4PT/c9/g2zeoJxXvf3WF8IBgWPzwQl3k/t/zBpZlseElWzvvEKRHx9ff7Ikx8
ZWplZHoN9lFSRl3+gJj3+XsfDIGD6b8Lmsm/31YPfwk0UEaNj0DC25C4AEcO2s5ykqL9pcgpSj8b
8Q3cMOCPeOCpwUFFkTLnXz3atygSWyzCTb1ytH/RIMcLnDhlmsSNWJFdzVTf9KohRciOxDMJoAbe
MUCL5wRpgujyJRyC02841X0VumPdOsMPwb7YPrgUhxwJb4a+xEj2rvdMOpi9GVLsfPwmTsjsMsa9
Sw71DieJed81FVOWCAMf8K4Qht4B0R3yEQcfMRSgoGsX0bs0dHXBP4hyGRiZkmpEw1gXkdTWFzgy
EIMfwj54g1x1TAz9apSvINtFPuLSpDIuOsErg6/qDxkrcIQcruKQI+ELwN/3x7ZF9hjV+tICdGzx
bg15vmfQ8BC5C+gIJI+nd4y+IJ+Zv3Y+9NIW6I2naPEosdBx7AFDgecT6dTuWZjZnU4n9gAMeafB
v0OaYJPHD6WPzwl7j3EHj+2L+odhpAP4Y/ez5GZhlC8huGuHSOPg8GXm29AK/BjegjVOO2wmhwKH
Y76p0QjRgznY1vfaDNCBE+N/MZrGMWso1Fv04EYgvC/XFCCKeejmVaAC08ghJPwGJzwCCV8rGx6B
2FQPrQgEEh6BQMIjEEh4BAIJj0BcPBjf02p/abADlEzKO1y1TdXfGsYXuYSpXiWILaG1zjXSG6+d
KPpaWF2guSOtha2poF/PeE7JL75NekO9vW1B+gxXjfD2F8c7DpWakVU3tXhHHl+ERLyrXHmKlSXV
1ni9U3iWZ901xtqRKpcBnFNBvZ7xHG+YCTwg3BPe0s/KG6y1XSmJL1lL1gJ8uW9v5ctOZqvVeP2q
LNRlZ5d9iy4V3nILFtDAJsKzIrt5ixoyqRi2LHOj+mCrUox1OZBsRVnJlng9Zcj4OtfuZXTJwnrG
tgQNz5puyaxzfQ33UWBronjqbzxVi8bUeMI78r+YMc27bTNrzS5fj+XxZcsVI7xtTGy9Kw+qtqmF
fuDr1D5lHc8ot8V1N4ZVyK1nZ50eAxrZ1KkfwrNWrWJPYy8msepDwZf1RMFWsu28ttqw0UgfroLM
JqsxY9iY7ZZ89kxtbA2+XvnOV7ExTv1rK8uyrDgjlA2ibA1vMFacTBqpk02baps0Lq5RnZo4S+Xl
x0eWt5nVihVSVKBexukKtlRVGdnPIdzD2R8e+7HuzCSXg1J3I9cQ/vDI94vI+I1m+UEDEB75ftHA
sut60mU3ytBxQ5lwjqH7vVQgEG6NVi5+Fv7ED1FXJo1waU7ICVv/HaBtVj4jbdu83k8+4n3Gtw8J
j9gQhOd++XtrQm5lbaZwtuh/fyL16N1vUZUwabiQjz4Q1GIxxtQI8VqGoSBYEiMMJEK0FONdDsLe
Sj8E8HUlxvvQrfSBkBQ72B+pesca4s1XEGLAfLFfcg5Sldj5ghYf312ceyFE+8KcIb8uX5GjxLdv
J/IDUUN+cYzkiwlB2hdUqiT4pOwJX0wP/9lASETZ8KcY2uu59sTk2XNvF+E7zBw+M/cHE6mm5gOh
cOtwGUGGvHpgsW2puQu/uvHzamy6TkiKm57Lk2qGk/qunMiNns1+ex9HwVx2+aqjk8kk3B4/ujr1
voelPFO7z5y9Z88XBJI3+KGfHq5qt019q5vU6OH99zyTm8tWTGp7kyh1W2rG1+cgdW0tzIW55eWr
Em8kpY5hPdzTJz7ruX2E9MHXHs5rZl//6FN7Pu7R8+vyO8UAyEKoV+55z+oW7r0TK3p+goc7Rt8k
Fwt3z/3w19PySEW6pezf6SGbpDJodYTOfBUS/t8zzRQ0fYXj51+kp+UIjG1K4N2i29nFXy3Mz33z
G31v0wH/8w97y9Lwn4YVYAaX1GjuAK1+JiGHXc/56DD4xF1RtzCq9urKHoFl4MRgvlvlZypjjPet
/UyEG5Ra4h3fWd1uNcWbrxjeJVHqOTgxbo+Rr8XOv1SLr+kU596ODOyfgN8x5LfI1+Lbp7Mzl4LH
kF+cZEDLJWf2y6GTQZDbKyw3ikqfGmoNM7c2N6VunjxzdnWasBdgVoxbXc722PlzJy9cm+Kv8AXD
j2a40gjfBLsZ04147Se9MSnsesuBI8G9LVlp90fLqd7HlQxZuAbuEEM65shcydDBWVOMdz9oMU7H
ocphqk3x5iuG0XPi53ZRas4xQxccgFVYvFM2Lxzi3Dv2OOmwo4b8Fvl6fHu487dGzhrygxggM00H
OKJ7ohllnn1TNjmbf1LvRBcyrQ8GfVS//9rkyXP/Mj0L4rNopf7+/fyZk7+/5GmmmK+HWUFwR/iF
Eei9V7fhASb9IL8DZy/sngA5sPtiUzgMjykZVsks8wOzSxwuTyrUfaUpxns/GNhXZcKb4s1XDOki
UqNpeAkgnurt/nO5wWCNc+8ACnY9I+8p+S3yU/oD2VfG+rYb8ouIDwd7tsOpkesOxU9JVXhOUmvt
n3hP3av24zCR8+SOVfMS05C7Zx4ufcUd4alzYyPQfYN+IrIPfiY/feqak/2btRPySCmjdH8inI17
IH2UEu/Lxhjvw3o434gxjnz1oMSbr5VUOXZ+OkvdBg9KZJT7xNgHDjg1mv7TOBjy56915ARR6Xp+
yczZN0HOsX2v3de/XbKr7pHP/1vd853aP/f3i0sra7/u2tl6+WcuAcUqqchfdEvHZTt2vB5ihaW0
h+f2uSM8RObOvUK0dlzVx0rUdpADuCs9Dqd089RDKE2lhHSuST02xnin4WptAag2fapEla8wDohx
6R2kJi7AqweN3egQ596Jxens4hptyJ9Pvi2/Dlq04aUHjH33ik9c0HNdTH3HVb1jH8d70g8LuRe7
dmynt0Yle1yyTMrZ/sal25id/tBq89Li/Px+N4uVBsL7Y5HI96GZ9P1UVDqx43Vix4h6WonWLkZg
b4Krx7QSzUQ/Mb72yAADgTuju8THWsjwaox3hv4rLiJHct8CVE2UiBxvvsKIw9glTlIPeiY5qZmj
XaTl5DHfIc69AwK08LP9tCG/o3xxLdc3tYv0up5fvJhviiHnKBjKkOlNzkmvZRlUNw2EyH5uPrWU
Xc1d1bLjn7ddGpVZDOBye8lntoe6lnLnlzNpnimFXIZhuTCapj+XeAH4+MdkCd6bj/0cHhq+HCaP
fzn98jwE4pdDYGT+/VqJb0AAgk3z6Q9zEHxi4d1HJ8UY7xT45Bjv0997bmuayJOetZpr0YlKvPkK
YzJxKH3UQWpWjp0fovYvHp+U1ojtce4d8GNv4MuvcIb8+eRv8e5IHZ/X8kuWz4J3R8vxJMwnDrSO
zsNGQGSan78rs7z669eJpdNxSVuR7NGt21p3PE1sl4dTC1xHGUsU6/qmldtGL7jK2JqZigCiGGIF
lHQ0nVmnhIvUplJdC17K/v7q2or8BZTuXRD1UF/5m6bmc+u2FNbnWhBZWnSVz//gR5HOxUGDJ++3
CMEZF6/cpD255QYnvKpLr1pdW10Vtp1taqIuRM79YlelFCb60iDqkfBVA4baQ2wqIOERSHgEAgmP
QCDhEQgkPAJRtzB8A6r84t0Y/dm654yaBDmoUuwbDNCweQlf13F9+OrUDsNaoElDWMDzSmAtac9y
GvQEkscxZ8MA9ftm1vBmZcpaXz1heueEMXY8a39JRaMA+Y4avggfxNDnrHOGGrzlCYGovIbPxzG+
APmqHk+1buPDIzYQ4c0vOWMLafOqmzRofSCqbtLYVDlvjx1fI3MDtTuiWhpeNU/Ex1Hju1YMVovF
gpFyVt2kQSWPWD/QHx5RVaA/PAKBhEcgkPAIBBIegUDCIxBIeASiMOF5w6d5zyV4hy+q3Erk7ak1
fO8xAjV8GXB6e++6iiMQNSG81SPe6PLO87JTvMEj3phNzy9xmLdJtJZVRSi+9gZxoKU0qLs9ov7g
6Dxm94jXd8X/YPGI193hSRneSVvrEm1l1Y2az35VaFR3e0SdE553Z20Y/XTtLBQ5zxqP8gpjHUWw
tgwIRHUIz2qGRfE5wLu01Z0YX9Q84df1LIBAlGbSAFv8QZIt/3nT7GbvKgPqekQ1H1oLK3m+sJK3
6HTHHyrxhhK8k3TeloJKHlEtDW/yiNdMbXlX8ZE3+6cbjhS285ZETSLoP9cTt/pGzcvaMqA3PKJi
KMsfvsiCicv1FPvUQGw81Js/fMnvXuKLWtTIYESjPbQWAFuBHKZ8OD0Q9fDQikAg4REIJDwCgYRH
IOr9oZV3fIhUFw9Lerg0+oOpxS0SdH8xx6vq6/rKAr4xcD3v+LDrXAbXjBB5CF/II3GdtOELEI91
EK97R5q9KtUzJZRhkfGIIiYNb3BKV5zfLa7xkCdavN1xXRVi8aiXXefzTicXvjzFgURHFNTwFlVp
VJAW13goEC3eTF+TZ73Rf148ZTdjXNDUaioVLYMqHlGY8EWUJGsmkzlavEtusU4cZiGPje/sX8y6
mB7IdYQLwitq073DFu+4az/my2Glk/mPPEZUkPBs8YfYfPyzebKX8I4Qk3ni1gGtoFxU8AiXJg3v
cj2P5W0E5QvSTn8CsCWzjgYN63KqId8RZRJed3w3Lf/l9YAHs9O86QcfpkIGj3pJLi8vljusqvPa
GrqlMgWeQZUsehkeF+IRNjRefPhSCYyEv6jA+PDrRYnvNkO+Ixqb8CUu0SDfEQ1OeAQCCY9AIOER
CCQ8AgmPQCDhEQgkPAKBhEcgkPAIBBIegUDCIxBIeAQCCY9AIOERCCQ8AoGERzQABDZIeYMtAhIe
seHBtYbo1InM2zNnJlPN/tb2alzDy2A/I6qIzqRLsj/S5H0hsZAGyEjHi6m52RATvOCtnoaPSVCP
ogFDgrSJ+EEI0b4cBwk5Z4uvFSCXUfIzNH23IOb11/5Xde1B2heQFEIgVjmpQ0GaDiYs/SIjSI65
kI/OCSDkaF+Ik+7Gd9N0KAGt1EMkw1BesazPx0QN8hVx8ghAe4AIUW7oCZ98PhSzXFqXoVxTqYut
ng2CobDvmokzU89aTs+cTaaamZapKmn4ZLITBrX52HO5ttsJ4i537j+z7PWPPtX3cc+/bb3twWQS
POHFFSHokSm3QJ396y2zAskbyL59uNZPIkKLb0//yyBs6YFkxaT+60p6avSLQjKZvHBpYtk4v5q6
yWW2pWZ8fXNZdmCW2nu3mMx6uKdPfNZz+8jR1amvPZxPauY9HLO0sqLL12tN+h/W1k4+untWZvyT
4mVg6lvdeqPkvJn3/OISWYZyza/sl+qS7Kxg82uk4QXWs/Z/plIz4n6boj0N28ULc18IMUyqUpre
wYa/2+cLA030DQiMj2Yiyumd415Ygv0T8DuwCp8Tz6xNr0KbXxnGAX+EGUyLu0f6umrdq6nl6VPw
BMAtFZWaWaZ8IFKPuxA3WX7vEqkGz8GJcVgm/yYmYL94YhnGdwMDj1E5eKcvr9S2ODedzRjlm2q9
lO14A2S+C1lp88drhuRbFBmMIkO55u/IdWk0RFnGm0pNzc62iY0CyLOdOZsimp4dqg7hW8YCR/a2
kM4bhDCXTfcuqjMRxsED5N59FD4PH/QFOGiaauKWT6ipb6oCroFs7bvu1kPHThEb4EyFxe6EO0Qt
1e+fNp4dPSd+bodIBHLkH9kcFU9Ie7eTvriDy57IK3L1I8E7g4JRfuK09aLyqDT/RNrcdtaQJueV
ZMwarnlUrksjof35oPfXJ87NgNiO4n/T505c2x9Y/+qNnfBZmAgrlM1sD38S1jTCR4CCXc+Q3b+M
PxDo2Q7+HcxO+v/SrWJqP6h3AjIrVmvffU98uPdKoukjFbYtF6GXKPi9cfN9OS1dZlwmXL92Wtp7
DJjgnp2+Tl9rHpn9477e7laj/FSb9aLS/aSdeY90fJexUXJeScaVhmsOyHVpKPzhaqnLMKdzuZnK
E57ojH0KZVuv+9vvyn0p8Rjg1G3pP42TXs9SE7ACc9kTmclPpT8kpsaBUwVcFFUTua0Kd/ShgwOv
fBSAyfmcJtKw3Ctx7URc7r655Q8uzWTDS3nFjqt1VeRbNN+BgTEp1lQ6VKBqqgzlmsPqCDUOpueX
zr+jdVubYr0U+4teduU7Xs0sdFTBhgeOg4Py0hB8+A3DROAgcld2MUepxwBjvkg/9Zh4RMFVWvGL
1PMV/0pBuCn3mki9dnB8YjoAnECa6hH764BcAbIn1mJXM9U3ne82N6zVVZVv7vyFpiNz8rLBdTHx
QQryzzX5mgnycUC8dGMRXlqG8WRmWr+4tU2yWtoU68W+bad3XDW9uDATqQpL/NA1BiOkTzliX16l
P3/S4qIfLfxswAeML8pIt933+WCXbFUxu5a4TCwo7m4p/fXe6wVDt78OvkpLbbu9RbqDrsKEU3Ic
xi4hvUK6YAx+KK7H0tDVBf8gmoIMjEzlm38MdO0iT/8kvyrfhO/AFkZeCh4cHBQfpMxrw5oMRpZB
QdctcFisS5c0Qg2HCPf32ay/davMbgDrNrptS2hlaX46UjW1mDyePnR8Hh4avhx647+pGSqi/Q4/
9ga+/AoHL3oXWnYTszbaNA17gpLBOf3d1a0txyXVtALfqHWvhaj5m0idK4zs+Lukhe0VcOztycSh
9NFZmDmaOpSQFPXM7nQ6sYdYKt5p8fkmj9T54yQXb5Rvwp/1v8t5NX3YKOPldKssY1a8Zq9alwYF
xXiyv+6695I2y/nf2LbjHdOZeaqS13IfPZjr8LujVHj5XAQQZSAG+UPtRtOZdUq4SG0qoULCJUsr
b0v31lmI0pRvugr1KSFc9tDNGVf5An4OuVsWaPDkXdENzrhwAqE9ueUGJrxE+qiwnKP8U5kqKU0P
RtdF1BPhG25pA4GoZyDhEUh4BAIJj0Ag4REIJDwCUbcweAEobh32VwIXexFedV+Up74utirvJ+Px
rWebl/BsXb7jkWe194JXvnY8i++1RJMGeJ5X3mMt7VlOg55A8jjmrCRYx93KC0dsOg1vVnusVa0a
D9R9KQ9bNQVssT6QnojqPrQ6MIzljcRma6IupQuKE6sastGi2fQaHmzPsfYD3j4PqqyA2WqJRcYj
4U3GjSPlWAc+Vos5yEhEjUwamyoX9bhmx0MBjd8gfOeRAKjhNfNEspp1w9lotVgsGNm+ZqvESUl0
dS7A4jr8ZgP6wyOqCvSHRyCQ8AgEEh6BQMIjEEh4hBP4OpAA/1YPleCR8IhNCuM6vPwVj3s/ePtE
sn9Rr63pKxnEueacBfK6vstf+LJ5CilC7evpvNW3n7d4EjjWRnXdUauCDsQbl/DrBus0BczOZqzt
FqVnKeD67nSsTSLTnHLMYjjB8maHY97x9qdXhWeR7xuf8LIulMZbcZPRdkWlp/jYyAkGpSwe8Vp+
lYQsb9SVNi9fm++lVZVLF7OwriQO8jY/S93neUN/0VoXRnxdVKII4e0e8fquzHxLgqZNWZVcVk8z
1drhjS5prBuy6g48joXMM8Exi2Wu8Kxu6thrY5sdDazg113zCrSdr4tK5CE8767rjJSwV4Z1NALY
AlqcB6vCNQnQLsfm7QfNFmdL0xVsEWLIzkT405ONatKoj3YGYvDuuLOuu47+JFmud7qrQiZXOJfq
hHV+FEdsMBueLU6lEmxqB7oUNmny8MtUyDlPQbls4cnLGq2cAg8AiA25SlNgdZJ3Np9Zg5Fs3HWi
JlvoQjzrfPdgi88Jtixb0LJus1HUOVsHEuquEs15bv66R7xm6Mq7imFg9iQ3HPEmK9yFwzmrrvBo
e8YF8zx2CK+tsuddNdTl2k8U5bRWb7lajToFbF9xuJ7NvFOAoovwyGn4BqW8MtaiZfnDF2lEZVSk
66FhS5e7SWxy21ccrp+/TV9isOuacuubLtpXLO6HzFTGVrRk1wKe52vCd/e3K76WGqfxZ0BNNXRF
9HtFy5T8TStbgRyVNd3Y0sVuVtKzNSlSOS6wlS+DzmOITQUkPAIJj0Ag4RGIDYD88eHND72lLS/Z
vo3nbavZBodFp6savvhUvXjd+7+bl2CNm821RmP7iqOMknXUjnLKsIXX4Xlnj/aSW24lvNMvQwp9
b2pePTUvp2p+l3nL2Nw7LRsEmjRm6six3vUw8cYQ8Lz6cwqnaPH2OPGqEGOiKpfPO8+KzcJytASO
NQIKxIc3/UDI4hoPBaLFW/x2jZ71Rv95o1d6IdvG7lnDuihT6E6HzEfCl6QWza7qrDlavEs2OXI4
j4+8kxXn1v+94NRBIOFNatP9kwLvuGs/5t3z0P4QkPdFDIg6ARdpUMLrvwNyqRNZMzHz6nLWxbRh
S1LLpZg0qOALISZ+rC/w6TazwMHypctlyScpN+z9yX6ASPdRL8fIctZVz2Z3yyxFTWLDmkpBotkX
fXjWPh1cc7Nkp1FEPqw/ym/fYOWlDwI3djPAVOc9P8qwoZnBdYcjbnIiseQPqWw0ArMmN0njkWGf
tbhSmgrpgll9uYeX/C95xyrwDnLyOkfqZcwN0M7LC0ZI+4IYYig/C/4ECH4QglRQkLUz+Yuxfoj4
aCYj5RMY+lHyGaKlHC230kMkD/nX4odEgGYSeaQHaH8r+AVIMFpZRXqrDyI0deuQrUzk4CrAVmY/
MMxSBRrY5KAwWZbVN6z2cKgcq1n1BGMKyyrPrqwxG2uUAKpctSyrnDdWRJNoklNQrxvKGBugtcN+
FYQNN3NCYBHoBXjRB23PCHSbIe0cpAPLnMKRH7T8CbEPqOVnJBvhiaOPE2VMdK/3HFzvX/Zfn0f6
j5fJhKFfhFtovayM709B+ofCd7/kMK4BAP8E2ZlYrjjhGwHr+o0pKvj8dnNMVLYZBrh+eOv34fsU
LO2GCYNSnYhAs5DJyGeWd08vSTwM+8hRMrJ/XM40HgH/OEz480jfDzyR/n0QnpXKGrJdS6QfyGR+
pGWXCog7784B9IvPwxFPBZrpZRpuZJiLVHZjo3MwmRRXWr61xGxPXnjr5X9fgBs+AYebV6GTnCd/
nZ8AiP+T7/4lr5idpMmfj4g5PiHnkDOJxZrWpGJW6YknKS+R/l9XPY9IZb0m6W99g/77yKKaPZkU
T5OdkftX4Oz0YVK3+1cBzHI3g4ZHVBOXedp+RnTpQy3EVI9zwMlnlQ3sy0wFQtJeXDo1THLkrCLE
Ynlo9R4PMZYgQrX45LJm6ZHF86EFe6GONYBsF9npojalSYOoJtb+Y/ygaDfuIU+PS69Dl8jMIW6H
eoPMqGYFNdZO7JHsLhjLamVpQU76JXTlebzMUeOi2f70HvKZZaSyuzK69EjkrEOh5wnPz2eGYCjz
ayQ8osIIfqxDpMRPhq8FWLmVXp4FmI91eNXU91PpOZmc9y+QZ6mVLH3bir4GIyt//hZfNs9zVnDv
1ofJJjxMLP6VKCWW/XDLB1UO/qSbbgnabH/698hDawf/JfpmvqMCDcS3+CE2FSrjD8+X6tOihIwo
M4hDtYLOm1ySS3G6LxZ0HqPN1yPhCw1GpUdpXc7p1Qo6bwypWTTovINPqaFtjqUw2nwdYH3+8Hrk
Vc3TnbfkBlAd4lXhoEjheUdfel6XZamL4cUGymo8rznkFwujZ/HPNLak/Fmdxz2UR1I3hIa36yOX
/vBgCBPPG20WazqAlgXMPvL2XasLPVgc6KsQdJ7NQ/18jvqmWIOsMXv+2uBcqD/C29VjnnNOX/Y7
vzYJHOO958nAOl+9QEjWImHe1ViDLoLOW3lewOlen22si3uKck2MNl+PhHfjD1/O72rz0sq+W1Jd
3NoffBkxyoons6X5duLvauuP8K784Su13sC6up+wRX7qV9D0WK9Hfcm/I8xfCqPN16lJU1QPWfzf
LUE3bANvfT9NPkY6xTKw1sVN0Hm7QcPmubGwJc3JEpavUI03CuEtET141smIMUeLV1bUDcHcHdPB
Hu/dHoDeYPBa61JO0HklkrxJQtGX37gIOm+vGc8Wtf8aO9r8hkDFv2l1HPa6sVox6Pxmx/8H4vN8
oLeSV6AAAAAASUVORK5CYII=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-05-05 14:56:20 +0100" MODIFIED_BY="Rebecca Gray">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2009-05-05 14:56:20 +0100" MODIFIED_BY="Rebecca Gray" NO="1">
<TITLE MODIFIED="2009-05-05 14:43:01 +0100" MODIFIED_BY="Rebecca Gray">Christy Ngo</TITLE>
<DATE_SUBMITTED>
<DATE DAY="26" MONTH="3" YEAR="2009"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2009-05-05 14:51:40 +0100" MODIFIED_BY="Rebecca Gray">
<P>I highly value the work that's been contributed to create the review on 'Normobaric and hyperbaric oxygen therapy for migraine and cluster headache'. I am part of a Technology Assessment Unit that reviews the literature on new and developing technologies for Kaiser Permanente and I find the systematic reviews to be extremely informative and useful. Please keep up the fantastic work and don't forget to update the reviews.</P>
<P>Submitter agrees with default conflict of interest statement, which reads as follows: 'I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback'.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2009-05-05 14:56:20 +0100" MODIFIED_BY="Rebecca Gray">
<P>The authors and the staff of the Pain, Palliative and Supportive Care Review Group thank Christy Ngo for her kind comments.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2009-05-05 14:52:08 +0100" MODIFIED_BY="Rebecca Gray">
<P>Feedback: Christy Ngo</P>
<P>Response: Jessica Thomas</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<APPENDIX ID="APP-01" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NO="1">
<TITLE MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">Search strategies used for this Cochrane review update</TITLE>
<APPENDIX_BODY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL (the Cochrane Library)</HEADING>
<P>#1 MeSH descriptor: [Headache] this term only</P>
<P>#2 MeSH descriptor: [Headache Disorders] explode all trees</P>
<P>#3 (headache* or migrain* or cephalgi* or cephalalgi* or cluster):ti,ab,kw (Word variations have been searched)</P>
<P>#4 #1 or #2 or #3</P>
<P>#5 MeSH descriptor: [Hyperbaric Oxygenation] this term only</P>
<P>#6 MeSH descriptor: [Oxygen Inhalation Therapy] this term only</P>
<P>#7 MeSH descriptor: [Oxygen] this term only and with qualifier(s): [Adverse effects - AE, Therapeutic use - TU, Toxicity - TO]</P>
<P>#8 MeSH descriptor: [Hyperoxia] this term only</P>
<P>#9 MeSH descriptor: [Atmosphere Exposure Chambers] this term only</P>
<P>#10 (hyperbar* or HBO*):ti,ab,kw (Word variations have been searched)</P>
<P>#11 (high pressure oxygen or 100% oxygen):ti,ab,kw (Word variations have been searched)</P>
<P>#12 ((monoplace or multiplace) near/5 chamber*):ti,ab,kw (Word variations have been searched)</P>
<P>#13 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12</P>
<P>#14 #4 and #13 Publication Date from 2008 to 2015</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (OVID)</HEADING>
<P>1. Headache/</P>
<P>2. exp Headache Disorders/</P>
<P>3. (headache$ or migrain$ or cephalgi$ or cephalalgi$ or cluster).tw.</P>
<P>4. or/1-3</P>
<P>5. Hyperbaric Oxygenation/</P>
<P>6. Oxygen Inhalation Therapy/</P>
<P>7. Oxygen/ae, tu, to</P>
<P>8. Hyperoxia/</P>
<P>9. Atmosphere Exposure Chambers/</P>
<P>10. (hyperbar$ or HBO$).tw.</P>
<P>11. (high pressure oxygen or 100% oxygen).tw.</P>
<P>12. ((monoplace or multiplace) adj5 chamber$).tw.</P>
<P>13. or/5-12</P>
<P>14. randomized controlled trial.pt.</P>
<P>15. controlled clinical trial.pt.</P>
<P>16. randomized.ab.</P>
<P>17. placebo.ab.</P>
<P>18. drug therapy.fs.</P>
<P>19. randomly.ab.</P>
<P>20. trial.ab.</P>
<P>21. or/14-20</P>
<P>22. exp animals/ not humans.sh.</P>
<P>23. 21 not 22</P>
<P>24. 4 and 13 and 23</P>
<P>25. (200805* or 200806* or 200807* or 200808* or 200809* or 200810* or 200811* or 200812* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015*).</P>
<P>26. 24 and 25</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE (OVID)</HEADING>
<P>1. Headache/</P>
<P>2. exp Headache/ and Facial Pain/</P>
<P>3. (headache$ or migrain$ or cephalgi$ or cephalalgi$ or cluster).tw.</P>
<P>4. or/1-3</P>
<P>5. Hyperbaric Oxygenation/</P>
<P>6. Oxygen Therapy/</P>
<P>7. Oxygen/ae, tu, to</P>
<P>8. Hyperoxia/</P>
<P>9. Air Quality Control/</P>
<P>10. (hyperbar$ or HBO$).tw.</P>
<P>11. (high pressure oxygen or 100% oxygen).tw.</P>
<P>12. ((monoplace or multiplace) adj5 chamber$).tw.</P>
<P>13. or/5-12</P>
<P>14. random$.tw.</P>
<P>15. factorial$.tw.</P>
<P>16. crossover$.tw.</P>
<P>17. cross over$.tw.</P>
<P>18. cross-over$.tw.</P>
<P>19. placebo$.tw.</P>
<P>20. (doubl$ adj blind$).tw.</P>
<P>21. (singl$ adj blind$).tw.</P>
<P>22. assign$.tw.</P>
<P>23. allocat$.tw.</P>
<P>24. volunteer$.tw.</P>
<P>25. Crossover Procedure/</P>
<P>26. double-blind procedure.tw.</P>
<P>27. Randomized Controlled Trial/</P>
<P>28. Single Blind Procedure/</P>
<P>29. or/14-28</P>
<P>30. (animal/ or nonhuman/) not human/</P>
<P>31. 29 not 30</P>
<P>32. 4 and 13 and 31</P>
<P>33. (200805* or 200806* or 200807* or 200808* or 200809* or 200810* or 200811* or 200812* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015*).dd.</P>
<P>34. 32 and 33</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL (EBSCO)</HEADING>
<P>S24 S14 AND S23</P>
<P>S23 S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22</P>
<P>S22 (allocat* random*)</P>
<P>S21 (MH "Quantitative Studies")</P>
<P>S20 (MH "Placebos")</P>
<P>S18 (random* allocat*)</P>
<P>S17 (MH "Random Assignment")</P>
<P>S16 (Randomi?ed control* trial*)</P>
<P>S15 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or</P>
<P>(doubl* mask* ) or (singl* mask* )</P>
<P>S14 S12 AND S13</P>
<P>S13 EM 20080501-20140430</P>
<P>S12 S3 AND S11</P>
<P>S11 S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10</P>
<P>S10 ((monoplace or multiplace) N5 (chamber*))</P>
<P>S9 (high pressure oxygen or 100% oxygen)</P>
<P>S8 (hyperbar* or HBO*)</P>
<P>S7 (MH "Hyperoxia")</P>
<P>S6 (MH "Oxygen/AE/TU")</P>
<P>S5 (MH "Oxygen Therapy")</P>
<P>S4 (MH "Hyperbaric Oxygenation")</P>
<P>S3 (S1 OR S2)</P>
<P>S2 (headache* OR migrain* OR cephalgi* OR cephalalgi* OR cluster)</P>
<P>S1 (MH "Headache+")</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson" NO="2">
<TITLE MODIFIED="2015-08-23 03:24:28 +0100" MODIFIED_BY="[Empty name]">Data extraction table for the relief of acute migraine attack</TITLE>
<APPENDIX_BODY MODIFIED="2015-12-18 10:48:15 +0000" MODIFIED_BY="Anna Hobson">
<TABLE COLS="7" ROWS="4">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Study ID</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Participants and condition</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Study design</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Treatment</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Treatment duration</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Data extracted</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>14 patients (23 to 67 years, 9 females) with a diagnosis of migraine documented by neurologist evaluation.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acute therapy trial. RCT with partial cross-over (patients with relief on first arm could not be crossed) with blinding of patients and investigators. Patients with no relief had the choice of undergoing the second arm of the study 30 minutes after completion of the first arm assigned.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Control: 10% oxygen breathing via Scott mask at 2 ATA.</P>
<P>HBOT: 100% oxygen at 2 ATA on the same schedule.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45 minutes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Proportion of patients with significant pain relief using a Blanchard pain inventory from 0 to 5. Significant relief defined as reduction on this scale of 2 or more points.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Fife-1992" TYPE="STUDY">Fife 1992</LINK> gave the response of all patients from both treatment periods. We have included responders for both initial treatment and on crossover. Total of 8 of 11 individuals obtained pain relief from HBOT and 2 of 7 obtained similar relief from air.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19 patients with a diagnosis of migraine according to the <LINK REF="REF-AHC-1962" TYPE="REFERENCE">AHC 1962</LINK>.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acute therapy trial. Cross-over RCT with blinding of patients and investigators. Cross-over was made 5 minutes after completing the first assigned treatment.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Control: Air breathing at 2.0 ATA.</P>
<P>HBOT: 100% oxygen breathing on the same schedule.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>45 minutes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Complete or partial pain relief.</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hill-1992" TYPE="STUDY">Hill 1992</LINK> reported no patients given air and all patients given oxygen obtained some pain relief. (10 had air first and 9 had HBOT first). We included the results given as prior to crossover because of limited reporting. This was a more conservation approach than imputing the response for all crossovers.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20 patients (14 female) with a diagnosis of migraine confirmed by a physician.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acute therapy trial. RCT with randomisation not described.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Control: 100% oxygen at 1 ATA for 40 minutes.</P>
<P>HBOT: 100% oxygen breathing using a hood at 2.0 ATA.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40 minutes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Proportion with significant headache relief on a 6 category scale from 'none' to 'most severe ever'.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Myers-1995" TYPE="STUDY">Myers 1995</LINK> reported 9 of 10 patients given HBOT obtained 'total' or 'near-total' relief of headache versus 1 of the 10 patients given air.</P>
</TD>
</TR>
</TABLE>
<P>
<B>Abbreviations: </B>ATA: atmospheres absolute; HBOT: hyperbaric oxygen therapy; RCT: randomised controlled trial. </P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="161">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="144">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 studies included in previous version of review&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="166"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 new studies included&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="179">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 full-text articles assessed for eligibility&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="141">
<FLOWCHARTBOX TEXT="&lt;p&gt;220 records screened&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="148">
<FLOWCHARTBOX TEXT="&lt;p&gt;220 records after duplicates removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="256">
<FLOWCHARTBOX TEXT="&lt;p&gt;216 records identified through database searching (2008 to 2015)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="129"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;4 additional records identified through other sources&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="113"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;213 records excluded&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="159"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;2 full-text articles excluded, with reasons:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;1 third party report of a primary trial&lt;/li&gt;&lt;li&gt;1 abstract of included study with no new data&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="162"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>